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ABSTRACT OF THE DISSERTATION 
PRENATAL ENVIRONMENTAL EXPOSURE AND NEURODEVELOPMENTALLY 
IMPORTANT GENE EXPRESSION IN MALFORMED BRAIN TISSUE FROM 
PEDIATRIC INTRACTABLE EPILEPSY PATIENTS 
by 
Brenda Luna 
Florida International University, 2011 
Miami, Florida 
Professor Deodutta Roy, Major Professor 
The primary objective of this proposal was to determine whether mitochondrial oxidative 
stress and variation in a particular mtDNA lineage contribute to the risk of developing cortical 
dysplasia and are potential contributing factors in epileptogenesis in children.  The occurrence of 
epilepsy in children is highly associated with malformations of cortical development (MCD).  It 
appears that MCD might arise from developmental errors due to environmental exposures in 
combination with inherited variation in response to environmental exposures and mitochondrial 
function.  Therefore, it is postulated that variation in a particular mtDNA lineage of children 
contributes to the effects of mitochondrial DNA damage on MCD phenotype.  Quantitative PCR 
and dot blot were used to examine mitochondrial oxidative damage and single nucleotide 
polymorphism (SNP) in the mitochondrial genome in brain tissue from 48 pediatric intractable 
epilepsy patients from Miami Children’s Hospital and 11 control samples from NICHD Brain and 
Tissue Bank for Developmental Disorders.   
Epilepsy patients showed higher mtDNA copy number compared to normal health 
subjects (controls). Oxidative mtDNA damage was lower in non-neoplastic but higher in 
neoplastic epilepsy patients compared to controls.  There was a trend of lower mtDNA oxidative 
vii 
damage in the non-neoplastic (MCD) patients compared to controls, yet, the reverse was observed 
in neoplastic (MCD and Non-MCD) epilepsy patients.  The presence of mtDNA SNP and 
haplogroups did not show any statistically significant relationships with epilepsy phenotypes. 
However, SNPs G9804A and G9952A were found in higher frequencies in epilepsy samples. 
Logistic regression analysis showed no relationship between mtDNA oxidative stress, mtDNA 
copy number, mitochondrial haplogroups and SNP variations with epilepsy in pediatric patients. 
The levels of mtDNA copy number and oxidative mtDNA damage and the SNPs G9952A and 
T10010C predicted neoplastic epilepsy, however, this was not significant due to a small sample 
size of pediatric subjects.  Findings of this study indicate that an increase in mtDNA content may 
be compensatory mechanisms for defective mitochondria in intractable epilepsy and brain tumor. 
Further validation of these findings related to mitochondrial genotypes and mitochondrial 
dysfunction in pediatric epilepsy and MCD may lay the ground for the development of new 
therapies and prevention strategies during embryogenesis.   
 
 
 
 
 
 
 
 
 
 
 
viii 
TABLE OF CONTENTS 
CHAPTER 
 
PAGE
I. INTRODUCTION 1
 Overview 1
 Research objectives  4
 Specific Aims 4
  
II. LITERATURE REVIEW 5
 Epilepsy 5
 Refractory (Intractable) Epilepsy 7
 Malformations of Cortical Development 9
 Origins of MCD 11
 Development of Cerebral Cortex 13
 Types of MCD 14
 MCD Genes 25
 Effects of Environmental Factors and MCD 25
 Gene-environment Interactions and MCD 29
 MCD Epileptogenesis 31
 Mitochondria and Oxidative Stress 34
 Mitochondrial DNA and Point Mutations 41
 Mitochondrial DNA Copy Number Variations 44
 Mitochondrial DNA Variations, Haplotypes, and Haplogroups 46
  
III. MANUSCRIPT 1  54
 Mitochondrial DNA background and oxidative damage in Miami Children’s Hospital intractable epilepsy pediatric patients 
54
 Abstract 54
 Methods 58
 Results 62
 Discussion 66
 References 75
 Figures and Tables 80
   
IV. MANUSCRIPT 2  110
 Mitochondrial DNA background and oxidative damage in Miami 
Children’s Hospital intractable epilepsy pediatric patients with brain 
tumors 
110
 Abstract 110
 Methods 114
 Results 119
 Discussion 123
 References 131
 Figures and Tables 136
ix 
V. CONCLUSIONS 166
 Directions for future research 167
  
LIST OF REFERENCES 169
  
APPENDIX 189
  
VITA 219
 
 
                                                                                                
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
LIST OF TABLES 
 
TABLE 
 
PAGE
Table 1.0 Cortical dysplasia classification in epilepsy 
 
48
Table 2.0 Classification of Malformations of Cortical Development 
(MCD) 
 
48
Table 3.0 Susceptibility genes of MCD syndromes 
 
49
Table 4.0 Environmental factors of MCD 
 
49
Table 5.0 Mitochondrial variants reported in diseases and haplogroups 
 
50
Table 6.0 Mitochondrial haplogroups 
 
53
Table 7.0 mtDNA lineages 
 
53
Table 1.1 Manuscript 1:   
Clinical profile of pediatric patients with intractable epilepsy 
 
80
Table 1.2   Manuscript 1:   
Profile of control samples obtained from NICHD Brain and 
Tissue Bank for Developmental Disorders at the University 
of Maryland 
 
81
Table 1.3   Manuscript 1:   
Mitochondrial SNPs and haplogroups used in this study 
 
82
Table 1.4   Manuscript 1:   
Comparison of demographic, mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients and non-epileptic 
control from NICHD Brain and Tissue Bank 
 
84
Table 1.5 Manuscript 1: 
Comparison of demographic, mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients and non-epileptic 
control from NICHD Brain and Tissue Bank by gender 
 
 
 
 
85
xi 
 
Table 1.6  Manuscript 1:   
Comparison of demographic, mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients with MCD and non-
epileptic control from NICHD Brain and Tissue Bank 
 
86
Table 1.7  Manuscript 1:   
Comparison of demographic, mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients with non-MCD and 
non-epileptic control from NICHD Brain and Tissue Bank 
 
87
Table 1.8 Manuscript 1:   
Comparison of demographic, mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients with MCD and non-
MCD 
 
88
Table 1.9 Manuscript 1:   
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric intractable 
epilepsy patients and non-epileptic control from NICHD 
Brain and Tissue Bank   
 
89
Table 1.10  Manuscript 1:   
The results of the Fisher’s exact test for individual 
haplogroups for in Miami Children’s Hospital pediatric 
intractable epilepsy patients and non-epileptic control from 
NICHD Brain and Tissue Bank 
 
90
Table 1.11 Manuscript 1:   
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric intractable 
epilepsy male patients and non-epileptic control from 
NICHD Brain and Tissue Bank 
 
91
Table 1.12 Manuscript 1:   
The results of the Fisher’s exact test for individual 
haplogroups for in Miami Children’s Hospital pediatric 
intractable epilepsy male patients and non-epileptic control 
from NICHD Brain and Tissue Bank 
 
 
 
92
xii 
Table 1.13 Manuscript 1:   
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric intractable 
epilepsy female patients and non-epileptic control from 
NICHD Brain and Tissue Bank 
 
93
Table 1.14 Manuscript 1:   
The results of the Fisher’s exact test for individual 
haplogroups for in Miami Children’s Hospital pediatric 
intractable epilepsy female patients and non-epileptic control 
from NICHD Brain and Tissue Bank 
 
94
Table 1.15  Manuscript 1: 
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric intractable 
epilepsy patients with MCD and non-epileptic control from 
NICHD Brain and Tissue Bank 
 
95
Table 1.16   Manuscript 1: 
The results of the Fisher’s exact test for individual 
haplogroups for in Miami Children’s Hospital pediatric 
intractable epilepsy patients with MCD and non-epileptic 
control from NICHD Brain and Tissue Bank 
 
96
Table 1.17   Manuscript 1: 
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric intractable 
epilepsy patients with non-MCD and non-epileptic control 
from NICHD Brain and Tissue Bank 
 
97
Table 1.18 Manuscript 1: 
The results of the Fisher’s exact test for haplogroups for in 
Miami Children’s Hospital pediatric intractable epilepsy 
patients with non-MCD and non-epileptic control from 
NICHD Brain and Tissue Bank 
 
98
Table 1.19   Manuscript 1: 
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric intractable 
epilepsy patients with MCD and non-MCD 
 
99
Table 1.20  Manuscript 1: 
The results of the Fisher’s exact test for haplogroups for in 
Miami Children’s Hospital pediatric intractable epilepsy 
patients with MCD and non-MCD 
100
xiii 
Table 1.21   Manuscript 1: 
The results of the logistic regression for SNPs/Hg, level of 
relative mtDNA copy number, level of oxidative mtDNA 
damage, and age in Miami Children’s Hospital pediatric 
intractable epilepsy patients and non-epileptic control from 
NICHD Brain and Tissue Bank   
 
101
Table 1.22 Manuscript 1: 
The results of the logistic regression for SNPs/Hg, level of 
index of level  relative mtDNA copy number by level of 
oxidative mtDNA damage, and age in Miami Children’s 
Hospital pediatric intractable epilepsy male patients and non-
epileptic control from NICHD Brain and Tissue Bank   
 
102
Table 1.23 Manuscript 1: 
The results of the logistic regression for SNPs/Hg, level of 
index of level  relative mtDNA copy number by level of 
oxidative mtDNA damage, and age in Miami Children’s 
Hospital pediatric intractable epilepsy female patients and 
non-epileptic control from NICHD Brain and Tissue Bank   
 
103
Table 1.24  Manuscript 1: 
The results of the logistic regression for SNPs/Hg, level of 
relative mtDNA copy number, level of oxidative mtDNA 
damage, and age for in Miami Children’s Hospital pediatric 
intractable epilepsy patients with MCD and non-epileptic 
control from NICHD Brain and Tissue Bank 
 
104
Table 1.25   Manuscript 1: 
The results of the logistic regression for haplogroups, level of 
relative mtDNA copy number, level of oxidative mtDNA 
damage, and age for in Miami Children’s Hospital pediatric 
intractable epilepsy patients with non-MCD and non-
epileptic control from NICHD Brain and Tissue Bank 
 
105
Table 1.26   Manuscript 1: 
The results of the logistic regression for haplogroups, level of 
relative mtDNA copy number, level of oxidative mtDNA 
damage, and age for in Miami Children’s Hospital pediatric 
intractable epilepsy patients with MCD and non-MCD 
 
 
106
xiv 
Table 1.27 Manuscript 1: 
Influence scores between selected variables for female 
samples 
 
107
Table 1.28 Manuscript 1: 
Pearson correlation between selected variables based on the 
influence scores for female samples 
 
108
Table 2.1   Manuscript 2: 
Clinical profile of pediatric patients with intractable epilepsy 
with brain tumors 
 
136
Table 2.2  Manuscript 2: 
Profile of control samples obtained from NICHD Brain and 
Tissue Bank for Developmental Disorders at the University 
of Maryland 
 
137
Table 2.3  Manuscript 2: 
Mitochondrial SNPs and haplogroups used in this study 
 
138
Table 2.4 Manuscript 2: 
Comparison of demographic,  mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients and non-
epileptic control from NICHD Brain and Tissue Bank 
 
140
Table 2.5 Manuscript 2: 
Comparison of demographic, mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients and non-
epileptic control from NICHD Brain and Tissue Bank by 
gender 
 
141
Table 2.6 Manuscript 2: 
Comparison of demographic, mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients with MCD 
and non-epileptic control from NICHD Brain and Tissue 
Bank 
 
 
 
 
 
142
xv 
Table 2.7 Manuscript 2: 
Comparison of demographic,  mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients with non-MCD and 
non-epileptic control from NICHD Brain and Tissue Bank 
 
143
Table 2.8 
  
Manuscript 2: 
Comparison of demographic,  mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients with MCD 
and non-MCD 
 
144
Table 2.9  Manuscript 2: 
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric intractable 
neoplastic epilepsy patients and non-epileptic control from 
NICHD Brain and Tissue Bank   
 
145
Table 2.10  Manuscript 2: 
The results of the Fisher’s exact test for individual 
haplogroups for in Miami Children’s Hospital pediatric 
intractable neoplastic epilepsy patients and non-epileptic 
control from NICHD Brain and Tissue Bank 
 
146
Table 2.11 Manuscript 2: 
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric intractable 
epilepsy male neoplastic patients and non-epileptic control 
from NICHD Brain and Tissue 
 
147
Table 2.12 Manuscript 2: 
The results of the Fisher’s exact test for individual 
haplogroups for in Miami Children’s Hospital pediatric 
intractable epilepsy male neoplastic patients and non-
epileptic control from NICHD Brain and Tissue Bank 
 
148
Table 2.13 Manuscript 2: 
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric intractable 
epilepsy female neoplastic patients and non-epileptic control 
from NICHD Brain and Tissue 
 
149
xvi 
Table 2.14 Manuscript 2: 
The results of the Fisher’s exact test for individual 
haplogroups for in Miami Children’s Hospital pediatric 
intractable epilepsy female neoplastic patients and non-
epileptic control from NICHD Brain and Tissue Bank 
 
150
Table 2.15 Manuscript 2: 
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with MCD and non-epileptic 
control from NICHD Brain and Tissue Bank 
 
151
Table 2.16 Manuscript 2: 
The results of the Fisher’s exact test for individual 
haplogroups for in Miami Children’s Hospital pediatric 
neoplastic intractable epilepsy patients with MCD and non-
epileptic control from NICHD Brain and Tissue Bank 
 
152
Table 2.17  Manuscript 2: 
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with non-MCD and non-
epileptic control from NICHD Brain and Tissue Bank 
 
153
Table 2.18 Manuscript 2: 
The results of the Fisher’s exact test for haplogroups for 
Miami Children’s Hospital pediatric intractable neoplastic 
epilepsy patients with non-MCD and non-epileptic control 
from NICHD Brain and Tissue Bank 
 
154
Table 2.19 Manuscript 2: 
The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with MCD and non-MCD 
 
155
Table 2.20 Manuscript 2:  
The results of the Fisher’s exact test for haplogroups for 
Miami Children’s Hospital pediatric intractable epilepsy 
patients with MCD and non-MCD 
 
 
 
 
 
 
156
xvii 
Table 2.21 Manuscript 2: 
The results of the logistic regression for SNPs/Hg, level of 
relative mtDNA copy number, level of oxidative mtDNA 
damage, and age in Miami Children’s Hospital pediatric 
neoplastic intractable epilepsy patients and non-epileptic 
control from NICHD Brain and Tissue Bank   
 
157
Table 2.22 Manuscript 2: 
The results of the logistic regression for SNPs/Hg, level of 
relative mtDNA copy number, level of oxidative mtDNA 
damage, and age in Miami Children’s Hospital pediatric 
intractable epilepsy male neoplastic patients and non-
epileptic control from NICHD Brain and Tissue Bank   
 
158
Table 2.23 Manuscript 2: 
The results of the logistic regression for SNPs/Hg, level of 
relative mtDNA copy number, level of oxidative mtDNA 
damage, and age in Miami Children’s Hospital pediatric 
intractable epilepsy female neoplastic patients and non-
epileptic control from NICHD Brain and Tissue Bank   
 
159
Table 2.24 Manuscript 2: 
The results of the logistic regression for SNP/ haplogroups, 
level of relative mtDNA copy number, level of oxidative 
mtDNA damage, and age  for in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients with non-
MCD and non-epileptic control from NICHD Brain and 
Tissue Bank 
 
160
Table 2.25  Manuscript 2: 
The results of the logistic regression for SNP/ haplogroups, 
level of relative mtDNA copy number, level of oxidative 
mtDNA damage, and age for in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients with non-
MCD and non-epileptic control from NICHD Brain and 
Tissue Bank 
 
161
Table 2.26 Manuscript 2: 
The results of the logistic regression for SNP/haplogroups, 
level of relative mtDNA copy number, level of oxidative 
mtDNA damage, and age for in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients with MCD 
and using non-MCD as control group 
 
162
xviii 
Table 2.27 Manuscript 2: 
Influence scores between selected variables for female 
samples 
 
163
Table 2.28 Manuscript 2: 
Pearson correlation between selected variables based on the 
influence scores for female samples 
 
164
Table A.1 Clinical characteristics of the intractable epilepsy patients 
and controls 
 
190
Table A.2  Mitochondrial copy number relative to 18s rRNA gene 
content as determined from the Ct differences 
 
193
Table A.3  Mitochondrial DNA oxidative damage determined from Ct 
differences 
 
195
Table A.4  Comparison of Malformation of Cortical Development 
intractable epilepsy patients and control group 
 
197
Table A.5 Comparison of Non Malformation of Cortical Development 
intractable epilepsy patients and control group 
 
198
Table A.6 Comparison of Malformation of Cortical Development 
intractable epilepsy patients and Non-MCD epilepsy patients 
 
199
Table A.7 Mitochondrial SNPs and haplogroups 
 
200
Table A.8 mtDNA haplogroups J, L, M, T, U, and X 
 
201
Table A.9 Sequences for amplifying mitochondrial genome 
 
202
Table A.10 Sequences for the mtDNA SNPs and haplogroups 
 
203
Table A.11 Hybridization temperatures for ASO Dot Blots 
 
205
Table A.12 The results of the Fisher exact test for individual SNP for 
Malformations of Cortical Development (MCD) and Non-
MCD pediatric intractable epilepsy patients 
 
206
Table A.13 The results of the Fisher exact test for individual haplogroups 
for Malformations of Cortical Development (MCD) and Non-
MCD pediatric intractable epilepsy patients 
 
208
xix 
Table A.14 Characteristics of Miami Children’s Hospital neoplastic 
intractable epilepsy patients 
 
209
Table A.15 Comparison of demographic, mitochondrial DNA copy 
number and oxidative damage in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients by tumor 
grade and non-epileptic control from NICHD Brain and 
Tissue Bank 
 
210
Table A.16 The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with high tumor grade and non-
epileptic control from NICHD Brain and Tissue Bank 
 
211
Table A.17 The results of the Fisher’s exact test for haplogroups for in 
Miami Children’s Hospital pediatric intractable epilepsy 
patients with MCD and non-MCD 
 
212
Table A.18 The results of the logistic regression for SNPs/Hg, level of 
relative mtDNA copy number, level of oxidative mtDNA 
damage, and age in Miami Children’s Hospital pediatric 
neoplastic intractable epilepsy patients by high tumor grade 
and non-epileptic control from NICHD Brain and Tissue 
Bank 
 
213
Table A.19 The results of the Fisher’s exact test for individual SNP loci 
for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with low tumor grade and non-
epileptic control from NICHD Brain and Tissue Bank  
 
214
Table A.20 The results of the Fisher’s exact test for haplogroups for in 
Miami Children’s Hospital pediatric intractable epilepsy 
patients by low tumor grade and non-epileptic control from 
NICHD Brain and Tissue Bank 
 
215
Table A.21 The results of the logistic regression for SNPs/Hg, level of 
relative mtDNA copy number, level of oxidative mtDNA 
damage, and age in Miami Children’s Hospital pediatric 
neoplastic intractable epilepsy patients by low tumor grade 
using non-epileptic control from NICHD Brain and Tissue 
Bank as reference 
 
216
 
 
1 
CHAPTER I 
 
INTRODUCTION 
Overview 
Epilepsy is a chronic neurological disorder, characterized by spontaneous 
recurring seizures.  The incidence of epilepsy is highest for children and the elderly.  A 
proportion of patients have seizures that are resistant to traditional anti-epilepsy 
medicines (intractable or refractory epilepsy) (Alexander and Godwin, 2006).  The 
occurrence of epilepsy is highly associated with malformations of cortical development 
(MCD), which are developmental brain lesions that consist of dysplastic neuronal lesions 
(malformations) (Schwartzkroin and Walsh, 2000; Hua and Crino, 2003; Hader et al., 
2004; Rickert, 2006; Wong, 2007).  MCD are increasingly being recognized as the cause 
of intractable epilepsy. MCD presents a broad spectrum of structural changes which 
appear to result from changes in precursor neuronal or neuronal cells during cortical 
development at various stages such as: proliferation, migration, differentiation, and 
apoptosis (Becker et al., 2004).   
Treatment with anti-epileptic drugs (AEDs) is usually ineffective, and children 
with MCD may require surgical removal of the affected area of the brain (Yasin et al., 
2010).  In surgical series, focal cortical malformations and low-grade tumors 
(gangliomas, gangliocytomas, dysembryoplastic neuroepithiliomas, and astrocytomas) 
(Saneto and Wyllie, 2000). Two of the most common MCD found in resected tissue from 
children afflicted with intractable epilepsy are tuberous sclerosis (TSC), and focal cortical 
dysplasia (FCD) (Fassunke et al., 2004).  A significant proportion of FCD patients are not 
2 
appropriate surgical candidates or continue to have seizures despite the surgery.  The 
molecular mechanisms underlying the formation of MCD are still largely unknown and 
the treatments for epilepsy due to MCD are often ineffective or limited (Wong, 2009).  
Therefore, MCD formation and the occurrence of epileptic seizures in children is a great 
public health concern.   
Several reports indicate prenatal events are likely to be involved in the 
pathogenesis of MCD (Montenegro et al., 2002). Since brain development commences 
early in fetal life and continues until adolescence, exposure to environmental chemicals at 
an early stage may be the leading cause of neurodevelopmental disorders (Allen and 
Walsh, 1999).  Several studies indicate that genetic and environmental factors contribute 
to causation of MCD and lead to neurodevelopmental delay (Kuzniecky and Barkovich, 
2001).  Human and animal studies have demonstrated that in utero exposure to 
environmental agents such as: chemical (ethanol), physical (ionizing radiation) and 
biological factors (toxoplasmosis) result in neuronal migrational disorders (Chevassus-
au-Louis et al., 1998; Gressens, 2000).  Environmental events causing injury to the 
central nervous system (CNS) that have been associated with MCD include: head injury, 
stroke, and hypoxic-ischemic injury.  Insights into the mechanisms of MCD formation 
during brain development may yield new therapies for seizures associated with MCD and 
may even provide new strategies for the preventions of MCD during embryogenesis 
(Kisby et al., 2006; Pettersson et al., 2003).  
 Oxidative stress is one of the major risk factors for neurodegenerative diseases. 
Recently, there has been increasing evidence supporting the association between 
oxidative stress and epilepsy (Kunz, 2002; Waldbaum and Patel, 2010).  Mitochondrial 
3 
function plays a crucial role in reactive oxygen species (ROS) production.  Mitochondrial 
DNA (mtDNA) variations can cause inefficient oxidative phosphorylation leading to the 
accumulation of ROS, DNA damage, and increased brain lesion risk.  During evolution, 
several mutations have accumulated in mtDNA, representing specific single nucleotide 
polymorphisms (SNPs), allowing human populations to be categorized into various 
mtDNA haplotypes and haplogroups (Petterson et al., 2003; Abu-Amero et al., 2006).  
The roles of various mtDNA variations in the pathogenesis of MCD are scarce.  In this 
study, it is proposed that mitochondrial haplogroup and mtDNA variations can be risk 
contributors to MCD.  It is possible that the effect of mitochondrial genetic background is 
influenced by physiologic or environmental conditions, such as the hormonal state of an 
individual.  Whether the same group of mtDNA SNPs or haplogroups affects the risk of 
greater oxidative damage to mtDNA and of developing epileptic lesion requires further 
investigation.  Since mitochondria may play an important role in modulating oxidative 
stress, the identification of significant mtDNA SNPs and haplogroups associated with 
MCD would suggest that mitochondria may be involved in gene-environment interactions 
that may affect the pathogenic mechanism of disease.  Overall, the goal of this study was 
to investigate the mtDNA background and oxidative damage with an individual's risk of 
MCD in intractable pediatric epilepsy patients.  To achieve this goal brain tissue samples 
from forty-eight pediatric intractable epilepsy patients (non-neoplastic, n=23 and 
neoplastic, n=25) who have undergone brain resection surgery at the Miami Children’s 
Hospital, Miami, FL, during 2008-2009 were collected, and as references, eleven normal, 
non-epileptic, pediatric brain tissues were obtained from the NICHD Brain and Tissue 
Bank for Developmental Disorders at the University of Maryland. 
4 
Research Objectives  
Specific Aims 
Aim 1:  To compare mitochondrial DNA damage and mitochondrial DNA copy number 
in MCD and non-MCD pediatric intractable epilepsy patients.   
 
Aim 2:  To determine the single nucleotide polymorphism (SNP) in 
neurodevelopmentally important mitochondrial genes that encode for enzymes known to 
generate and detoxify reactive oxygen species (ROS) and mitochondrial haplotypes in 
MCD and non-MCD pediatric intractable epilepsy patients.   
 
Aim 3:  To determine the relationship between mitochondrial DNA damage, 
mitochondrial DNA copy number, mitochondrial haplotypes, and SNP variations in genes 
that encode for enzymes known to generate and detoxify ROS with the phenotype of 
MCD and non-MCD in pediatric intractable epilepsy patients. 
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CHAPTER II 
 
LITERATURE REVIEW 
Epilepsy 
Epilepsy is a neurological disorder of the central nervous system (CNS) which is 
characterized by recurrent seizures.  Epilepsy results from excessive synchronous firing 
of neurons in cortical networks (Prasad et al., 1999; Paredes and Baraban, 2002).  Seizure 
disorders are often classified as either symptomatic or idiopathic (cryptogenic) epilepsies.  
Symptomatic epilepsies are due to an identifiable cause, such as a metabolic disorder, 
brain trauma, or intracranial tumors; whereas, idiopathic disorders occur in the absence of 
identifiable causal factors (Mefford et al., 2010).  
 The overall incidence of epilepsy in North America is approximately 50 per 
100,000 persons each year, and the prevalence is 5-10 per 1,000 (Theodore et al., 2006).  
Thus, more than 3 million people in North America have epilepsy.  The incidence of 
epilepsy is highest for children below five years of age, and the elderly (Donner and 
Snead, 2006).  The majority of epilepsy in North Americans is cryptogenic, that is, there 
is no identifiable condition or insult.  Many childhood epilepsies are refractory to medical 
medicine (Statstrom et al., 2000).  
According to Shinnar and Pellock (2002), epilepsy affects approximately 0.5 to 
1% of all children through the age of 16 years.  The majority of active epilepsy cases are 
of childhood onset.  About 1.5 million Americans, including as many as 325,000 children 
between 5 and 14 years of age, have active epilepsy.  Every year in the United States, 120 
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of every 100,000 persons seeks medical attention for a newly recognized seizure, and of 
these 300,000 patients (40%, 120,000) are children under the age of 18 (Shinnar and 
Pellock, 2002).  The median age of seizure onset is between 5 and 6 years (Shinnar and 
Pellock, 2002).  Overall, epilepsy is the most common treatable serious neurologic 
disorder in children and young adults. It is also the third most common of all serious 
neurologic disorders. 
Persons afflicted with epilepsy are more likely to report reduced health-related 
quality of life than controls (Theodore et al., 2006).  Individuals with epilepsy tend to 
have reduced income, less likely to have full-time employment, and suffer from the 
persistent stigma.  According to Smeets et al. (2007), people with epilepsy experience 
objective restrictions, including those related to driving or working in situations in which 
they might be liable for injuries. “Mortality is increased in patients with epilepsy, and 
increased mortality risk in childhood-onset mortality is primarily seen in patients with 
neurologic abnormalities or intractable epilepsy (Shimmar and Pellock, 2002).”  The 
occurrence of childhood epilepsy appears to have long-term impact on education, 
employment, marriage, and fertility (Shimmar and Pellock, 2002).  Despite the high costs 
and severe disability, epilepsy may attract somewhat less research funding from public 
and private sources than other less common chronic neurological disorders (Theodore et 
al., 2006). 
A person with epilepsy may periodically experience epileptic seizures.  The most 
common types of epilepsy include petit mal, psychomotor epilepsy, and grand mal.  Petit 
mal occurs almost exclusively in children.  Children experiencing a petit mal seizure lose 
contact with reality for 5 to 30 seconds but do not lose consciousness or display 
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convulsions (Van De Graff, 2000).  Psychomotor epilepsy involves involuntary lip 
smacking or hand clapping.  In addition, if motor areas in the brain are not stimulated, a 
person with psychomotor epilepsy may wander aimlessly until the seizure subsides.  A 
serious form of epilepsy, grand mal seizure, is characterized by periodic convulsive 
seizures that render a person unconscious (Van De Graff, 2000).  According to Scher 
(2003), comparatively less attention has been focused on the pathogenic mechanisms 
leading to epileptogenesis during the perinatal stage of brain development through one 
month of postnatal life.  Thus, profound brain injury from maternal-placental-fetal-
neonatal disease has profound effects on brain development contributing to a spectrum of 
neurologic disorders including epilepsy, cognitive and behavioral disorders. 
Refractory (Intractable) Epilepsy 
 A significant number of patients with epilepsy will have continued uncontrolled 
seizures despite the availability of many anti-epileptic medications (Saneto and Wyllie, 
2000).  According to Beleza (2009), refractory epilepsy is established when there is 
inadequate seizure control despite using potentially effective AEDs at tolerable levels for 
1 to 2 years.  Refractory epilepsy patients show increased risk of psychiatric, 
psychosocial, and medical morbidities. Various studies have suggested that onset of early 
intractable seizures may be a significant risk factor for impairment of intellectual 
functioning and adaptive abilities (Saneto and Wyllie, 2000).  Resective surgery, based 
on the removal of the entire epileptogenic area without causing permanent neurological 
deficit, is one of the treatment forms for refractory epilepsy (Beleza, 2009).  In surgical 
series, focal cortical malformations and low-grade tumors were the most common in 
infants with intractable epilepsy.  According to Saneto and Wyllie (2000), low-grade 
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tumors included gangliomas, gangliocytomas, dysembryoplastic neuroepithiliomas, and 
astrocytomas.   
  The occurrence of epilepsy is highly associated with malformations of cortical 
development (MCD) which consists of dysplastic neuronal lesions (malformations) 
(Schwarktzkroin and Walsh, 2000; Hua and Crino, 2003; Hader et al., 2004; Rickert, 
2006).  The seizure type usually reflects the topology of the malformation.  Focal seizures 
occur with focal or multifocal MCD and secondarily generalized seizures with diffuse or 
bilateral MCDs (Kuzniecky and Jackson, 2008).  Currently, the molecular mechanisms 
responsible for the pathogenesis of MCD are not known.   According to Paredes and 
Baraban (2002), early-onset epileptic disorders associated with MCD are often resistant 
to conventional antiepileptic treatments and the regions characterized by disorganized 
cortex act as seizure foci.   
Focal cortical dysplasia (FCD) is commonly found in resected tissue from 
children afflicted by refractory epilepsy (Hader et al., 2004; Munkata et al., 2007).  
According to Guerrini et al. (2003), about 40% of children with drug-resistant epilepsy 
demonstrate cortical malformations.  In addition, there is an incidence of about 80% of 
cortical dysplasia in epileptic children younger than 3 years of age and is the most 
frequent pathology found in pediatric surgery patients (Cepeda et al., 2006).  However, 
the specific role played by the malformations in epileptogenesis remains unclear.  
Therefore, neuronal lesion formation and the occurrence of epileptic seizures in children 
is a great public health concern.   
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Malformations of Cortical Development 
 Malformations of cortical development (MCD) are developmental brain lesions.  
MCD are characterized by abnormal formation of the cerebral cortex (Crino, 2004).   
MCD appear to represent a profound maldevelopment of the cerebral cortical mantle 
(Crino et al., 2002).  MCD are lesions that may be focal or diffuse.  MCD include 
assorted groups of disorders known as neuronal migration disorders (NMDs) and cortical 
dysplasia (CD).  MCD can affect broad regions of the cerebral cortex such as 
hemimegalencephaly and classical lissencephaly, or may be restricted to focal areas such 
as Taylor-type focal cortical dysplasia (FCD) or tuberous sclerosis complex (TSC) 
(Crino, 2004; Montenegro et al., 2007).  In lissencephaly and polymicrogyria the normal 
6-layered organization of the cerebral cortex is replaced by a more primitive 4-layered 
organization.  MCD present a broad spectrum of structural changes which appear to result 
from changes in precursor neuronal or neuronal cells during cortical development at 
various stages such as:  (1) proliferation, (2) migration, (3) differentiation, and (4) 
apoptosis (Becker et al., 2002).     
There is a high clinical association between MCD and epilepsy in infants, 
children, and adults (Hannan et al., 1999; Schwartzkroin and Walsh, 2000; Pillai et al., 
2002; Crino, 2004).  However, not all cortical malformations are linked to epilepsy 
(Schwartzkroin and Walsh, 2000; Crino et al., 2002).  It is estimated that MCD accounts 
for about 20% of all epilepsies (Crino et al., 2002).  MCD-related epilepsy may be 
resistant to anti-epileptic drugs (AEDs) and may require resection.  MCD is the most 
common neuropathologic abnormality encountered in studies from several major 
pediatric epilepsy surgery centers in which resection was performed to treat infantile 
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spasms and intractable seizure disorders of childhood (Crino et al., 2002).  Advances in 
brain imaging have demonstrated high frequencies of cortical malformations in childhood 
epilepsy (Chevassus-au-Louis et al, 1998).  In addition, the more severe the MCD, the 
earlier onset of symptoms and the more severe the epileptic syndrome (Mischel et al., 
1995).  Thus, MCD are increasingly recognized as causes of mental retardation and 
epilepsy.  Yet, the sequence of events which lead to abnormal cortical development 
epileptogenesis is not known.    
According to Montenegro et al. (2002), there are several reports that indicate 
prenatal events are likely to be involved in the pathogenesis of MCD.  Since brain 
development commences early in fetal life and continues until adolescence, exposure to 
environmental chemicals at an early stage may be the leading cause of 
neurodevelopmental disorders (Allen and Walsh, 1999).  In 2006, the National Research 
Council has concluded that 3% of developmental disabilities are a direct consequence of 
exposure to environmental neurotoxins such as alcohol, pesticides, heavy metals, and 
polychlorinated biphenyls (PCBs), and that 25% result from the interaction between 
environmental factors and genetic susceptibility.  In addition, several studies indicate that 
genetic and environmental factors contribute to causation of MCD and lead to 
neurodevelopmental delay (Kuzniecky and Barkovich, 2001).  Therefore, insights into 
the mechanisms of MCD formation during brain development may yield new therapies 
for seizures associated with MCD and may even provide new strategies for the 
preventions of MCD during embryogenesis (Price and Willshaw, 2000). 
 According to Schwarzkroin and Walsh (2000), the majority of diffuse types of 
malformations exhibit normal cell types that are abnormally localized and/or oriented and 
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are associated with abnormal circuits.  In contrast, abnormal cell types such as giant cells 
and balloon cells that may serve as “pacemakers” of epileptic discharge are 
characteristics of focal malformations.  MCD result from abnormalities occurring in the 
three different stages of brain development.  The three stages of brain development 
include: (1) neuronal and glial proliferation, (2) migration, and (3) cortical organization 
(D’Incerti, 2003).  The morphology of individual neurons in most MCD is abnormal, 
which suggests a pervasive disruption of many steps important in neuronal development 
(Crino et al., 2002).  In the occurrence of a seizure, the type of malformation associated 
with any given type of seizure disorder may vary significantly.  For example, infantile 
spasms (IS) have been associated with lissencephaly, tuberous sclerosis, and cortical 
dysplasia (CD) (Schwartzkroin and Walsh, 2000).  On the other hand, distinct forms of 
structural malformations may be associated with diverse manifestations of seizure types 
(Schwartzkroin and Walsh, 2000).  Thus, the variability in types of malformations and 
seizure types reflects the maturational state of the brain, and the brain’s tendency to 
generate either focal or generalized seizures.  In addition, the complexity of these 
relationships is aggravated due to the lack of uniformity in the nomenclature of MCD 
describing both structural and functional abnormalities.   
Origins of MCD 
 It has been postulated that the stage of development in which the abnormality 
occurs is linked with the nature of the dysplastic lesion.  Developmental neurobiologists 
have described six distinct periods of cortical development (Schwartzkroin and Walsh, 
2000).  The six periods of cortical development identified are:  (1) pattern formation, (2) 
cell proliferation, (3) cell fate specification, (4) cell migration, (5) cell differentiation, and 
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(6) synapse/circuitry formation.  During pattern formation the gross divisions of the brain 
are specified.  Neural and glial precursor cells are generated in the ventricular 
proliferative zone during the cell proliferation period.  During cell fate specification the 
destination and general cell type is determined.  Cells migrate from the proliferative zone 
to travel to their designated destination occurs during cell migration.  Cell type 
manifestation is achieved during cell differentiation.  Lastly, specific networks of 
connectivity, as well as, synaptic pruning and apoptosis are determined during 
synapse/circuitry formation (Schwartzkroin and Walsh, 2000; Crino et al., 2002; 
Montenegro et al., 2002).   
 Complex patterns of gene expression occur in each period of development 
resulting in specific intracellular and extracellular mechanisms.  It is stipulated that a 
disruption and/or modification of these signal mechanisms result in abnormalities in the 
cortical structure.  For example, increased cell proliferation may produce too many cells 
and result in an abnormally thickened cortex.  Alterations or absence of appropriate 
migration cues may result in heterotopically placed neuronal populations (Schwartzkroin 
and Walsh, 2000).   Thus, the timing of the abnormality greatly determines the nature of 
the malformation.  Overall, prenatal and/or genetic factors are suspected to play a 
pathogenic role since neuronal migration to cerebral cortex in humans are believed to 
occur in the first half of gestation (Palmini et al., 1994). 
Etiology of Malformations of Cortical Development 
MCD result from abnormalities occurring in the three different stages of brain 
development.  The three stages of brain development include: (1) neuronal and glial 
proliferation, (2) migration, and (3) cortical organization.  The morphology of the 
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individual neurons found in MCD is abnormal, which suggest a pervasive disruption of 
many important steps in neuronal development.  In the occurrence of a seizure, the type 
of malformation associated with any given type of seizure disorder may vary 
significantly.  For example, infantile spasms (IS) have been associated with 
lissencephaly, tuberous sclerosis (TSC), and cortical dysplasia.  The variability in the 
types of malformations and seizure types reflects the maturational state of the brain, and 
the brain’s tendency to generate either focal or generalized seizures.  In addition, the 
complexity of these relationships is aggravated due to the lack of uniformity in the 
nomenclature of MCD describing both structural and functional abnormalities.  However, 
little is known regarding the molecular and biochemical signals that control proliferation, 
migration, and organization of the cells involved in either normal or abnormal cerebral 
cortical development. Yet, several environmental agents such as rubella, lead, methyl 
mercury, alcohol, retinoids, and thalidomide have been identified to be toxic to the 
developing central nervous system (CNS) by interfering with specific developing 
processes (Rodier, 1995).    
Development of Cerebral Cortex 
 The development of the cerebral cortex commences on the seventh week of 
gestation and continues through the twenty-fourth week (Crino et al., 2002).  The cerebral 
cortex is formed in four stages.  During the first stage, mitosis and proliferation of the 
progenitor cells in the embryonic vascular zone (VZ) and from the ganglionic eminence 
(GE) occurs.  In the second stage of cerebral cortex formation, cells exit mitotic phases of 
the cell cycle and commit to neural lineage.  The third stage is characterized by the 
dynamic migration of post-mitotic neurons from the VZ and GE.  The final stage of 
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cerebral cortex formation is the establishment of the cortical laminae consisting of six 
layers (layers I-VI) (Crino et al., 2002).  Through the process of cortical lamination, 
nascent cells migrate from the VZ along the radial glial fibers into the developing cortical 
plate through an “inside-out gradient.”  Neurons which are destined to reside in the 
deeper laminae (layer VI) arrive first in the cortical plate.  Thus, the subsequent groups of 
neurons migrate through each preceding layer and established layer (Crino et al., 2002).   
Types of MCD 
 MCD may be categorized as: (1) cell fate, proliferation, and specification 
disorders, (2) disorders of neuronal migration, or (3) disorders of unspecified mechanism 
or developmental context.   
Cell fate, Proliferation, and Specification Disorders 
Tuberous sclerosis (TS) 
 MCD that are considered cell fate, proliferation, and specification disorders 
includes tuberous sclerosis (TS).  Tuberous sclerosis (TS) is a disorder which involves 
multiple organs and occurs in about 1 in 6000 live births (Miloloza et al., 2002; 
Hengstschlager and Rosner, 2003; Shah and Hunter, 2005).   TS is a complex disorder 
characterized by cortical tubers which are strongly associated with epilepsy (Crino et al., 
2002).  In TS, neuroradiological features include: (1) subependymal hamartomas, (2) 
cortical hamartomas, (3) subcortical hamartomas, (4) linear white matter abnormalities, 
and (5) giant cell subependymal astrocytomas (D’Incerti, 2003).  On imaging studies, 
subependymal hamartomas appear as nodules bulging into the lateral ventricles.  
According to D’Incerti, the nodules are often calcified and easily recognized on CT.  
Both cortical and subcortical hamartomas involve the cortex and subcortical white matter, 
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and there is usually an enlargement of the affected areas.  Giant cell astrocytomas are 
extremely similar to subependymal hamartomas, except that they develop proximally to 
the foramina of Monro and often cause obstructive hydrocephalus, a disorder often 
referred to as “water on the brain” (D’Incerti, 2003).  Giant cells are a unique cell type 
that is not seen in other neurological disorders, except severe FCD.  Hence, giant cells are 
a defining facet of TS.   
 Dysplastic stem cells in the germinal zone give rise to the hamartomas (tubers).  
In addition, the dysplastic stem cells give origin to dysplastic glial cells, dysplastic 
neurons, and cells containing both dysplastic glial and neuron characteristics (Soucek et 
al., 2001; D’Incerti, 2003).  The accumulation of disorganized collections of dysplastic 
cells in the subependymal and cortical regions are a result of the abnormal differentiation 
of dysplastic cells.  Interestingly, the cellular compositions of hamartomas are the same 
as those found in focal cortical dysplasia with balloon cells (D’Incerti, 2003).  Thus, TS 
involves incomplete or defective migration of cortical neurons. 
 Tuberous sclerosis is an autosomal dominant genetic disorder (Crino et al., 1996; 
Ito and Rubin, 1999; Soucek et al., 2001; Wataya-Kaneda et al., 2001; D’Incerti, 2003; 
Narayanan, 2003, Wong, 2007).  TS results from mutations in TSC1 and TSC2, which are 
two non-homologous genes.  Mutations in the TSC1 and TSC2 genes have been 
identified.  In TSC1 the mutation location is 9q34, whereas, the mutation location for 
TSC2 is 16p13.3 (Soucek et al., 2001; Wataya-Kaneda et al., 2001; D’Incerti, 2003; 
Narayanan, 2003, Wong, 2007).  The TSC1 gene encodes for the 130kDa protein known 
as hamartin (Miyata et al., 2004).  According to Crino et al. (2004), hamartin has virtually 
no homology to known vertebrate genes.  The TSC2 gene encodes for the 200K protein 
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tuberin (Crino et al., 2004; Miyata et al., 2004).  Tuberin’s structure differs from that of 
hamartin’s.  The mRNA and proteins of both hamartin and tuberin are expressed in 
normal tissue.  Hamartin and tuberin has been found to be expressed in the brain, liver, 
cardiac muscle, kidney, adrenal cortex, and skin (Crino et al., 2004).  Studies have 
demonstrated that hamartin interacts with the ezrin-radixin-moesin (ERM) family of the 
actin-binding proteins which may contribute to the cell-cell interactions, cell adhesion, 
and cell migration (Lamb et al., 2000).  According to Paredes and Barbaran (2002), 
tuberin displays GTPase activating protein (GAP) activity on Rap1 and Rab5, members 
of the super family of Ras-related proteins.  Rap1 is believed to function in the regulation 
of DNA synthesis and cell cycle transition (Crino et al., 2004).  Tuberin promotes entry 
of the cell cycle into Go phase and inhibits the G1/S phase transition (Astridinis et al., 
2003).  In addition, phosphorylation of tuberin by Akt negatively regulates the inhibition 
of p70S6K.  Hamartin is thought to regulate cell adhesion.  According to Becker et al. 
(2002), loss of heterozygosity (LOH) studies show allelic losses at TSC1 (9p434) and 
TSC2 (16.6p13.3) in lesions of TSC patients and in sporadic tumors of individuals not 
afflicted with TSC indicates a tumor suppressor gene function   Tuberin and hamartin 
serve to form a tumor suppressor complex that plays a central role in the insulin/PI3K-
signalin pathway (Paredes and Barbaran, 2002; Schick et al., 2007a, Wong, 2007).  
Mutations in TSC1 and TSC2, that promote activation of mTOR, cause benign 
hamartomas that rarely metastasize (Fisher and White, 2004).  Therefore, mutations of 
hamartin or tuberin in TSC results in the hyperactivation of the downstream of the mTOR 
pathway and the associated kinase signaling cascades and translational factors which 
result in increased cell growth and proliferation.  
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Disorders of Neuronal Migration 
Lissencephaly 
 Lissencephaly is a severe developmental malformation which is highly associated 
with neurological deficits and epilepsy (Willmore and Ueda, 2002).  According to Crino 
et al. (2004), there are two pathological subtypes of lissencephaly, referred to as (1) type I 
(classical), and (2) type II (cobblestone).  In lissencephaly, there is poor sulcation or the 
smooth surface of the brain is absent (D’Incerti, 2003).  In lissencephaly, there is stunt or 
arrest of neuronal migration resulting by a disruption of radial glial fibers.  As a result of 
the disruption, there is abnormal lamination of the cortex (usually there is disruption of 
the neurons in four layers) (D’Incerti, 2003).  The terms agyria (no gyri) and pachygyria 
(broadened gyri) are used to describe the appearance of the surface the brain.   
Agyria 
 Agyria (complete lissencephaly) refers to the absence of sulci on the brain’s 
surface, whereas, pachygyria (few and broadened gyri) is incomplete lissencephaly.  
Agyria is associated with the deletion of chromosome 17 and it is observed in patients 
with Miller-Dicker syndrome, which was one of the first MCD genes discovered, LIS-1 
(D’Incerti, 2003; Crino et al., 2004).  According to Crino et al. (2004), Miller-Dieker 
lissencephaly syndrome is an autosomal recessive disorder which is characterized by type 
I (classic) lissencephaly, craniofacial dysmorphism, profound mental retardation, and 
epilepsy.   
 Agyria has been observed in the male offspring of women with affected by band 
heterotopia.  These male offspring present with a mutation in the doublecortin gene 
(DCX) in chromosome Xq 22.3, also known as X-linked lissencephaly (XLIS) (Wilmore 
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and Ueda, 2002; D’Incerti, 2003; Crino et al., 2004; Wang et al., 2006).  XLIS is also 
characterized by type I lissencephaly.  Interestingly, DCX gene mutations in females 
results in the subcortical band heterotopia syndrome.  The mutations which occur in the 
DCX gene may result from deletion, nonsense, missense, or splice donor mutations.  DCX 
gene encodes a 40kDa protein that is normally expressed during neuronal migration 
(gestational weeks 12 through 20) (Crino et al., 2004).  Thus, DCX mutational effects will 
only be exerted during this neuronal migration.   Overall, LIS-1 and DCX mutations 
account for 70 to 80% of classical lissencephaly syndromes (Crino et al., 2004).   
Microlissencephaly 
 Microlissencephaly is categorized as one of the generalized forms of MCD.  
Severe microcephaly is the main feature always observed in microlissencephaly 
(D’Incerti, 2003).  It has been postulated that microcephaly may be caused by a 
disturbance in neuron proliferation.  In addition, an abnormal gyral pattern with few gyri 
and shallow sulci are also observed in microlissencephaly.  Yet, based on MRI features 
and clinical course, the thickness of the cortex is predominantly normal in 
microlissencephaly.   
Microcephaly 
 Microcephaly has been associated with maternal problems such as: (1) 
alcoholism, (2) diabetes, and (3) German measles (rubella).  Genetic factors may play a 
role in causing some cases of microcephaly.  Newborns affected with microcephaly 
generally exhibit neurological defects and seizures.  In addition, severe impairment in 
intellectual development and disturbances in motor functions may appear later in life. 
Waterham et al. (2007) examined a newborn girl with microcephaly and found defects of 
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the fission of both mitochondria and peroxisomes and a dominant-negative mutation in 
the dynamin-like protein 1 gene (DLP1).  DLP1 has been implicated in the fission of 
mitochondria and peroxisomes.  In addition, over expression of the mutant DLP1 in 
control cells reproduced the defects in mitochondria and peroxisome fission (Waterham 
et al., 2007). 
Periventricular nodular heterotopia (PNH) 
 Periventricular nodular heterotopia (PNH) consists of nodules of gray matter that 
are located along the ventricles which result from a total failure of the migration of some 
neurons (Guerrini and Marini, 2006).  Many PNH patients present with epileptic seizures.  
PNH is an X-linked dominant disorder.  PNH displays high rates of male hemizygous 
lethality (Guerrini and Marini, 2006).  Mutations in the FLNA gene which is located in 
Xq28 have been identified in PNH.  FLNA codes for the protein Filamin A.  Models of 
FLNA function postulate that FLNA acts early in development and acts as a switch 
required to neurons to become competent for subsequent migration (Guerrini and Marini, 
2006).  Interestingly, heterozygous FLNA females present borderline to normal 
intelligence and mild to intractable epilepsy.   
Disorders of Unspecified Mechanism or Developmental Context 
Fukuyama muscular dystrophy syndrome (FCMD) 
 Fukuyama muscular dystrophy syndrome (FCMD) is an MCD of unspecified 
mechanism.  FCMD is a rare autosomal recessive disorder which exhibit type II 
lissencephaly (cobblestone lissencephaly) (Crino et al., 2004).  FCMD is associated with 
seizures and debilitating muscular dystrophy.  FCMD has been primarily observed in 
Japan.  FCMD gene is found in chromosome 9q31 and encodes for the protein fukutin.  
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FCMD has been primarily observed in Japan, and it is the most common congenital 
muscular dystrophy in Japan.   
Polymicrogyria (PMG)  
 Polymicrogyria (PMG) is a neuronal disorder in which the cortex exhibits various 
small microgyri which expose a pattern of a 4-layered lamination (Crino et al., 2004).  
PMG reflects an irregular process occurring during the late stages of corticogenesis.  
Montenegro et al.’s (2002), pathologic findings of a necrotic layer in patients with 
layered PMG supports the traditional theory that these abnormalities are a form of 
destructive lesion.  PMG has been associated with a variety of neurological syndromes.  
The majority of children with polymicrogyria have some degree of developmental delay 
or disabilities, feeding difficulties, respiratory problems, mental retardation, and seizures.  
PMG results from differing causes that may be both genetic and non-genetic in nature, 
such as: (1) a genetic disorder (inherited in a sporadic manner), (2) viral infection of the 
baby during the second trimester (i.e. cytomegalovirus infection), (3) insufficient blood 
supply to the baby’s brain during the second trimester (i.e., umbilical cord entanglement), 
and (4) other causes that have yet to be identified.  Yet, the molecular pathogenesis of 
PMG has not been identified.  However, the molecular basis of PMG is beginning to be 
elucidated with the identification of GPR56 gene (for bilateral frontoparietal PMG).  It is 
believed that functional studies of the GPR56 gene product will clarify the causes of 
PMG, possibly the mechanisms of normal cortical development, and the regional 
patterning of the cerebral cortex.   
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Hemimegalencephaly (HME) 
 Hemimegalencephaly, also known as unilateral megalencephaly, is characterized 
by a disproportionately enlarged hemisphere (D’Incerti, 2003).  The affected hemisphere 
contains malformations in the cortex and the white matter.  Abnormal lamination, cortical 
heterotopia, and focal pachygyria are cortical abnormalities found in 
hemimegalencephaly.   Calcification of the intracortical may also be present in 
hemimegalencephaly.  The white matter is abnormally increased in this disorder. The 
opposite hemisphere may be normal.  However, subtle malformations and/or even focal 
dysplasias have been observed radiographically (Crino et al., 2004).  Typical clinical 
manifestations of hemimegalencephaly are hemiparesis, developmental delay, and 
intractable epilepsy.         
Focal Cortical Dysplasias (FCD) 
 Focal cortical dysplasias (FCD) belong to a group of disorders described as 
disorders of cortical development, cortical dysgenesis, cortical dysplasias, or neuronal 
migration disorders (Wang et al., 2006).  FCD is closely associated with medically 
intractable epilepsy (Montenegro et al., 2002; Hua and Crino, 2003).  One of the most 
common neuropathological findings in tissue resected from refractory epileptic pediatric 
patients is FCD.  A surgical series for childhood temporal lobe epilepsy (TLE) revealed 
FCD in 18% of pediatric patients (Miyata et al., 2004).  According to Rickert (2006), 
studies indicate the pathogenesis for FCD may result from multifactorial influences such 
as (1) gene mutations, (2) in utero injuries, (3) peri-natal injuries, or (4) post-natal 
injuries.   
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According to Hildebrandt et al (2005), FCD present with aberrant architectural 
organization of the neocortex and the adjacent white matter.  Histologically, FCD are 
defined by disorganized cortical lamination and the presence of a disorganized cortical 
lamination, heterotopic neurons (HNs), dysplastic neurons (DN), and balloon neurons 
(BN) that derive from a population of cells or post-mitotic neurons during cortical 
development (Hua and Crino, 2003).  FCDs are classified on either their pathological 
characteristics or origin of the pathological elements.  Histological findings in FCD 
include architectural abnormalities.  The observed abnormalities include columnar 
disorganization and cortical laminar disorganization.  Severe forms of FCD are 
characterized by the occurrence of abnormal neuronal elements, such as dysmorphic 
neurons, giant cells, balloon cells, and immature neurons (Wang et al., 2006).  
Dysmorphic neurons have a distorted axon, cell body, and dendrite morphology which 
are caused by the accumulation of neurofilaments in the cytoplasm.  Giant cells are 
normal in shape but have an increased cell size, and there appears to be no accumulation 
of neurofilaments.  According to Hua and Crino (2003), FCD’s histological features 
suggest developmental abnormalities affecting select steps during neural proliferation, 
differentiation or migration.  Nevertheless, the precise developmental stage in which 
FCD are generated is unknown. 
The molecular etiology of FCD has been difficult to define since FCD appears to 
be a sporadic disorder and no family pedigrees have been identified.  In addition, since 
monozygotic twins are discordant for FCD, it has been suggested that FCD may arise 
through non-inherited and possibly multifactorial mechanisms (Hua and Crino, 2003).  
However, a study has suggested that polymorphisms in TSC1 gene is associated with 
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some FCD cases provides a genetic backdrop for environmental events to alter cortical 
lamination.  Hence, gene mutations or altered gene expression induced by environmental 
events in several progenitor cells may alter the structural integrity of nascent neurons 
leading to the heterogeneous and aberrant cell morphologies found in FCD.  Over time, 
researchers have attempted to classify FCD (Rickert, 2006).  
 Currently, there is no uniform classification system for FCD.  Barkowich 
introduced a classification system which organized several types of MCD according to 
embryologic and pathophysiologic features.  Utilizing Barkovich’s classification system, 
cortical dysplasias associated with FCD may be categorized as (1) mild MCD, (2) FCD 
type I, and (3) FCD II (Taylor-type) (Rickert, 2006) (Table 1.0).  
Taylor-Type FCD 
 Taylor-Type FCD, also known as FCDbc (FCD-balloon cell type), is a subtype of 
FCD which has been linked to chronic intractable epilepsy (Becker et al., 2002; Hua and 
Crino, 2003; Hildebrandt et al., 2005; Wang et al., 2006).  In Taylor-Type FCD, 
histopathological analysis has demonstrated glioneuronal malformations which are 
greatly similar to cortical tubers in patients with tuberous sclerosis.  Taylor-Type FCD 
lesions display a derangement of the cortical laminar structure, and are composed of 
dysplastic cytomegalic neurons, and balloons cells.  In a surgical series, Taylor-Type 
FCD was the most common developmental pathology identified (Sisodaya, 2004).  The 
incidence for Tyler-Type FCD is not well known because high-resolution magnetic 
resonance imaging (MRI) in studies may not always allow its detection.   
The molecular etiology of FCD has been difficult to define since FCD appears to 
be a sporadic disorder and no family pedigrees have been identified.  Monozygotic twins 
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are discordant for FCD.  Therefore, it has been suggested that FCD may arise through 
non-inherited and possibly multifactorial mechanisms.  Currently, the exploration for 
FCD candidate genes is an area of intense research.   
Gangliogliomas and Dysembrioplastic neuroepithelial tumors 
 Gangliogliomas are composed of neoplastic, highly differentiated glial cells, and 
dysplastic neurons (Schick et al., 2007a).  Gangliogliomas are the most frequent tumors 
found in patients with focal epilepsy (Schick et al., 2007b).  Gangliogliomas account for 
5% of childhood tumors (Schick et al., 2007a).  The histological hallmarks of 
gangliogliomas are the combination of dysplastic neurons that are combined with 
neoplastic glial cells.  According to Schick et al. (2007a), gangliogliomas’ neoplastic 
nature is provided by the proliferative activity of the glial cells.  Several features of 
gangliogliomas, such as (1) their focal nature, (2) differentiated glioneuronal phenotype, 
and (3) clinical character, indicate an origin of a developmentally compromised or 
dysplastic precursor lesion.  CD34, a stem cell epitope, is greatly expressed in 
gangliogliomas (Rickert, 2006; Schick et al., 2007a).   Gangliomas are low grade tumors 
classified as WHO grade I or II (Rickert and Paulus, 2001).  Dysembrioplastic 
neuroepithelial tumors (DNETs), which are comprised of ‘floating neurons’ and 
oligodendroglial-like elements, are the second major group of glioneuronal tumors (Table 
2.0).   DNETs are classified as WHO grade I and considered as a mixed neuroglial tumor 
and research has suggested a probable developmental defect occurring during the second 
trimester in utero (Chang et al., 2010; Spalice et al., 2010). 
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MCD Genes 
 Information regarding the molecular pathogenesis of MCD has been available 
only since the past decade.  According to Crino et al (2002), MCD may be observed in 
large chromosomal rearrangements and as the consequence of a single gene mutation.  
Eight genes have been identified through positional cloning strategies in human pedigrees 
with inherited types of MCD (Table3.0) (Crino et al, 2002).  These genes include: TSC1, 
TSC2, LIS-1, DCX, and FCMD.  Further research is needed to elucidate other genes 
involved in MCD.  Montenegro et al. (2002) believe that abnormal migration in MCD is 
mainly genetically determined, either as a familial trait or a de novo mutation, however, 
prenatal events could act in conjunction with genetic predisposition to determine the final 
phenotype.   
Effects of Environmental Factors and MCD 
 The developing central nervous system (CNS) is much more vulnerable to injury 
from toxic agents than the adult (developed) CNS (Rodier, 1995).  Environmental events 
causing injury to the CNS that have been associated with MCD include: hypoxic-
ischemic injury, head injury, and stroke.  According to Ottman (1997), approximately 
25% of prevalent epilepsy is associated with an antecedent central nervous system injury 
(e.g., head trauma, stroke, or brain infection) and, accordingly, is classified as 
"symptomatic."  Human and animal studies have demonstrated that in utero exposure to 
environmental factors such as (1) teratogenic, (2) physical, and (3) biological factors 
result in neuronal migrational disorders (Table 4.0).  These environmental factors 
include: (1) infection with cytomegalovirus, (2) infection with toxoplasmosis, (3) ethanol, 
(4) cocaine, and (5) ionizing radiation (Chevassus-au-Louis et al., 1999; Gressens, 2000).  
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In addition, the effect of environmental agent on the developing brain differs depending 
on the stage in which the insult is delivered (Rodier, 1995). 
Teratogenic Factors 
 Alcohol and cocaine interfere with neurogenesis and neuronal migration which 
results in microcephaly and disorganized cortical cytoarchitecture.  In addition, 
administration of cocaine to pregnant mice and monkeys induce abnormal addressing of 
neurons in the neocortical plate (Fantel, et al, 1997; Gressens, 2000).  Animal models 
induce cortical dysplasia though the exposure of (1) freeze lesion, (2) irradiation, and (3) 
methlylazoxymethanol (MAM) (Bernadete and Kriegstein, 2002).  The MCD model that 
most realistically replicates the morphology of human cortical dysplasia is based on the 
prenatal exposure to MAM (Chevassus-au-Louis,1998; Gressens, 2000; Choi, 2005; 
Harrington et al., 2007).  MAM is an anti-proliferative, cytotoxic, and DNA alkylating 
agent that induces cerebral heterotopias that are very similar to those observed in human 
cortical dysplasia.  MAM alters migration and differentiation of neurons leading to 
heterotopia.  Injection of MAM into a pregnant rats at day 14 or 15 exposes the fetuse(s) 
disrupts cell proliferation at the time of neocortical and hippocampal neuron formation.  
Prenatal MAM exposure results in cortical dysplasia, microcephaly, periventricular 
heterotopia, and hippocampal heterotopia (Watanabe, et al., 1998).  Prenatal exposure to 
thalidomide in the rat model results in the inhibition of angiogenesis and significant 
morphological alterations in cortical and hipocampal regions (Hallene et al., 2006). 
Thalidomide exposure resulted in abnormal neuronal development that was associated 
with vascular malformations and a leaky blood-brain barrier.  In addition, neuronal 
hyperexcitability was found in these abnormal regions (Hallene et al., 2006).  However, 
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the mechanisms by which all of these teratogenic environmental factors disturb neuronal 
migration are not known.       
Physical Factors 
 In animal studies, freeze lesions are produced by touching a freezing probe to the 
skull surface of the newborn rats.  Loss of normal cortical layering beneath the site of 
contact occurs.  As a result of microgyrus develops with the formation of a four-layered 
cortex instead of a normal neocortex (Schwartzkroin and Walsh, 2000).  In addition, the 
number of cells reduces in the dysplastic region in freeze lesion. Ionizing radiation is an 
environmental agent with the property of killing neurons (Rodier, 1995).  Irradiation of 
fetal rats at day 12 through 19 produces cortical abnormalities which range from subtle 
cortical thinning to a dramatic cell loss and dysplasia.  Irradiation exposure interferes 
with DNA replication in proliferating cells (Schwartzkroin and Walsh, 2000).  Irradiation 
treatment effects range from subtle cortical thinning, loss of cell numbers, to severe 
dysplasia.  Lastly, other prenatal traumas such as hypoxia can damage the radial glial 
fibers and may give rise to migration abnormalities resulting in heterotopic cell clusters 
and/or thinned cortex and may be accompanied by abnormal cortical lamination.  
 Studies have shown that during and after hypoxic injury vascular endothelial 
growth factors (VEGF) is upregulated.  There are four VEGF-like families: (1) placental 
growth factor (PIGF), (2) VEGFB, (3) VEGFC, and (4) VEGFD.  VEGF induces 
angiogenesis, vascular permeability, and inflammation (Croll et al., 2004; Troost et al, 
2008).  VEGF has been implicated in the breakdown of the blood-brain-barrier after 
hypoxic injury.  After pilocarpine-induced status epilepticus (SE) there is an increase of 
VEGF in neurons and glia.  In addition, to the breakdown of the blood-brain-barrier, 
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hypoxic injury also results in endothelial apoptosis, upregulation of adhesion molecules, 
and angiogenesis.  VEGF also activates glia and could impact seizure.  VEGF also 
induces inflammation that is characterized by monocytic infiltrate.  VEGF is upregulated 
by IL-1 and TNF-α, coincidentally, these cytokines are upregulated after seizures.  
Hence, suggesting that IL-1 and TNF-α increase the potential for seizures (Croll et al., 
2004).  Interestingly, VEGF also presents neuroprotective and could protect vulnerable 
cells from damage associated with seizures.  VEGF protects cultured hippocampal 
neurons against glutamate excitotoxicity and seizure-induce injury (Croll et al., 2004).  
VEGF exerts its neuroprotective actions by activating the Akt survival pathway.  Thus, in 
response to hypoxic insult VEGF’s actions are both damaging and neuroprotective.   
 According to Troost et al. (2008), members of the VEGF family are key signaling 
proteins in angiogenesis induction and regulation during development and pathological 
conditions.  Signals mediated through the VEGF family proteins and their receptors have 
demonstrated direct effects on neurons and glial cells.  Troost et al (2008) investigated 
the expression of VEGFA, VEGFB, and their receptors (VEGFR-1 and VEGF-2) in FCD 
type IIB with intractable epilepsy.  Their study findings demonstrated a high expression 
of VEGFA, VEGFB, and VEGF receptor in the dysplastic neurons.  The high expression 
of both VEGFA and VEFG with their receptors in the FCD specimens suggests 
autocrine/paracrine effects on dysplastic neurons.  These effects could play a role in FCD 
development by the death of abnormal neurons (Troost et al., 2008).   
Biological Factors 
 Maternal disease may contribute to uteroplacental insufficiency syndromes that 
may alter brain development after injury throughout the ante partum period or during 
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stresses of labor and delivery.  For example, pathophysiologic mechanisms that are 
involved in asphyxia and inflammation may be expressed by placental function and 
structures.  Placental vasculopathies or pathological lesions which may adversely affect 
fetal organ structure and function may result from the injury to the villus, stromal, or 
vascular components within maternal or fetal surfaces of the placenta (Scher, 2003).  In 
addition, fetal brain infections may result in brain malformation.  Prenatal infection with 
toxoplasmosis has resulted in brain malformation, mental retardation, and seizures 
(Gressens, 2000).  Other fetal brain infections that have been found in brain 
malformations are rubella, cytomegalovirus, and herpes simplex. 
Gene-environment Interactions and MCD 
 Since MCD may result from an abnormality during prenatal brain development, 
the gene-environment interactions must be considered.  The developing organism is a 
biological system that is maturing over specific time intervals during which adverse 
conditions result in environmental stress. The time intervals in which environmental 
stress may occur are embryonic, fetal, and perinatal periods.  These adverse conditions 
include exposure to environmental factors (teratogenic, physical, or biological) and 
environmental events (i.e. hypoxic-ischemic injury, head injury, and stroke).  The stage 
in brain development in which these events occurs influence the expression of a disease 
process resulting in brain injury that may expressed as neonatal seizures and epileptic 
disorders (Kisby et al., 2006).  Thus, post-mitotic alterations in structure and functions 
may result epigenetic effects combined with inherited traits.   
 As previously mentioned, MCD are traditionally classified by the prenatal stages 
of brain development.  Yet, there is genetic variability of expression are observed through 
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the variable phenotype expressions of the same disorders as described for tuberous 
sclerosis.  After environmental stress pleomorphisms can define a disease with differing 
patterns of malformation.  Differing brain lesions reveal the stage of neural 
developmental process and the susceptibility of the specific brain regions in response to 
injury.  Gene expression alterations for specific molecular processes on the cells, such as 
neurotransmitters and synapses will later assist in the occurrence of neonatal seizures and 
later as epilepsy during childhood.   
Epigenetics 
 Epigenetics refers to the heritable traits (over rounds of cell division and 
sometimes transgenerationally) that do not involve changes to the underlying DNA 
sequence.  It is important to recognize that a large percentage of early-onset seizure 
disorders, mainly associated with cortical encephalopathy, are generated by epigenetic 
influences, such as trauma to the immature brain which occur during pregnancy or during 
the birth process (Schwartzkroin and Walsh, 2000).  The effects of epigenetics on brain 
function and structure have been demonstrated in animal models of asphyxia.  After an 
acute asphyxial insult there are changes in global gene expression within the immature 
brain.  In presynaptic and postsynaptic activities epigenetic effects result in either up-
regulation or down-regulation of gene activities.  Hence, epigenetic alterations in gene-
expression the asphyxial model resulted in global alterations in synaptic brain activity 
(Schwartzkroin and Walsh, 2000).  Hence, in MCD gene-environment interactions may 
grade degrees of risk in the context of genetic pleomorphism and environmental factors.  
Gene profiles may predispose specific mother-fetal pairs to the harmful effects of 
environment factors such as trauma, infection, and asphyxia.  
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MCD Epileptogenesis 
 Many studies addressing environmental factors that result in MCD try to identify 
the mechanisms that result in the epileptogenesis in MCD.  Abnormal electrical discharge 
in the brain results in epileptic activity (Paredes and Baraban, 2002).  Currently, there are 
several hypotheses regarding the mechanisms of epileptogenesis in MCD, primarily in 
FCD.  These hypotheses may be classified whether they stipulate that the seizure starts 
within the lesion or the perilesional (surrounding) regions.  According to Paredes and 
Baraban (2002), aberrant electrical activity in cortical malformations could result from 
synaptic changes that may occur on the postsynaptic cell itself, such as receptor 
alterations.  Various studies have demonstrated abnormalities in postsynaptic 
neurotransmitter receptor subtypes in resected dysplasia tissue.   
Neuronal Excitotoxicity 
Neurons are specialized brain cells for the rapid transmission of information over 
long distances.  Neurons receive information at their dendrites and integrate the 
information in the cell body (Raven and Johnson, 1996).  Information is transmitted in 
neurons in the form of electrical impulses that are sent out from the cell body along the 
axon.  Excitotoxicity contributes to neuronal degeneration and may play a role in epilepsy 
(Arundine and Tymianski, 2003).  Excitotoxicity is the pathological process in which 
neurons are damaged and killed by the over- activation of receptors by excitotoxins such 
as neurotransmitters (Aarts and Tymianski, 2003).  Neurotransmitters which act as 
excitotoxins are N-methyl-D-aspartate (NMDA), kainic acid, and glutamate.  High levels 
of calcium ions (Ca++) enter the cell due to the excitotoxin’s actions.  The high influx of 
Ca++ activates several enzymes which damage the cell’s structures and DNA.  The 
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activated enzymes include phospholipases, endonucleases, and proteases.  Neuronal 
damage and death are associated with lesions which result in epileptic seizure. In 
addition, among the mechanisms that govern neuronal migration, the neurotransmitters 
GABA and glutamate deserve particular attention because neurotransmitters and 
receptors are expressed early in the developing brain, neurotransmitters may act as 
paracrine signaling molecules in the immature brain, and neurotransmitters regulate 
intracellular calcium required for many cellular functions, including cytoskeletal dynamic 
changes (Manent and Represa, 2007). 
Transmission of Nerve Impulses:  Neuron Communication 
 Neurons are known as voltage-gated ion channels because membrane potential 
changes in response to neurotransmitter stimulation (Raven and Johnson, 1996).  The 
diffusion of Na+ and K+ can result in an impulse (action potential).  In neurons, the Na+ 
and K+ channels differ from those in most cells because the channels have gates that 
open and close when the membrane potential is altered.  Action potentials result when 
depolarization reaches a threshold.  Action potentials follow an all-or-none law (Raven 
and Johnson, 1996).  Action potentials pass down the axon and eventually reach the end 
of the axon and its branches.  The arrival of the action potential to the end of the axon 
causes the membrane to depolarize and results in the release of neurotransmitters from 
the synaptic cleft.  The neurotransmitter, glutamate, binds to the receptor proteins of the 
postsynaptic cell.  The binding of glutamate to the receptor open chemically gated ion 
channels found on the postsynaptic membrane.  In contrast to the voltage-gated channels 
in the axon membrane, these postsynaptic channels are not opened by membrane 
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depolarization (Raven and Johnson, 1996).  Chemical junctions are an advantage because 
different neurotransmitters can elicit postsynaptic cell response.   
Glutamate Receptors  
 Glutamate receptors play a vital role in the mediation of excitatory synaptic 
transmission.  Glutamate exerts its signaling role by acting on glutamate receptors 
(Danbolt, 2001).  Activation of glutamate receptors is responsible for synaptic 
transmission, and several forms of synaptic plasticity.  Glutamate receptors are 
categorized as either metabotropic (G-protein coupled) receptors or ionotropic (ion 
channel gated) receptors.  A review of the literature available on glutamate receptors 
revealed more information regarding ionotropic glutamate receptors actions in glutamate 
mediated excitotoxicity than metabotropic glutamate receptors.  
Mitochondria can modulate neuronal excitability and synaptic transmission.  In 
epilepsy, the energy consumption and the Ca++ load of neuronal cells increases during 
epileptiform activity (Kunz et al., 1999).  The opening of the Ca++ channels in the 
mitochondria causes oxidative stress through the release of free radicals.  The free 
radicals cause DNA damage which lead to cell damage and/or apoptosis.  In addition, 
mitochondria lack many of the mechanisms to repair DNA damage caused by radical 
oxidation.  Therefore, the mitochondria can be damaged at the DNA level.  Neuronal 
damage and death leads to lesions which are associated with epileptic seizures.  
According to Waldbaum and Patel (2010), mitochondrial oxidative stress and dysfunction 
are emerging as key factors that not only result from seizures, but may also contribute to 
epileptogenesis. 
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Mitochondria and Oxidative Stress 
Mitochondria  
 Mitochondrial oxidative stress and dysfunction are contributing factors to various 
neurological disorders (Waldbaum and Patel, 2010).  Mitochondria are tubular organelles 
1 to 3 μm long that are found in all types of eukaryotic cells.  Mitochondria are double 
membrane organelles that change their size and position in their dynamic movement.  
Mitochondrial morphology varies in response to environmental and cellular 
differentiation.  They form connected and filamentous network structures in fibroblast 
and are arranged along the myofibrils in skeletal muscle, and are coiled around the 
flagella in sperm (Tagauchi et al., 2007).  The outer membrane in mitochondrion is 
smooth, whereas the inner membrane is folded into numerous layers referred to as cristae 
(Raven and Johnson, 1996, p.102).  There are two compartments to the cristae: (1) a 
matrix (lye inside the inner membrane) and (2) the outer compartment /intermembrane 
space (lye between the two mitochondrial membranes).  Proteins that carry out oxidative 
metabolism (the oxygen-requiring process by which energy in macromolecules are stored 
in adenosine triphosphate [ATP]) are found on or within the surfaces of the inner 
membrane.  Biochemical evidence suggests the majority of cerebral ATP consumption is 
used for operation of the electrogenic activity of neurons (Chen et al., 2010). 
Mitochondria also functions in heme, lipid, amino acid biosynthesis, and fatty acid 
oxidation among other functions (Sugimoto, 2008).  Hence, mitochondria are essential 
for energy production in the cell and are often referred to as the “power plant” for 
eukaryotic cells.   
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Mitochondrial Production of Reactive Oxygen Species 
 ATP is the energy currency utilized by cells. The ATP molecule transfers the 
energy captured during respiration to the many sites in the cell where it is used (Raven 
and Johnson, 2004, pp.187).  ATP is composed of a sugar (ribose) which is bound to an 
organic base (adenine) and a chain of three phosphate groups (each phosphate group is 
negatively charged).  Energy is released when the phosphate bonds in ATP are 
hydrolyzed.   
Cells produce ATP in two different ways: (1) substrate-level phosphorylation, and 
(2) electron transport chain.  In substrate-level phosphorylation, ATP is formed by 
transferring a phosphate group to an adenosine diphosphate (ADP) from a phosphate-
bearing intermediate (Johnson and Raven, 1996).  For example, during glycolysis the 
chemical bonds of glucose are shifted around in reactions that provide the energy needed 
to form ATP.  Even though this process is inefficient, many cells utilize substrate-level 
phosphorylation to derive their ATP.  In the second process, electrons are harvested and 
transferred in the electron transport chain.  Most organisms combine these two processes 
in the oxidative phosphorylation.   
 Oxidative phosphorylation is accomplished through a complex series of enzyme-
catalyzed reactions that may be broken down into four stages.  For example, the first 
stage of extracting energy from glucose is a 10-reaction biochemical reaction pathway 
known as glycolysis.  During glycolysis, the enzymes needed to catalyze the glycol tic 
reactions are found in the cytoplasm of the cell.  During glycolysis two ATP molecules 
are utilized to prepare glucose, and four ATP molecules are created through substrate 
level phosphorylation.  Thus, glycolysis only yields two ATP molecules per glucose 
36 
molecule that is catabolized (Raven and Johnson, 1996).  In addition, once the glycolysis 
process is complete two pyruvate molecules are formed.  In the second stage, the 
pyruvate is converted into carbon dioxide and acetyl-CoA.  In the third stage, acetyl-CoA 
is introduced into a cycle of nine reactions known as the Krebs cycle (citric acid cycle), 
which generate two ATP molecules.  In the final stage, the electrons carried by NADH 
are used to drive the synthesis of ATP by the electron transport chain.  In addition, 
glycolysis can occur in the absence of oxygen.  However, the harvesting of electrons for 
the electron transport chain can’t take place indefinitely in anaerobic conditions because 
oxygen serves as the final electron acceptor of the electrons harvested from glucose.  
Therefore, without oxygen cells are restricted to substrate-level phosphorylation to obtain 
ATP, and some organisms respire by utilizing different electron acceptors. Overall, 
pyruvate oxidation, Krebs cycle, and ATP production takes place in the mitochondria of 
all eukaryotic cells.   
 Mitochondrial metabolism also generates the majority of the reactive oxygen 
species (ROS) production in cells (St-Pierre et al., 2006).  ROS results when unpaired 
electrons escape the electron transport chain.  The generation of ROS in normal cells, 
including neurons, is under tight homeostatic control.  Antioxidants such as glutathione, 
vitamin E, carotenoids, and ascorbic acid help to detoxify ROS by reacting with most 
oxidants (Klein and Ackerman, 2003).  ROS react with molecular oxygen to generate 
superoxide.  It is estimated that under normal physiological conditions up to 1% of the 
mitochondrial electron flow leads to the formation of superoxide (O2-) and interferences 
in electron transport increases O2-.  However, oxidative stress in not limited to 
mitochondrial metabolic processes because ROS may be produced by environmental 
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events such as: (1) ionizing radiation exposure, (2) cytotoxic chemical exposure, (3) drug 
exposure, or (4) by professional phagocytosis resulting from the defense against invading 
pathogens (Langley and Ratan, 2004).                                                                        
 Superoxide is the primary ROS created by mitochondria.  Within the cell O2- is 
rapidly converted to hydrogen peroxide (H2O2) by superoxide dismutases, SOD1, SOD2, 
and SOD3.  Through a Fenton reaction H2O2 reacts with reduced transition metals to 
produce the high reactive hydroxyl radical (-OH). O2- also reacts with nitric oxide (NO) 
to create cytotoxic peroxynitrite anions (ONOO-).  Peroxynitrite reacts with carbon 
dioxide which results in protein damage through the formation of nitrotyrosine and lipid 
oxidation (Klein and Ackerman, 2003).  Hence, ROS can also react with nitrous oxide 
(NO) to generate reactive nitrogen species (RNS).  Superoxide reacts with DNA, 
proteins, and lipids.  O2- selectively attacks guanine.  The most commonly produced base 
lesion, and the most often measured as an index of oxidative DNA damage is 8-
hydroxyguanosine (8-OHdG) (Wiseman and Halliwell, 1995).  O2- plays an important 
role in several physiological and pathophysiological conditions such as ischemia-
reperfusion injury, neurodegenerative disease, and aging (St-Pierre et al., 2006).  
 According to Finkel and Gutkind (2003), there is a growing consensus that 
oxidative stress plays an integral role in both aging, and the pathophysiology of most 
neurodegenerative diseases.  It is apparent that oxidative stress induced injury in the 
nervous system results from the overproduction of oxidants and/or the dysfunction of 
endogenous oxidant defenses (Langley and Ratan, 2004; Harrison et al., 2005).  In 
addition, ROS can also cause damage to the mitochondrial genome (Fishel et al., 2007).  
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Therefore, the maintenance of low ROS levels is crucial to normal cell functions, and 
prolonged increase in mitochondrial activity inherently risk increasing ROS levels.   
Mitochondrial DNA damage during epileptogenesis 
 Acute consequences of status epilepticus (SE) are oxidative stress and 
mitochondrial dysfunction (Jarret et al., 2008).  Currently, the role of mitochondrial 
oxidative stress and genomic instability during epileptogenesis is not known.  Jarret et al. 
(2008) used the kainite rat model of temporal lobe epilepsy (TLE) to investigate 
mitochondrial DNA (mtDNA) damage and changes in the mitochondrial base excision 
repair pathway (mtBER) in the hippocampus for 3 months after SE.  Results of the study 
demonstrated a time-dependent increase in the frequency of mtDNA lesions.  The 
increase in mtDNA lesions was accompanied by an increase in mitochondrial H2O2 
production and a decrease of mtDNA repair capability (Jarret et al., 2008).  In addition, 
there was an elevated expression mRNA and protein of the mtBER protein 8-oxoguanine 
glycosylase (Ogg1) and DNA polymerase gamma (Pol gamma).  Hence, the increase of 
oxidative mtDNA damage, mitochondrial H2O2 production and alterations in the mtBER 
pathway present evidence for mitochondrial oxidative stress in epilepsy.  Thus, 
suggesting that mitochondrial injury may be a contributing factor in epileptogenesis.  
ROS, Mitochondria and the Neuron Cell Cycle 
 Examination of the current literature on the effect of oxidative stress on the cell 
cycle reveals increases in ROS-induced DNA damage are correlated with cell cycle 
arrest.  ROS have been implicated in cell signaling, specifically through mitogens (Klein 
and Ackerman, 2003).  The discovery that oxidative stress can trigger a program of cell 
death in neurons with features of apoptosis was significant (Langley and Ratan, 2004).  
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During embryonic development neuronal precursors produce larger numbers of neurons 
than needed, and this excess in neurons are later eliminated by apoptosis during a 
restricted embryonic period (Langley and Ratan, 2004; Liu et al., 2004).  Even though 
neuronal apoptosis plays a crucial role in the development of the nervous system, it is 
also an underlying element in neurodegenerative diseases (Becker and Bonni, 2006).  
According to Langley and Ratan (2004), there is a growing body of evidence indicating 
that deregulation of the cell cycle can either (1) trigger apoptosis, or (2) increase 
sensitivity to apoptotic inducers.  In 1994, the first indication that mitochondria play an 
active role apoptosis occurred.  The observation that mitochondria were needed for 
nuclear apoptotic changes, such as: (1) chromatin condensation, and (2) nuclear 
fragmentation, in the extracts of Xenopus eggs (Crompton, 2000).  These observations 
lead to insights of mitochondrial role in apoptosis.  According to Crompton (2001), 
apoptosis is executed by caspases, proteolytic enzymes that are expressed constitutively 
as inactive proenzymes, and that are activated by cleavage of the N-terminal prodomain.  
In addition, it is well recognized that ROS are formed during the reperfusion of ischemic 
tissue and may result in brain malformations and uteroplacental ischemia during the fetal 
stages of gestation (Fantel et al., 1998).   
 The central nervous system (CNS) is vulnerable to oxidative stress.  The major 
reasons being that the CNS (1) posses a low level of antioxidant enzymes, such as 
catalase and gluthathione peroxidase, (2) have a high content of easily oxidized substrates 
such as membrane polyunsaturated lipids, and (3) an inherently high flux of ROS 
generated during neurochemical reactions such as dopamine oxidation and energy 
metabolism (Langley and Ratan, 2004).  The increased and unobstructed ROS can lead to 
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death via several pathways including necrosis or apoptosis.  The most common oxidative 
product of DNA is 8-hydroxy-2’-deoxyguanosine (8-OHdG), a major DNA lesion 
resulting from free radical attack that has been demonstrated to alter the base-pairing 
properties (GC -> TA transversions) of guanine in in vitro assays (Kasai, 1997).  
According to Lin et al (2002), under enhanced oxidative stress, the amount of 8-OHdG in 
mtDNA has been found to increase although base excision repair (BER) system of 
oxoguanine glycosylase (hOGG) and DNA ligase are present in the mitochondria.  
Human oxoguanine glycosylase 1 (hOGG1) recognizes 8-OHdG and catalyze, through 
cleavage of the N-glycosyl bond between the sugar and the base to generate an 
apurinic/apyrimidinic (AP) site, resulting in the removal of phosphodiester bond in 
modified DNA (Wei and Lee, 2002).  Inactivation of hOGG1 may result in the 
accumulation of point mutations and deletions in mtDNA (Higushi, 2007).  The amount 
of 8-OHdG is elevated in both neuronal nuclear and mitochondrial DNA in disease 
regions of patients with neurodegenerative disorders and has been correlated with 
increase incidence of cancer and cell cycle abnormalities (Klein and Ackerman, 2003).   
According to Wiseman and Halliwell (1995), oxidative DNA base damage, measured as 
8-OHdG, has been detected in mitochondrial DNA at steady-state levels several-fold 
higher than in nuclear DNA.  This apparent increased net oxidative damage in 
mitochondrial DNA compared with nuclear DNA may be due the proximity of 
mitochondrial DNA generated during electron transport, lack of histone proteins to 
protect DNA against attack, or inefficient repairs, resulting in base damage accumulates 
in higher levels in mitochondrial DNA.  Two markers of oxidative DNA damage are 
thymine glycol (TG) and 8-OHdG.  According to Waldbaum and Patel (2010), TG is an 
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adduct that can lead to cell death by blocking polymerase action.  It has been shown that 
8-OHdG is one of the important oxidative lesions related to mitochondrial dysfunction 
and aging (Lin et al., 2002).  Mutations that impair the mtDNA BER pathway have been 
linked with chronic epilepsy (Jarrett et al., 2008).   
Oxidative stress can cause other mutational events such as: (1) strand breaks, (2) 
discontinuous loss of heterozygosity, (3) large deletions, (4) protein/DNA-cross-links, 
and (5) modification of base pairs (Waldbaum and Patel, 2010).  Hence, mutations may 
result if the oxidation of DNA surpasses the cell’s DNA-repair capacity leads to loss of 
genome stability.  However, cumulative damage in neurons is contingent on other factors 
of susceptibility, such as: (1) exposure to environmental genotoxins, (2) polymorphisms 
in genes that are involved in either cellular functions or in metabolism of toxins (Klein 
and Ackerman, 2003).  Animal models of hypoxia-ischemia and traumatic brain injury 
(TBI) has demonstrated developmental differences in apoptotic neuronal death.  
According to Robertson (2004), the mechanisms responsible for these differences are 
unknown, but it is stipulated that they are likely multifaceted and related to mitochondrial 
response to injury.  Mitochondrial involvement and oxidative stress may be contributing 
factors in neurodegenerative disorders (Sas et al., 2007).  Currently, there is ongoing 
research in the field of neurodegeneration to understand how genetic and environmental 
factors plot to tip the balance of oxidant and antioxidants in favor or oxidants in the CNS 
(Langley and Ratan, 2004).    
Mitochondrial DNA and Point Mutations 
Mitochondria contain their own DNA as a circular duplex.  mtDNA is inherited 
maternally with a vertical non-Mendelian pattern (Solano et al., 2001).  Interestingly, 
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mtDNA located in the cytoplasm from the ovum is transmitted to the zygote and sperm 
rarely contribute mtDNA to the zygote.  This results because there is a high number of 
mtDNA in the ovum, about 100,000 and 200,000 copies compared to the few hundred in 
spermatozoids (Solano et al., 2001).  In addition, the spermatozoid mitochondria that can 
enter the fertilized egg are eliminated through an active process.  Hence, mothers and all 
of their offspring share the same mtDNA.  mtDNA is randomly distributed to daughter 
cells in a process known as replicative segregation; and only the daughters will pass the 
mitochondrial genome to all of the members of the next generation.  Heteroplasmy occurs 
if there is a mixture of mutant and normal mtDNA.  According to Sherman (1997), the 
proportion of mutant to normal mtDNA can change after one cell division.  Any two 
offsprings are likely to receive differing proportions of mutant mtDNA from a 
heteroplasmic mother. Therefore, the mtDNA resulting in the offspring can be in one of 
three states: (1) a mixture of normal and mutant mtDNA (heteroplasmy), (2) purely 
normal, or (3) purely mutant mtDNA (homoplasmy).  Hence, this trend may potentially 
cause the variable phenotypes observed in the offspring.  Mitochondrial genetics differ 
from Mendelian genetics.  Some of the peculiarities of mitochondrial genetics are 
uniparental inheritance, cellular polyploidy, and a deviation from the standard genetic 
code.  These features dictate the functional consequences of pathogenic mtDNA 
mutations (Tuppen et al., 2010). 
mtDNA produces some of the proteins needed for mitochondrial oxidative 
metabolism (Raven and Johnson, 1996; Wang et al., 2006).  Each mitochondrion contains 
multiple copies of a 16,569 base-pair circular DNA duplex.  mtDNA encodes 13 subunits 
of enzyme complexes which play a role in energy production, including seven subunits 
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(ND1, ND2, ND3, DN4L, ND5L, and ND6) of rotenone-sensitive NADH-ubiquinone 
oxidoreductase (complex I), one subunit (cytochrome b) of ubiquinol-cytochorme c 
oxidoreductase (complex III), three subunits (COI, COII, and COIII) of cytrochrome c 
oxidase (complex IV), and two subunits (ATPases 6 and 8) of complex V with 22 tRNAs 
and two rRNA  (12S and 16S) subunits (Tsutsui et al. 2009).  However, the majority of 
the genes that produce the proteins (enzymes) utilized in oxidative metabolism and 
divisions are located in the nucleus (Sherman, 1997; Jeng et al., 2008).  Mitochondrial 
replication would be impossible without nuclear participation, and mitochondria cannot 
be grown in a cell-free culture (Johnson and Raven, 1996). Damaged mitochondrion can 
replicate because the nuclear DNA (nDNA) encodes the enzymes needed for 
mitochondrial replication.  Increased abundance of defective mtDNA that encodes for 
respiratory enzymes may lead to impaired electron transport, result in enhanced 
production of ROS, further oxidative damage, and damage to the mitochondria (De la 
Monte et al., 2000).   mtDNA mutations can be categorized as those that impair 
mitochondrial protein synthesis and those that affect any of the 13 respiratory chain 
subunits encoded by the mitochondrial genome (DiMauro, 2007).  For example, 
deficiency of primary coenzyme Q10 (CoQ10) is included as a respiratory chain disorder 
due to its pivotal role as an electron carrier from complex I and II to complex III.  CoQ10 
deficiency encompasses fiver major phenotypes such as encephalomyopathy, severe 
infantile multisystemic disease, Leigh syndrome, isolated myopathy, and cerebellar ataxia 
(DiMauro, 2007).  Advances in mitochondria research have revealed that mutations in the 
mtDNA lead to a number of genetic disorders.   
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According to Sherman (1997), the full range of diseases that have a mitochondrial 
component are unknown, yet, clearly involve disorders such as: acute leukemia, 
Alzheimer’s disease (AD), cardiomyopathy (CM), chronic progressive external 
ophthalmoplegia, colorectal cancer, deafness, fatal infantile cardiomyopathy (FICP), 
gastroesopageal reflux (GER), mitochondrial encephalomyopathy, lactic acidosis and 
stroke-like episodes (MELAS), myoclonic epilepsy with ragged red fibers (MERRF), 
Leber Hereditary Optic Neuropathy (LHON),  Parkinson’s disease (PD), maternally 
inherited hypertropic cardiomyopathy (MHCM), multiple sclerosis (MS), non-insulin 
dependent diabetes mellitus (NIDDM), Chronic intestinal pseudo-obstruction (CIPO), 
non-syndromic hearing loss, progressive encephalopathy (PEM), sensorineural hearing 
loss (SNHL), strokes, and sudden infant death syndrome (SIDS) (Table 5.0) (Filiano et 
al., 2002; Bai et al., 2007; Tzen et al., 2007).  A list of all of the known disorders 
associated with mtDNA variations is available at MITOMAP:  Human Mitochondrial 
Genome Database.  Diminished mtDNA repair mechanisms and mitochondrial genomic 
instability have been implicated as important factors in several neurodegenerative 
diseases (Jarrett et al., 2008).  MEERF and MELAS are the most prominent examples of 
the occurrence of epileptic seizures caused by mitochondrial dysfunction (Kunz, 2002; 
Chen et al., 2010).  The mechanisms of mitochondrial dysfunction during epileptogenesis 
are unclear. 
Mitochondrial DNA Copy Number Variations 
 According to Liu et al. (2006), the number of mitochondria per cell is maintained 
within a constant range in response to the energy need of the cell to maintain normal 
physiologic functions.  mtDNA mutations often result in respiratory chain defects 
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resulting in decreased ATP production, enhanced ROS and free radical production in 
mitochondria.  Mitochondrial dysfunction or cell apoptosis result upon the decline in the 
copy number of mtDNA or the accumulation oxidative damage and mtDNA mutations 
reaches a critical point, thus, resulting in defective energy metabolism of the target 
tissues (Liu et al., 2006).  Alteration of mtDNA copy number in affected copy numbers 
has been suggested play a role in the pathogenesis and progression of mitochondrial 
diseases (Liu et al., 2006; Park et al., 2009).  Studies have documented the presence of 
inheritable copy number variations (CNVs) in the human genome, and copy number 
aberrations (CNAs), which are acquired somatic alterations, have been observed in tumor 
tissues (Sun et al., 2009; Zhang et al., 2010).  For example, in nasal polyp tissues, an 
increase of mtDNA is the result of a compensatory mechanism thought to be triggered by 
endogenous and exogenous oxidative stress elicited by mtDNA mutations (Park et al., 
2009).  Additionally, in the skeletal muscle of patients with mitochondrial 
encephalomyopathies such as MERRF, MELAS, and CPEO demonstrated proliferation 
of abnormal mitochondria (Liu et al., 2006).  Research has suggested that an increase in 
mtDNA content in affected tissues result from a compensatory mechanisms triggered by 
elevated endogenous and exogenous stress that may be elicited by mtDNA mutations.  
Diseases caused by an excess mtDNA proliferation are less common (Montier et al., 
2009).   
In contrast, mtDNA copy number was found to decrease in tissues from patients 
with neonatal giant-cell hepatitis, mtDNA depletion syndrome, mitochondrial 
neurogastrointestinal enchephalomyopathy, renal cell carcinoma, liver disease, biliar 
atresia, type 2 diabetes, cardiomyopathy, and breast cancer (Liu et al., 2006; Montier et 
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al., 2009).  Interestingly, even though there are a limited number of human studies which 
directly evaluate mitochondrial function after a traumatic brain injury (TBI), they have 
generally supported the findings seen in animal models of TBI.  Mitochondria isolated 
from the brain of human victims of TBI have demonstrated impaired rates of respiration 
and ATP synthesis (Robertson, 2004).  In addition, depletion of mtDNA is one of the 
hallmarks of mtDNA dysfunction (Lewit et al., 2007).  These findings indicate that either 
and increase or decrease in mtDNA copy number may play a role in the pathogenesis of 
mitochondrial disorders.   
Mitochondrial DNA Variations, Haplotypes, and Haplogroups 
 Point mutations, nucleic acid modifications, and large-scale deletions are the most 
prevalent forms of mtDNA mutations.  All of which play a role in mitochondrial 
dysfunction and apoptosis.  mtDNA damage, as a result of environmental insults and/or 
enhanced by genetic predisposition, is attracting attention as the origin of mitochondrial 
dysfunction.  During evolution, several mutations have accumulated in mitochondrial 
DNA (mtDNA), representing specific single nucleotide polymorphisms (SNPs), allowing 
human populations to be categorized into various mtDNA haplotypes (combination of 
several SNPs on single chromosomes) and haplogroups (Petterson et al, 2003; Pakendorf 
and Stoneking, 2005; Abu-Amero et al, 2006) (Table 6.0).    
According to Pakendorf and Stoneking (2005), haplogroups represent related 
groups of sequences that are defined by shared mutations and tend to show regional 
specificity.  Analysis of population-specific mtDNA polymorphisms has allowed the 
reconstruction of human pre-history, and analysis of maternally inherited diseases has 
demonstrated that some mtDNA diseases show a strong continental bias (Wallace et al., 
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1999).  mtDNA polymorphism have sequentially accumulated as women migrated west 
of Africa and into the other continents.  According to Wallace et al. (1999), selection and 
drift may have influence the rapid shift in the mtDNA lineages that are observed between 
continents.  Thus, the accumulated mtDNA mutations and variations that are observed in 
high frequency are associated with specific mtDNA haplotypes and haplogroups.   
Analysis of human mtDNA evolution has been necessary for addressing 
anthropological questions and clinical studies addressing age and origin of Africans, 
Europeans, Asians, and Native Americans (refer to Table 7.0 for mtDNA haplogroups).   
Two major databases regarding human mitochondrial genome and variations are: (1) 
MITOMAP:  Human Mitochondrial Genome Database and (2) GiiB-JST mtSNP 
database:  Human Mitochondrial Genome Polymorphism Database (Umetsu and Yuasa, 
2005).  Studies investigating the role of various mitochondrial haplogroups in the 
pathogenesis of MCD are scarce. 
Oxidative stress is one of the major risk factors for neurodegenerative diseases.  
Mitochondrial DNA (mtDNA) variations can cause inefficient oxidative phosphorylation 
leading to the accumulation of ROS, DNA damage, and may lead to increased brain 
lesion risk.  Since the roles of various mtDNA variations in the pathogenesis of MCD are 
scarce.  Studies exploring the presence and the roles of mitochondrial haplogroup 
background and mtDNA variations as risk contributors to MCD are needed.  Overall, the 
goal of this study is to investigate the mtDNA background and oxidative damage in 
intractable pediatric epilepsy patients with MCD phenotype.  
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Table 1.0.   
Cortical dysplasia classification in epilepsy 
 
Type of                            
Focal Dysplasia 
              
Subtype 
                                                                                
Major morphological feature(s) 
Mild MCD Type I 
Type II 
Excess neurons in layer I 
Excess neurons outside layer I 
FCD Type I Type Ia 
Type Ib 
Cortical dislamination only 
Cortical dislamination and giant neurons 
FCD Type II 
(Taylor-Type FCD) 
Type IIa 
Type IIb 
Cortical dislamination and dysmorphic neurons 
Cortical dislamination, dysmorphic neurons and 
balloon cells 
 
Table 2.0.   
Classification of Malformations of Cortical Development (MCD) 
 
Malformations due to abnormal glial 
and neuronal proliferation 
 
Dysembrioplastic neuroepithelial tumors 
(DNET) 
Focal cortical dysplasia (FCD) 
Fukuyama muscular dystrophy syndrome 
(FMDS) 
Gangliomas 
Hemimegalencephaly 
Microcephaly 
Microlissencephaly 
Megalencephaly 
Malformations due to abnormal 
neuronal migration  
Lissencephaly 
Cobblestone dysplasia 
Periventricular nodular heterotopia (PNH) 
Malformations due to abnormal 
cortical organization 
Polymicrogyria 
Schizencephaly 
Malformations due to abnormal cell 
fate proliferation 
Tuberous sclerosis (TS) 
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Table 3.0.  
 Susceptibility Genes of MCD Syndromes 
 
MCD Gene Locus Protein 
Tuberous Sclerosis (TS) TSC1 9q34 Hamartin 
Tuberous Sclerosis (TS) TSC2 16p13 Tuberin 
X-linked lissencephaly 
(XLIS) 
DCX Xq22 Doublecortin (DCX) 
Subcortical band 
heterotopia** 
DCX Xq22 Doublecortin (DCX) 
Miller-Dieker lissencephaly LIS-1 17p13 PAFAH1B1*** 
Fukuyama congenital 
muscular dystrophy (FCMD) 
FCMD 9q31 Fukutin 
Muscle-eye-brain disease 
(MEB)** 
POMGnT1 1p32 POMGnT1*** 
Periventricular nodular 
heterotopia (PH) 
 
FLN1 Xq28 Filamin 1 
**Not discussed in this review 
***PAFAH1B1 – platelet activating factor acetyldydrolase β subunit 
     POMGnT1- protein O-manose β 1,2-N-acetylglucosaminyltransferase 
 
 
Table 4.0.   
Environmental Factors of MCD 
 
Environmental Factor Agent 
Teratogenic Alcohol 
Cocaine 
Methlylazoxymethanol (MAM) 
Thalidomide 
Physical Freeze lesion  
Hypoxic-ischemic injury 
Head Trauma 
Ionizing radiation 
Ultraviolet (UV) radiation 
Biological Cytomegalovirus 
Herpes simplex 
Rubella 
Toxoplasmosis 
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Table. 5.0.   
Mitochondrial variants reported in Diseases and Haplogroups 
 
Region Variant Reported in Patients 
tRNA Phe G583A Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) 
tRNA Phe A606G Exercise intolerance/ myoglobinuria 
tRNA Phe T618C Mitochondrial myopathy 
12S rRNA G709A Non-syndromic hearing loss 
12S rRNA T1095C Sensorineural Hearing Loss (SNHL) 
12S rRNA T710C Colorectal tumor; mtDNA haplogroup (Hg)-L1b 
12S rRNA C1310T Diabetes mellitus 
12S rRNA A1555G Maternally inherited deafness  or aminoglycoside-induced deafness 
tRNA Val G1606A Ataxia, myoclonus, and deafness 
tRNA Val G1642A MELAS 
16S rRNA G1719A Hg-I, X 
16S rRNA T1738C colorectal tumor 
16S rRNA C3093G MELAS 
16S rRNA G3196A Alzheimer’s Disease and Parkinson’s Disease (ADPD) 
16S rRNA T3197C Hg-U5 
tRNA Leu A3243G MELAS, (Chronic Progressive External Ophthalmoplegia) CPEO; Diabetes/deafness 
tRNA Leu A3243T Mitochondrial myopathy 
ND1 T3308C MELAS, colorectal tumor 
ND1 T3394C Leber Hereditary Optic Neuropathy (LHON);  Non-insulin dependent diabetes mellitus 
(NIDDM); acute leukemia 
ND1 C3594T Hg-L(L1 or L2) 
ND1 A3397G ADPD 
ND1 A4136G LHON 
tRNA Ile A4269G Fatal Infantile Cardiomyopathy (FICP) 
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Table. 5.0.  (cont.) 
Mitochondrial variants reported in Diseases and Haplogroups 
 
Region Variant Reported in Patients 
tRNA Ile T4274C CPEO 
tRNA Ile A4295G Maternally inherited hypertropic cardiomyopathy (MHCM) 
tRNA Ile G4298A CPEO / Multiple Sclerosis (MS) 
tRNA Ile G4309A CPEO 
tRNA Ile A4317G Fatal Infantile Cardiomyopathy (FICP) 
tRNA Ile A4320T Mitochondrial encephalocardiomyopathy 
tRNA Gln T4336C ADPD 
tRNA Met T4409C Mitochondrial myopathy 
ND2 A4917G LHON, Hg-T 
tRNA Trp G5521A Mitochondrial myopathy 
tRNA Trp G5549A Dementia/ chorea 
tRNA Ala T5628C CPEO 
tRNA Asn A5692G CPEO 
tRNA Cys A5814G Mitochondrial encephalopathy 
tRNA Tyr T5874G Exercise intolerance 
tRNA Ser(UCN) A7445G SNHL 
tRNA Ser(UCN) A7497A Mitochondrial myopathy 
tRNA Ser(UCN) T7511C SNHL 
COX II G8251A SNHL; Hg-I,W 
ATP6 G8994A SNHL; Hg-W 
ATP6 G9055A Hg-K, longevity, ↓PD 
CO III G9438A LHON 
CO III G9738T LHON 
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Table. 5.0.  (cont.) 
Mitochondrial variants reported in Diseases and Haplogroups 
 
Region Variant Reported in Patients 
CO III G9804A LHON 
CO III G9952A Mitochondrial Encephalopathy 
CO III T9957C Progressive encephalopathy (PEM); MELAS 
tRNA Gly T9997C MHCM 
tRNA Gly A10006G Chronic intestinal pseudo-obstruction (CIPO) 
tRNA Gly T10010C PEM 
tRNA Gly T10034C Hg-I 
tRNA Gly A10044G Gastroesophageal reflux (GER) / Sudden infant death syndrome (SIDS) 
ND3 A10398G ↓PD, ↓AD;A-↑Breast Cancer  (BRCA) in AA; Hg-I, J, L, M 
ND3 C10400T Hg-M 
tRNA LeuCUN A12308G Hg-U&K; CPEO / Stroke / Cardiomyopathy (CM) 
ND5 G13368A Hg-T 
ND5 G13708A Hg-J; LHON 
tRNA Thr G15915A Mitochondrial myopathy 
tRNA Thr A15923G Lethal infantile mitochondrial myopathy 
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Table 6.0.   
Mitochondrial haplogroups 
 
Haplogroup Diagnostic mtDNA Variation (SNP) 
A A663G 
B 8280:8290 =A[delCCCCCTCTA]G 
C A13263G 
D C5178A 
E C13626T 
F T6392C 
G A4833G 
H C7028C 
I A4529T , T10034C, A10398G 
J A10398G and G13078A 
L0, L1, L2 C3594T 
L3 C3594C 
M C10400T + A10398G 
N C10400C + A10398A and T10873T 
P T10118C 
Q A5843G 
R C12705C 
S T8404C 
T A4917G 
V G4580A 
W A11947G 
X C6371T 
Y G8392A 
Z T9090C 
HV-group C14766C 
TJ-group T4216C 
UK-group  A12308G and G9055A 
  
 
Table 7.0.   
mtDNA lineage 
 
Ancestry Haplogroups 
African L0, L1, L2, L3, M, and N 
Asian A, B, C, D, E, F, G, M, N P, Q, Y, and Z 
European F, B, H, Hv, I, J, K, P, R, T, U, V, X, and W 
Native American A, B, C, and D 
Siberia G, Y, and Z 
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CHAPTER III 
 
MANUSCRIPT 1 
MITOCHONDRIAL DNA BACKGROUND AND OXIDATIVE DAMAGE IN 
INTRACTABLE EPILEPSY  
PEDIATRIC PATIENTS  
Abstract 
Objectives:  Research mitochondrial background and mitochondrial DNA 
(mtDNA) damage in pediatric intractable epilepsy patients.  mtDNA oxidative 
damage and copy number are indices of mitochondrial damage. Mitochondrial 
damage may play a role in the pathology of intractable epilepsy.  The purpose of 
this study is to determine and compare mtDNA variants (SNPs) and mtDNA 
oxidative damage in intractable epilepsy patients with malformations of cortical 
development (MCD) and non-MCD with non-epileptic controls. 
 
Methods:  Brain tissue specimens were collected from 21 pediatric intractable 
epilepsy patients from Miami Children’s Hospital and 11 controls (non-epileptic) 
from UMB.  Oxidative mtDNA damage as indicated by mtDNA∆Ct (formation of 
8-OHdG) and relative mtDNA copy number were determined for each tissue by 
quantitative real-time PCR (QPCR).  A total of 10 SNPs associated with 
mitochondrial myopathies were genotyped by allele-specific oligonucleotide dot 
(ASO) blot analysis. In female samples, a summary Bayesian network was 
created to investigate the relationship of these variables. 
 
Results:  In female samples, relative mtDNA copy number were higher in 
intractable epilepsy patients compared to non-epileptic control samples (p=0.01).  
Oxidative mtDNA damage was lower in epileptics compared to non-epileptic 
control samples (p=0.24), and lower in MCD compared to non-MCD (p=0.58). 
mtSNP G9952A was found in higher frequencies in epilepsy samples. Bayesian 
network showed several significant relationships (p < 0.05) between epilepsy, 
MCD, oxidative mtDNA damage, mtDNA copy number, and the mtSNPs 
G9952A, G3196A, T3197C, A10006G, and A10398G in female samples. 
 
Conclusion:  These data suggest that the mtSNPs explored are associated with 
intractable epilepsy phenotypes.  mtDNA copy number and mtDNA∆Ct may serve 
as useful biomarkers of mtDNA damage and can be used to evaluate 
mitochondrial oxidative damage in epilepsy etiologies.  These results indicate 
that increases in mtDNA content may be compensatory mechanisms for defective 
mitochondria in intractable epilepsy.  Findings suggest mitochondria play a role 
in the development of epilepsy.  Thus, means to suppress oxidative damage may 
be beneficial to intractable epilepsy patients. 
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Epilepsy is a chronic neurological disorder characterized by spontaneous 
recurring seizures.  The incidence of epilepsy is highest for children and the elderly.  A 
proportion of patients have seizures that are resistant to traditional anti-epilepsy 
medicines (intractable or refractory epilepsy) (Alexander and Godwin, 2006).  Over 30% 
of epileptic patients are medically intractable (Lopez et al., 2007).  The occurrence of 
epilepsy is highly associated with malformations of cortical development (MCD) which 
are developmental brain lesions that consist of dysplastic neuronal lesions 
(malformations) (Schwartzkroin and Walsh, 2000; Hua and Crino, 2003; Hader et al., 
2004; Rickert, 2006; Wong, 2007).  MCD are increasingly being recognized as the cause 
of intractable epilepsy.  
 MCD presents a broad spectrum of structural changes which appear to result 
from changes in precursor neuronal or neuronal cells during cortical development at 
various stages such as: proliferation, migration, differentiation, and apoptosis (Becker et 
al., 2004).  Treatment with anti-epileptic drugs (AEDs) is usually ineffective, and 
children with MCD may require surgical removal of the affected area of the brain (Yasin 
et al., 2010).  Two of the most common MCD found in resected tissue from children 
afflicted with intractable epilepsy are tuberous sclerosis (TSC), and focal cortical 
dysplasia (FCD) (Fassunke et al., 2004).  The molecular mechanisms underlying the 
formation of MCD are still largely unknown and the treatments for epilepsy due to MCD 
are often ineffective or limited (Wong, 2009).   
Epilepsy results from excessive synchronous firing of neurons in cortical 
networks (Prasad et al., 1999; Paredes and Baraban, 2002).  Despite several attempts to 
elucidate the cause of epilepsy, to date, results have not been satisfactory.  Epilepsy is a 
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common feature of mitochondrial encephalopathies that are caused by defective oxidative 
phosphorylation in the CNS (Zsurka et al., 2010).  It has been proposed that the 
accumulation of mitochondrial DNA (mtDNA) mutations and the alteration in the 
execution of apoptosis, contribute to the onset of neurodegenerative diseases (Lee et al., 
2005).  A role for mitochondrial dysfunction and oxidative stress in intractable epilepsy 
patients has been suggested (Shah et al., 2002; Waldbaum and Patel, 2010a). 
Mitochondria contain their own genome, mtDNA, which consists of a 16.5-kb 
circular double-stranded DNA (dsDNA) molecule containing 37 genes (Bai et al., 2008). 
Mitochondria functions in oxidative phosphorylation, heme, lipid, amino acid 
biosynthesis, and fatty acid oxidation among other functions (Sugimoto, 2008).  
Mammalian cells contain several hundreds to more than a thousand mitochondria.  The 
size, shape and abundance of mitochondria vary drastically in different cell types and 
may change under differing energy demands and physiological or environmental 
conditions.  In a cell, the abundance of mitochondria is determined by biogenesis and 
division of the organelles.  The quantity of mitochondria per cell is tighly regulated by 
activation of specific transcription factors and signaling pathways (Lee and Wei, 2005).  
The major source of ATP in cortical neurons is provided by mitochondrial oxidative 
phosphorylation (Chuang, 2010).  Mitochondrial metabolism also generates the majority 
of the reactive oxygen species (ROS) production in cells (St-Pierre et al., 2006).  ROS 
results when unpaired electrons escape the electron transport chain.  The most commonly 
produced base lesion by ROS, and the most often measured as an index of oxidative 
DNA damage is 8-hydroxyguanosine (8-OHdG) (Wiseman and Halliwell, 1995).  The 
brain is believed to be particularly susceptible to the damaging effects of ROS damage 
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due to its high metabolic rate and reduced capability for cellular regeneration compared 
to other organs (Anderson, 2004).  Mitochondria can modulate neuronal excitability and 
synaptic transmission since oxidative phosphorylation provides the major source of ATP 
in neurons and participate in cellular calcium homeostasis (Devi et al, 2008).   
Mitochondrial oxidative stress and dysfunction are contributing factors to several 
neurological disorders (Shokolenko et al., 2009; Waldbaum and Patel, 2010b).  
Encephalomyopathies have been found in children in association with defects in 
mitochondrial structure and function.  Some of these disorders are acute leukemia, 
Alzheimer’s disease (AD), cardiomyopathy (CM), chronic progressive external 
ophthalmoplegia, colorectal cancer, deafness, fatal infantile cardiomyopathy (FICP), 
gastroesopageal reflux (GER), mitochondrial encephalomyopathy, lactic acidosis and 
stroke-like episodes (MELAS), myoclonic epilepsy with ragged red fibers (MERRF), 
Leber Hereditary Optic Neuropathy (LHON),  Parkinson’s disease (PD), maternally 
inherited hypertropic cardiomyopathy (MHCM), multiple sclerosis (MS), non-insulin 
dependent diabetes mellitus (NIDDM), non-syndromic hearing loss, progressive 
encephalopathy (PEM), sensorineural hearing loss (SNHL), strokes, and sudden infant 
death syndrome (SIDS) (Filiano et al., 2002; Bai et al., 2007; Tzen et al., 2007).  Among 
mitochondrial disorders, infantile spasms have been reported in complex III deficiency 
(Shah et al., 2002).  In this study, we investigate the presence of oxidative mtDNA 
damage, constitutional mtDNA copy number, mtDNA SNPs, and haplogroups as sources 
of genetic diversity that may contribute to the development of pediatric intractable 
epilepsy. 
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Methods 
Collection of brain tissue from pediatric intractable epilepsy patients 
Brain tissue samples from 21 pediatric non-neoplastic intractable epilepsy patients 
who have undergone brain resection surgery at the Miami Children’s Hospital, Miami, 
FL, during 2008-2009 were collected.  Tissues obtained during surgical resection were 
immediately snap-frozen in liquid nitrogen and stored at -80°C.  As references, eleven 
normal, non-epileptic, pediatric brain tissues were obtained from the NICHD Brain and 
Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD 
and stored at -80°C.  This study was approved by the Florida International University’s 
Institutional Review Board. 
DNA extraction  
Freshly excised human neuronal (brain) tissue was stored in liquid nitrogen and 
frozen in -80°C until ready for processing.  The frozen neuronal tissue was homogenized, 
while on ice, using a Janke and Kunkle TP-18-10 blade type homogenizer in which 1 ml 
of Trizol® was added.  The homogenate was transferred to a 2.0-ml microcentrifuge 
tube. DNA was then isolated and purified via Phenol-Chloroform extraction.  The 
precipitated DNA was pelleted and resuspended in1X TE buffer.  The integrity of the 
DNA was verified following electrophoresis through 2% agarose gels.  
Determination of and mtDNA copy number and mitochondrial DNA oxidative damage 
by quantitative real time PCR 
 Quantitative real-time PCR (QPCR) assays were performed using Applied 
Biosystems 7300 System with a final volume of 25uL reaction mixture containing 50ng 
DNA template, 12.5uL SYBR Green PCR Master Mix (Qiagen), and 10mM of each 
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primer.  The sequences for the primers used for the amplification of the mitochondrial 
gene NADH Dehydrogenase 1 (ND1) were: mtF3212, 5’-
CACCCAAGAACAGGGTTTGT-3’ and  mtR3319, 5’-TGGCCATGGGATTGTTAA-
3’.  The sequences of the primer for the nuclear housekeeping gene 18s rRNA, used for 
the normalization in the QPCR analysis, were: 18s1546F, 5’-
TAGAGGGACAAGTGGCGTTC-3’and 18s650R, 5’-CGCTGAGCCAGTCAGTGT-3’ 
(Bai et al., 2004; Lin et al, 2008).  The QPCR conditions were set up as follows: hot start 
at 95° C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute.  The fluorescence intensity was measured at the end of the extension phase at 
60°C.  All samples were performed in duplicated and a non-template negative control 
was included in each reaction.   
A total of 50ng of DNA was used in QPCR for the determination of the threshold 
cycle number (Ct) of the 18s rRNA and ND1 genes.  Ct values can be used as a measure 
of input copy number and the Ct value differences were used to quantify the mtDNA 
copy number relative to the 18s rRNA gene with the following equation:                         
Relative copy number= 2∆Ct, where ∆Ct is the Ct 18s rRNA – Ct ND1 (Szuhai et al., 
2001; Bai et al., 2004; Lewis et al., 2007; Edwards, 2009; Lee et al, 2010). 
Since degree of oxidative mtDNA damage is reflected by an abundance of 8-
OHdG formation in mtDNA, the content of 8-OHdG in mtDNA, an index for cellular 
oxidative damage, was determined by QPCR and presented as ∆Ct (Ayala-Torres et al., 
2000).  As indicated by Lin et al (2008), the amplification efficiency would decrease after 
treatment of the DNA sample with hOGG1 to remove the 8-OHdG residue to form an 
abasic site.  The content of 8-OHdG in the samples’ mtDNA was determined by treating 
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the 200ng sample with 2 units of hOGG1 (New England Biolabs, M024S) at 37° C for 1 
hour and 5 minutes to remove the 8-OHdG residue to form a basic site.  The digested 
mtDNA were amplified by QPCR using the primers for ND1 gene.  PCR amplification 
efficiencies of DNA templates containing a single 8-OHdG or two 8-OHdGs at least 13 
base pairs apart are not significantly disturbed (Ct1), however, the presence of an abasic 
site in DNA after treatment of hOGG1 would dramatically reduce the PCR efficiency, 
thus, increasing the Ct value (Ct2) (Lin et al., 2008).  The degree of oxidative mtDNA 
damage, mtDNA∆Ct, was defined as ∆Ct= Ct2 (hOGG1 treatment) – Ct1 (no hOGG1 
treatment) (Lin et al., 2008; Su et al., 2010).  Each analysis was performed in duplicate, 
and the mean value of ∆Ct was calculated for each sample.  Hence, the larger the ∆Ct, the 
more abundant the 8-OHdG and more oxidative damage present in the sample.   
mtDNA genotyping 
A total of 50ng of DNA was used in Quantitative PCR (QPCR) to amplify the 
mitochondrial genome with 19 primer sets (Table A.8) designed by Bai et al. (2007) to 
include the mtDNA regions containing 10 reported mtDNA variations (SNPs).  The 
mtDNA variations are distributed along the rRNA, tRNA, COIII and ND3 regions of the 
mitochondrial genome.  The mtDNA variations studied have been reported in patients 
with varying diseases such as:  Alzheimer’s disease, Parkinson’s disease, Leber’s 
hereditary optic neuropathy (LHON), deafness, chronic progressive external 
ophthalmoplegia (CPEO), chronic intestinal pseudo-obstruction (CIPO) and other 
diseases (Table 1.3). 
QPCR assays to amplify 19 regions of the mitochondrial genome (Table A.8) 
were performed using Applied Biosystems 7300 System with a final volume of 25uL 
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reaction mixture containing 50ng DNA template, 12.5uL SYBR Green PCR Master Mix 
(Qiagen), and 10mM of each primer.  The QPCR conditions were set up as follows: hot 
start at 95° C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 
1 minute.  Two microliters of QPCR products were spotted on Hybond N+ membrane 
(GE).  Dot blot preparation and hybridization conditions are available in the Appendix 
(Table A.11).  The allele-specific oligonucleotide (ASO) probes for the mtDNA variants 
are listed in Table A.9 (Bai et al, 2007).  These probes were labeled with Dioxigenin 
(DIG) (Roche, DIG Oligonucleotide 3'-End Labeling Kit).  Both the variant and wild type 
controls for each ASO blot were included as controls.  mtDNA haplogroups I, J, L, M 
and U5 were classified according to Table A.7. 
Bayesian network 
 In female samples, Bayesian Network Inference with Java Objects (Banjo) ©  
software was used to determine influence scores and to create a directed acyclic graph 
(DAG) to represent the Bayesian network showing  the probablilistic relationships 
between epilepsy status, MCD status, relative mtDNA copy number, oxidative mtDNA 
damage, and the mtSNPs with influence scores (absolute value) higher than 0.1.  The top 
three scoring networks were used to generate a consensus network. 
Statistical Analysis 
Continuous variables were studentized to identify and remove outliers. 
Logarithmic transformation of data was used since the original values of the relative 
mtDNA copy number and the content of 8-OHdG in mtDNA showed non normal 
distributions.  The continuous variables between groups were compared using the 
Student’s t-test and Fisher’s exact test for comparisons of the frequency of dichotomous 
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features.  Pearson’s correlation test was used to test the relationship between mtDNA 
copy number and the content of 8-OHdG in mtDNA.  Analysis was carried out using 
Fisher’s exact test for each individual mtSNP and haplogroup.   
Logistic regression was used to determine the adjusted odds ratio.  Epilepsy 
patients were sub-divided as those being malformations of cortical development (MCD) 
and non-MCD as per Barkovich MCD classification system (Barkovich et al., 2005).  
Logistic regression was also used to explore if epilepsy, MCD, or non-MCD phenotypes 
were dependent on mtSNPs, haplogroups, level of mtDNA oxidative damage, and level 
of relative mtDNA copy number, model adjusted by age.  In female samples, Banjo © 
software was used to determine influence scores and to create a directed acyclic graph 
(DAG) to represent the Bayesian network showing  the probablilistic relationships 
between epilepsy status, MCD status, relative mtDNA copy number, oxidative mtDNA 
damage, and the mtSNPs.  In addition, Pearson correlations were determined for these 
relationships.  Statistical analyses were performed using SPSS version 18.0 for Microsoft 
Windows.  Statistical significance was set at P < 0.05. 
Results 
Demographics and clinical information 
The demographic and pathology information of the pediatric non-neoplastic 
intractable epilepsy patients are shown in Table 1.1, and for the 11 control samples in 
Table 1.2.  After the removal of outliers there were 18 pediatric non-neoplastic epilepsy 
patients (MCD=12, non-MCD=6).  MCD cases accounted for ~66% of the non-neoplastic 
intractable epilepsy cases.  The majority (92%) of patients with MCD are classified as 
malformations due to abnormal glial and neuronal proliferation.  The groups did not 
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significantly differ in ages.  Using correlation methods, we demonstrate that mtDNA 
copy number and the degree of oxidative DNA damage were not significantly correlated 
(Pearson correlation= -0.28, p=0.19) (Fig. 1.1). 
Relative mtDNA copy number 
The measurement of DNA in individual amplifiable DNA segments is measured 
by quantitative real-time PCR (QPCR).  The use of SYBR green in QPCR assays allows 
for the detection of small difference in the starting template using nanograms of DNA.  
The higher threshold cycle (Ct), or shift of the amplification curve to the right, indicates a 
low amount of starting DNA template, thus, decreased DNA content.  Ratios of 
mtDNA/nuclear DNA were used to obtain the relative mtDNA copy number, where a 
lower ratio is representative of a lower initial DNA template, demonstrating a decrease in 
the amount of mtDNA.  We selected the nuclear 18s rRNA gene and mtDNA coding 
region of ND1 gene.  We used QPCR to analyze the relative mtDNA copy number of the 
pediatric intractable epilepsy brain tissues (non-neoplastic) and non-epileptic control 
brain tissues.  Tables 1.4 - 1.8 show the average relative mtDNA copy number for each 
group.  The relative mtDNA copy number (p=0.44) did not significantly differ between 
male and female epilepsy patients (Table 1.5).   A 70% increase in relative mtDNA copy 
number for non-neoplastic epilepsy samples was observed compared to controls                 
(p < 0.001).  Both MCD (2.34, p < 0.001) and non-MCD (2.60, p=0.02) samples 
demonstrated higher relative mtDNA copy numbers compared to controls (1.33).  MCD 
patients presented a lower relative mtDNA copy number (2.34) than non-MCD (2.60) 
epileptic patients, however, statistical significance was not achieved (p=0.58).  Higher 
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relative copy numbers were found in female non-neoplastic epilepsy samples compared 
to controls (p=0.01). 
Oxidative mtDNA damage  
The degree of oxidative mtDNA damage is reflected by an abundance of 8-OHdG 
formation in mtDNA, the content of 8-OHdG in mtDNA, an index for cellular oxidative 
damage, was determined by QPCR and presented as ∆Ct.  The degree of oxidative 
mtDNA damage, mtDNA∆Ct, was determined as ∆Ct= Ct2 (hOGG1 treatment) – Ct1 (no 
hOGG1 treatment), thus, the larger the ∆Ct, the more abundant the 8-OHdG and more 
oxidative damage present in the sample.  Tables 1.4 -1.8 show the oxidative mtDNA 
damage for each group.  Controls had higher oxidative mtDNA damage (0.59) compared 
to non-neoplastic epilepsy (0.43, p=0.47) and MCD (0.30, p=0.28), but lower oxidative 
mtDNA damage compared to non-MCD (0.77, p=0.21) groups, yet, statistical 
significance was not reached.  The degree of oxidative mtDNA damage (p=0.35) did not 
significantly differ between male and female epilepsy patients, and female epilepsy 
samples presented lower oxidative mtDNA damage than controls (p=0.24) (Table1. 5).    
mtDNA genotyping 
 In this study we analyzed the association between ten mitochondrial SNPs and 
non-neoplastic intractable epilepsy (MCD and non-MCD).  Alleles G9804A (p=0.51; 
Adjusted OR=1.27E9, 95% CI [0, NaN]) and G9952A (p=0.27; Adjusted OR=1.48E9, 
95% CI [0, NaN]) were found at higher frequencies in epilepsy samples compared to 
controls.  Controls had higher frequencies for the mitochondrial SNPs G3196A, T3197C, 
A10006G, A10398G, and the haplogroups I, J, L, M, and U5 compared to all non-
neoplastic epilepsy samples (Tables 1. 9 and 1.10), including MCD  (Tables 1.15 and 
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1.16) and non-MCD (Tables 1.12 and 1.13) sub-groups.  The European (I and J), African 
(L and M), and Asian (M) haplogroups were observed in both epilepsy and control 
samples.  The European haplogroup (U5) was not observed in the epilepsy (MCD and 
Non-MCD) samples.  However, no differences in the frequencies of SNPs and 
haplogroups were observed when comparing MCD and Non-MCD sub-groups (Tables 
1.19 and 1.20).  The same trends were observed when comparing female epilepsy 
samples with controls.  In addition, logistic regression revealed that epilepsy, MCD or 
non-MCD phenotypes did not significantly depend on level of relative mtDNA copy 
number, level of oxidative mtDNA damage, mtSNP or haplogroup status (Tables 1.21-
1.26).  A trend that the levels of relative mtDNA copy number and oxidative mtDNA 
damage and for the SNPs A4317G (OR= 1.00E8, 95% CI [0, NaN]) and T10010 (OR= 
1.69E38, 95% CI [0, NaN]) predicted epilepsy phenotype was observed, yet, there were 
large confidence intervals due to large standard error (Table 1.21).   
Bayesian network 
 In the female samples we used Banjo© software to learn a Bayesian network to 
study the relationships among epilepsy status, MCD status, relative mtDNA copy 
number, oxidative mtDNA damage, and the mtSNPs. A summary Bayesian network 
based on the top three Bayesian networks for the female samples was created (Figure 
1.2).  In this network epilepsy status is connected to oxidative mtDNA damage, relative 
mtDNA copy number, and to 6 mtDNA SNPs (T3197C, G3196A, A10398G, A10006G, 
G9952A, and A1555G).  The paths of oxidative mtDNA damage-A10006G-epilepsy; 
oxidative mtDNA damage-relative mtDNA copy number; epilepsy- relative mtDNA copy 
number; G9952A-epilepsy; epilepsy-A103098G, T3197C, G3196A, and A1555G are 
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shown in the summary Bayesian network.  The influence scores between several of these 
variables are depicted on Table 1.27.  The Pearson correlation of between selected 
variables based on the influence scores are found in Table 1.28.  Signficant correlations 
(p < 0.05) were found between epilepsy and MCD status, epilepsy and MCD with 
G9952A, epilepsy and MCD with oxidative mtDNA damage by relative mtDNA copy 
number, epilepsy and MCD with T3197C, G3196A, A10006G, and A10398G, to name a 
few.  Thus, the summary Bayesian network summarizes the relationship between mtDNA 
oxidative damage and copy number, SNPs (genes) and disease (phenotype).   
Discussion 
A role for mitochondrial dysfunction and oxidative stress in intractable epilepsy 
patients has been suggested (Shah et al., 2002; Waldbaum and Patel, 2010a).  Results of 
this study suggest mitochondria may play a critical role in the development of epilepsy. 
In this study we demonstrated that pediatric non-neoplastic intractable epilepsy patients 
(both MCD and non-MCD syndrome) have significantly higher mtDNA copy number 
than controls.  Female epilepsy samples presented signficantly higher mtDNA copy 
number and a trend of lower oxidative mtDNA damage compared to controls.  The 
degree of oxidative mtDNA damage was lower among epilepsy patients, including MCD, 
compared to controls.  No significant differences by gender, regarding relative mtDNA 
copy number and degree of oxidative mtDNA damage, as well as mtDNA SNP and 
haplogroup background, were observed among pediatric epilepsy patients.  The mtDNA 
variants G9804A and G9952A, which code for COIII, were found in higher frequencies 
in the intractable epilepsy patients.  A trend in which G9804A and G9952A, along with 
the level of mtDNA copy number and the level of oxidative mtDNA damage, predict 
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MCD and non-MCD epilepsy phenotypes was observed.  In the female samples G9952A 
was found in higher frequency than controls.  In addition, in female samples, the 
summary Bayesian network demonstrated the statistically significant relationships 
between the oxidative mtDNA damage, relative mtDNA copy number, SNPs (T3197C, 
G3196A, A10398G, A10006G, G9952A, and A1555G), and epilepsy.  Additionally, the 
majority of the epilepsy patients were categorized as MCD that may be further classified 
as malformations due to abnormal glial and neuronal proliferation.  A key event in brain 
development is proliferation which begins around the 20th week of gestation (Lenroot and 
Giedd, 2006). 
Mammalian cells contain several hundreds to more than a thousand mitochondria. 
The size, shape and abundance of mitochondria vary drastically in different cell types and 
may change under differing energy demands and physiological or environmental 
conditions.  In a cell, the abundance of mitochondria is determined by biogenesis and 
division of the organelles.  The quantity of mitochondria per cell is tightly regulated by 
activation of specific transcription factors and signaling pathways (Lee and Wei, 2005).  
The assembly and functioning of the respiratory enzyme complexes in cells require 
coordinated expression the interaction of gene products between the mitochondrial and 
nuclear genomes.  Gene expressions of the mitochondria and nucleus respond in a 
complex manner to various physiological and developmental signals such as growth 
activation, neoplastic transformation, muscle contraction, cell differentiation and 
hormone action (Lee and Wei, 2005).  Control of biogenesis in mitochondria is a 
complex process.  Alterations in intracellular level of ROS are associated with changes in 
mitochondrial abundance, mtDNA copy number, and the expression of respiratory genes.  
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Persistent oxidative stress in mitochondria not only contributes to the somatic mtDNA 
mutations but also alter mtDNA replication rate, leading to an overall decline in the 
mitochondrial respiratory function.   
Replication of mtDNA occurs primarily during the S and G2 phases of the cell 
cycle, but most importantly can occur at any point of the cell cycle.  In addition, mtDNA 
replication does not occur concurrently with the growth and division of organelles, hence, 
mtDNA replication can occur without mitochondrial proliferation.  The copy number of 
mtDNA varies with cell type and is maintained within a range.  mtDNA copy number 
may be modulated according to the energy needs of the cell.  Changes in mtDNA copy 
number in response to exercise and hormone treatment have been observed (Lee and Wei, 
2005).  Currently, it is unclear how copy number of mtDNA and the abundance of 
mitochondria are regulated under different physiological and developmental conditions.   
mtDNA copy numbers can be modulated when physiological conditions are 
changed.  Environmental exposures can generate ROS and may induce the accumulation 
of mtDNA mutations in human tissue. mtDNA is more susceptible to oxidative damage 
due to its lack of histones and limited capacity to repair DNA damage, thus, consequently 
acquires mutations at greater rates than nuclear DNA.  Mitochondrial function is 
compromised as a result of oxidative damage and damage to mtDNA.  Oxidative stress 
stimulates mitochondrial proliferation to meet the energy needs for cell survival including 
repair of damage and synthesis of new proteins.   Oxidative stress causes excess ROS 
production resulting in further oxidative damage.  The increase of mtDNA copy number 
is dependent of the level of oxidative stress, the capacity of intracellular antioxidant 
system, the quality of mitochondria and mtDNA.  The increase of ROS production from a 
 69 
defective respiratory chain is thought to play a role in the increase of mitochondrial 
content.  ROS act as a second messenger to trigger the expression of nuclear respiratory 
factors and mitochondrial transcription factor to induce mitochondrial biogenesis and 
mitochondrial proliferation (Jiang et al., 2005).  Oxidative damage induces an increase in 
mitochondria and mtDNA to compensate for the decline in the function of mitochondrial 
respiration (Shen et al., 2008).  In other words, ROS resulting from oxidative stress 
interact with genetic signaling systems that upregulate gene expression to counteract 
stressor challenges and to re-establish hemeostatis.  Increase in mtDNA copy number has 
been found in diseases. 
The mtDNA copy number in leukocytes from patients aged 30 years and younger 
with MELAS and MERFF showed an increase in mtDNA copy number, and a depletion 
of mtDNA was found in patients 40 years and older (Liu et al., 2006).  Brinckmann et al. 
(2010), found increased mtDNA copy number in the brain tissue of a 16 year old girl 
with MERRF.  According to Lee and Wei (2005), increase in mtDNA copy number is 
associated with elevated levels of oxidative stress in the aging tissues, brain, lung, and 
skeletal muscle of aged individuals. Chen et al. (2007) found increased total mtDNA 
copy number in peripheral leukocytes in Huntington’s disease patients, and the 
transcription levels of mtDNA-encoded enzymes were not significantly elevated.  Chen et 
al. (2007) suggested that the oxidative damage to mtDNA in HD leukocytes has reached 
a threshold over which mtDNA-encoded mRNA expression was suppressed. 
Treatment of human cells with H2O2 and buthionine suphoximine, which deplete 
intracellular glutathione, an anti-oxidant, induces an increase in mtDNA copy number 
and mitochondrial mass (Lee et al., 2000).  Gamma-irradiated mice showed an increase in 
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relative mtDNA copy number in brain and spleen tissues, suggesting that the major 
mechanisms for maintenance of the mitochondrial genome is the induction of synthesis of 
new mtDNA copies because the repair systems in the mitochondria function at a low 
level efficiency (Malakhova, et al., 2005).  It has been suggested that increases of 
mtDNA copy number in aging tissue cells are a result of the feedback response that 
compensates for defective mitochondria bearing impaired respiratory chain or mutated 
mtDNA.  Mitochondrial copy number may be an influence on phenotypic expression.  
There have been several reports showing that oxidative stress may be an 
important mechanism of CNS damage.  Findings by Fukuda et al. (2008) suggest that 
oxidative stress plays an important role in brain damage in children and this damage 
correlates with disease state.  For example in status epilepticus excitatory glutamic acids 
released in massive amounts might injure neurons and the production of free radicals by 
excessive stimulation of excitatory amino acid receptors are considered to be the cause of 
epilepsy (Fukuda et al., 2008).  Increased oxidation by ROS in cellular macromolecules 
after prolonged seizures has been observed, and experimental seizures have shown 
impaired Ca2+ sequestering, excessive ROS production, increased nitric oxide and 
peroxynitrite generations after prolonged seizures at time points preceding neuronal death 
(Waldabaum and Patel, 2010).  Oxidative stress and mitochondrial dysfunction occur as a 
consequence of prolonged epileptic seizure and may contribute to seizure-induced brain 
damage (Patil et al., 2011). 
Temporal lobe epilepsy studies have suggested that preceding neuronal death, 
after status epilepticus, is the increased level of ROS observed in brain slices and slice 
cultures of several models of experimental epilepsy, such as kainite-induced hippocampal 
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damage or pilocarpine damage (Baron et al., 2007).  Concentrations of 8-OHdG in the 
cerebral spinal fluid (CSF) in samples from children with epilepsy were slightly higher 
than control group, but the differences were not statistically significant (Fukuda et al., 
2008).  Shokolenko et al. (2009) provided evidence that in the human colon carcinoma 
(HCT116) cell model treated with H2O2, both DNA repair and degradation processes 
operate on oxidatively damaged mtDNA.  They found that the elimination of damaged 
mtDNA is followed by an accumulation of linear mtDNA molecules, which are thought 
to represent degradation intermediate, that unlike undamaged circular mtDNA molecules, 
they are susceptible to exonucleolitic degradation.  Shokolenko et al. (2009) suggest that 
trends that if a cell is unable to repair all of the damage inflicted by the environmental 
insult (H2O2) in the mitochondrial genome, a fraction of the mtDNA molecules 
undergoes double-strand breaks and is degraded, while moderately damage genomes are 
repaired, reflected by the increase in mtDNA quantity.  Hence, the model presented by 
Shokolenko et al. (2009) provides a mechanistic explanation, in which moderately 
damaged mitochondrial genomes are repaired, for the observation that non-neoplastic 
MCD pediatric epilepsy patients presented a low oxidative mtDNA damage, as indicated 
by the low mtDNA∆Ct (formation of 8-OHdG), and increased mtDNA copy number. 
Overall, in our results, we interpret the increase in relative mtDNA copy number 
as a result of compensatory responses induced by mtDNA damage, in order to repress the 
actions of the oxidative damage.  The increase in mtDNA replication, as a response to 
oxidative damage, provides a propagation of mtDNA that has not been damaged by 
oxidative stress.  The resulting mtDNA copies do not contain the damage (DNA adducts), 
presenting an overall lower oxidative mtDNA damage.  Thus, the increase in undamaged 
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mtDNA dilutes the presence of damage mtDNA.  Understanding oxidative-stress induced 
alterations in mtDNA copy number is important for the development of novel drugs to 
prevent and treat intractable epilepsy. 
In addition, our study found that the mitochondrial SNP, G9952A, was found in 
the female epilepsy patients and not the control samples.  This mitochondrial variant 
codes for COIII.  It is believed that the majority of the ROS are generated by complexes I 
and III, likely due to the release of electrons by NADH and FADH into the ETC.  Hanna 
et al. (1998) identified the G9952A point mutation in a patient with encephalopathy and 
exercise intolerance.  This point mutation is located in 3’ end of the gene for the subunit 
of COIII and is thought to result in the loss of the last 13 amino acids of the C-terminal 
region of this subunit.  Epilepsy has been reported in only a few cases of LHON (Kudin 
et al., 2009; Niehusman et al, 2011).  Our results suggest that the presence of these 
mitochondrial mutations in COIII, in conjunction with environmental insults, may induce 
mitochondrial dysfunction in epilepsy.  Hence, the role and mechanisms dysfunction of 
COIII of the respiratory chain in epileptogenesis and MCD needs to be explored further.  
In addition, the Bayesian network shows a relationship between mitochondria, mtSNP 
G9952A, and epilepsy phenotype.  
In summary, our study shows increased relative mtDNA copy number in brain 
tissues from pediatric non-neoplastic epilepsy patients.  The use of a summary Bayesian 
network of the female samples demonstrated the statistically significant relationships 
between the oxidative mtDNA damage, relative mtDNA copy number, SNPs (T3197C, 
G3196A, A10398G, A10006G, G9952A, and A1555G), and epilepsy.  Additionally, the 
majority of epilepsy patients belonged to MCDs due to abnormal glial and neuronal 
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proliferation indicating that environmental insults during this process of brain 
development should be explored.  The strength of this study is the direct measurements of 
relative mtDNA copy number, oxidative mtDNA damage, and genotyping for mtSNPs 
from the lesioned brain tissues resected from the pediatric epilepsy patients.  The 
summary Bayesian networks for the female samples indicate statistically significant 
relationships between disease phenotype with several of the mtSNPs, oxidative mtDNA 
damage, and relative mtDNA copy number.  Qualitative changes in mitochondrial 
genome with specific mutations or deletions in mtDNA have been frequently reported in 
patients with mitochondrial diseases.  However, there are limited studies that have 
addressed the change in mtDNA copy number in mitochondrial diseases and epilepsy 
disorders.  Many studies have investigated acute consequences of status epilepticus on 
cellular constituents but less is known about the role of oxidative stress and 
mitochondrial dysfunction in chronic epilepsy.  To our knowledge, this is the first study 
to explore mtDNA copy number, oxidative mtDNA oxidative stress in MCD pediatric 
epilepsy patients.   
A major limitation of this study is the small sample size.  However, results from 
this study provide the foundation, for proper determination of sample size in pediatric 
intractable epileptics, such as the frequency of mtSNPs in pediatric epilepsy patients, and 
the mean and standard deviation for further research regarding measurement of oxidative 
mtDNA damage.   For example, utilizing the results from this study, in order to compare 
oxidative mtDNA damage between epilepsy (non-tumor) and control samples, and for the 
study to reach 80% power with an alpha level of 0.05 requires a sample size of 558 (279 
disease and 279 control samples).  In order to acquire these sample sizes, a multi-facility 
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(and institution) study is needed to explore the oxidative mtDNA damage, mtDNA copy 
number, and mtSNPs in children with intractable epilepsy.  Findings from this study raise 
the possibility that inhibition of mitochondrial dysfunction may play a role in successful 
treatment of epilepsy.  Overall, findings of this study indicate a role of mitochondria in 
epilepsy.  
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Table 1.1.   
Clinical profile of pediatric patients with intractable epilepsy 
 
Sample  Age (years) Gender Diagnosis MCD Status Pathology 
7 15 F intractable epilepsy MCD cortical dysplasia, type IA 
9 18 F intractable epilepsy MCD focal cortical dysplasia, Taylor type IIB 
10 6 M intractable epilepsy Non-MCD mild neuronal disorganization 
11 13 F intractable epilepsy Non-MCD cystic encephalomalacia 
18 3 F intractable epilepsy Non-MCD meningioangiomatosis 
20 2 M intractable epilepsy Non-MCD gliosis 
23 7 F intractable epilepsy MCD cortical dysplasia with Rasmussen's 
encephalitis 
24 4 M intractable epilepsy MCD cortical dysplasia, type IIA 
25 4 F intractable epilepsy MCD tuberous sclerosis 
27 16 F intractable epilepsy MCD cortical dysplasia,  type IIB 
30 5 M intractable epilepsy MCD glioneuronal neoplasm/possible ganglioglioma 
31  N/A N/A  intractable epilepsy Non-MCD Information not available 
33 N/A  N/A  intractable epilepsy Non-MCD Information not available 
34 3 M intractable epilepsy MCD cortical dysplasia 
37 2 F intractable epilepsy MCD cortical dysplasia with Rasmussen's 
encephalitis 
38 17 F intractable epilepsy Non-MCD Information not available 
40 10 F intractable epilepsy MCD cortical dysplasia, Palmini type IA 
42 3 F intractable epilepsy MCD cortical dysplasia, type 1A 
43 9 M intractable epilepsy MCD cortical dysplasia, type 1A 
45  N/A N/A  intractable epilepsy Non-MCD Information not available 
48 6 M intractable epilepsy MCD cortical dysplasia, Palmini type 1B 
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Table 1.2   
Profile of control samples obtained from NICHD Brain and Tissue Bank for 
Developmental Disorders at the University of Maryland 
 
Sample  Age (years) Gender History/ Cause of Death 
Control 1 15 F car accident, multiple injuries 
Control 2 18 F car accident, multiple injuries 
Control 3 13 F asphyxia by hanging 
Control 4 2 F drowning 
Control 5 2 F drowning 
Control 6 8 F  asphyxia and multiple injuries 
Control 7 4 F lymphocytic myocarditis  
Control 8 16 F car accident, multiple injuries 
Control 9 2 F car accident, multiple injuries 
Control 10 17 F car accident, multiple injuries 
Control 11 10 F Asthma 
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Table 1.3.   
Mitochondrial SNPs and haplogroups used in this study 
  
Variant Region Reported in Patients 
A1555G 12S rRNA Maternally inherited deafness or aminoglycoside-induced deafness 
G3196A 16S rRNA Alzheimer’s Disease and Parkinson’s Disease (ADPD) 
T3197C 16S rRNA Haplogroup (Hg)-U5 
G4309A tRNA Ile Chronic Progressive External Ophthalmoplegia (CPEO) 
A4317G tRNA Ile Fatal Infantile Cardiomyopathy (FICP) 
G9804A CO III Leber Hereditary Optic Neuropathy (LHON) 
G9952A CO III Mitochondrial Encephalopathy 
A10006G tRNA Gly Chronic intestinal pseudo-obstruction (CIPO) 
T10010C tRNA Gly Progressive encephalopathy (PEM) 
A10398G ND3 ↓PD, ↓AD;A-↑Breast Cancer  (BRCA) in AA, Hg-I, J, L, M 
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Figure 1.1.   
Correlation between the mtDNA copy number and degree of oxidative mtDNA 
damage.  The relative mtDNA copy numbers of the intractable epilepsy tissues and 
control tissues with their relationship to degree of oxidative mtDNA damage are plotted.  
The results show that the two parameters were not significantly correlated (Pearson 
correlation coefficient= -0.28, p= 0.19).
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Table 1.4.   
Comparison of demographic, mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients and non-epileptic control from NICHD Brain and Tissue Bank 
 
  
All Cases  
(n=29) 
Non-neoplastic 
epilepsy    
(n=18)  
Control          
(n=11) P-value 
          
Age (years) 8.13 + 5.89  6.96 + 5.37  9.73 + 6.44  0.24 
Sex (M/F) 7/19 7/8 0/11 0.01 
log Relative mtDNA copy number          
Median 1.67 1.92 1.37   
Mean + S.D. 1.87 + 0.79 2.26 + 0.84 1.33 + 0.21 <0.001 
> 1.67 (high) (%)   13 (87) 0 (0) <0.001 
< 1.67 (low) (%) 2 (13) 11 (100)   
          
log Degree of oxidative mtDNA 
damage (∆Ct)         
Median 0.66 0.74 0.63   
Mean + S.D. 0.51 + 0.49 0.43 + 0.66 0.59 + 0.27 0.47 
> 0.66 (high damage) (%)   6 (40) 5 (45) 0.69 
< 0.66 (low damage) (%) 9 (60) 6 (55)   
          
Degree of oxidative mtDNA damage/ 
log Relative mtDNA copy number          
Median 0.40 0.33 0.42   
Mean + S.D. 0.36 + 0.30 0.24 + 0.31 0.46 + 0.25 0.09 
> 0.40 (high damage) (%)   4 (27) 6 (55) 0.66 
< 0.40 (low damage) (%) 6 (60) 4 (36)   
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Table 1. 5.   
Comparison of demographic, mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients and non-epileptic control from NICHD Brain and Tissue Bank by gender 
 
 
  
All Cases 
(n=29) 
Epilepsy 
Male    
(n=7) 
Epilepsy  
Female        
(n=8) 
Control 
Female      
(n=11) aP-value bP-value cP-value 
Age (years) 8.13 + 5.89 4.33 + 2.91 9.25 + 6.13  9.73 + 6.44 0.70 0.03 0.87 
log Relative mtDNA copy number                
Median 1.67 2.05 1.88 1.37       
Mean + S.D. 1.87 + 0.79 2.45 + 1.02 2.10 + 0.67 1.33 + 0.21 0.44 0.03 0.01 
> 1.67 (high) (%)   7 (100) 2 (25) 0 (0) 0.007 <0.001 0.001 
< 1.67 (low) (%) 0 (0) 6 (75) 11 (100)       
log Degree of oxidative mtDNA 
damage (∆Ct)               
Median 0.66 0.90 0.36 0.63       
Mean + S.D. 0.51 + 0.49 0.77 + 0.40 0.20 + 0.72 0.59 + 0.27 0.20 0.35 0.24 
> 0.66 (high damage) (%)   3 (43) 3 (38) 5 (45) 0.57 0.56 1.00 
< 0.66 (low damage) (%) 1 (14) 3 (38) 6 (55)       
Degree of oxidative mtDNA 
damage/ log Relative mtDNA copy 
number                
Median 0.40 0.37 0.19 0.42       
Mean + S.D. 0.36 + 0.30 0.35 + 0.20 0.17 + 0.37 0.46 + 0.25 0.40 0.44 0.07 
> 0.40 (high damage) (%)   2 (29) 2 (25) 6 (55) 1.00 1.00 0.61 
< 0.40 (low damage) (%) 2 (29) 4 (50) 4 (36)     
 
aP-value for Epilepsy, Male vs. Epilepsy, Female 
bP-value for Epilepsy, Male vs. Control 
cP-value for Epilepsy, Female vs. Control 
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Table 1.6.  
Comparison of demographic and mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients with MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
 
  
All Cases 
(n=23) 
MCD         
(n=12)  
Control   
(n=11) P-value 
          
Age (years) 8.10 + 5.83  6.61 + 5.02  9.73 + 6.44  0.21 
Sex (M/F) 5/18 5/7 0/11 0.04 
log Relative mtDNA copy number          
Median 1.53 2.03 1.37   
Mean + S.D. 1.86 + 0.85 2.34 + 0.93 1.33 + 0.21 0.002 
> 1.53 (high) (%)   10 (83) 1 (9) 0.002 
< 1.53 (low) (%) 2 (17) 9 (82)   
          
log Degree of oxidative mtDNA 
damage (∆Ct)         
Median 0.63 0.44 0.63   
Mean + S.D. 0.47 + 0.49 0.30 + 0.68 0.59 + 0.27 0.28 
> 0.63 (high damage) (%)   4 (33) 5 (45) 1.00 
< 0.63 (low damage) (%) 4 (33) 4 (36)   
          
Degree of oxidative mtDNA damage/ 
log Relative mtDNA copy number          
Median 0.36 0.20 0.42   
Mean + S.D. 0.34 + 0.31 0.18 + 0.32 0.46 + 0.25 0.05 
> 0.36 (high damage) (%)   2 (17) 7 (64) 0.15 
< 0.36 (low damage) (%) 5 (42) 3 (27)   
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Table 1.7. 
Comparison of demographic and mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients with non-MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
 
  
All Cases 
(n=17) 
Non-MCD 
(n=6)  
Control          
(n=11) P-value 
          
Age (years) 8.33 + 7.77 6.96 + 5.37  9.72 + 6.44  0.24 
Sex (M/F) 2/12 2/1 0/11 0.03 
log Relative mtDNA copy number          
Median 1.49 2.43 1.37   
Mean + S.D. 1.78 + 0.82 2.60 + 0.88 1.33 + 0.21 0.02 
> 1.49 (high) (%)   6 (100) 8 (73) 0.01 
< 1.49 (low) (%) 0 (0) 2 (18)   
          
log Degree of oxidative mtDNA 
damage (∆Ct)         
Median 0.69 0.77 0.63   
Mean + S.D. 0.65 + 0.26 0.77 + 0.21 0.59 + 0.27 0.21 
> 0.69 (high damage) (%)   4 (67) 4 (36) 0.28 
< 0.69 (low damage) (%) 1 (17) 7 (64)   
          
Degree of oxidative mtDNA damage/ 
log Relative mtDNA copy number          
Median 0.41 0.28 0.42   
Mean + S.D. 0.42 + 0.23 0.24 + 0.31 0.46 + 0.25 0.31 
> 0.41 (high damage) (%)   1 (17) 6 (55) 0.57 
< 0.41 (low damage) (%) 3 (50) 5 (45)   
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Table 1.8.  
Comparison of demographic, mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients with MCD and non-MCD 
 
  
All Cases 
(n=18) 
MCD           
(n=12)  
Non-MCD      
(n= 6) P-value 
          
Age (years) 6.96 + 5.37 6.6 + 5. 01 8.33 + 7.78 0.63 
Sex (M/F) 2/12 2/1 5/12 0.57 
log Relative mtDNA copy number          
Median 2.09 2.03 2.43   
Mean + S.D. 2.43 + 0.89 2.34 + 0.93 2.60 + 0.89 0.58 
> 2.09 (high) (%)   6 (50) 3 (50) 1.00 
< 2.09 (low) (%) 6 (50) 3 (50)   
          
log Degree of oxidative mtDNA damage 
(∆Ct)       
Median 0.75  0.44 0.76   
Mean + S.D. 0.48 + 0.58 0.30 + 0.68 077. + 0.21 0.10 
> 0.75 (high damage) (%)   3 (25) 3 (50) 0.55 
< 0.75 (low damage) (%) 5 (42) 1 (17)   
          
Degree of oxidative mtDNA damage/ 
log Relative mtDNA copy number          
Median 0.29  0.20 0.29   
Mean + S.D. 0.24 + 0.27 0.18 + 0.32 0.33 + 0.17 0.36 
> 0.29 (high damage) (%)   3 (25) 2 (33) 1.00 
< 0.29 (low damage) (%) 4(12) 3 (50)   
  
89
Table 1.9.   
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric intractable epilepsy 
patients and non-epileptic control from NICHD Brain and Tissue Bank   
 
SNPs 
Epilepsy          
(n=18) 
       Controls            
         (n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/   
    SNP % 
Positive/   
   SNP % 
  
A1555G 15 83 11 100 0.27 0 0, NaN 0 0, NaN 
G3196A 7 39 11 100 <0.001 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
G4309A 15 83 11 100 0.27 0 0, NaN 0 0, NaN 
A4317G 15 83 11 100 0.27 0 0, NaN 0 0, NaN 
G9804A 2 11 0 0 0.51 1.11E9 0, NaN 1.27E9 0, NaN 
G9952A 3 17 0 0 0.27 1.19E9 0, NaN 1.48E9 0, NaN 
A10006G 1 5 11 100 <0.001 0 0, NaN 0 0, NaN 
T10010C 5 28 7 64 0.12 0.22 0.04, 1.09 0.29 0.05, 1.55 
A10398G 1 5 11 100 <0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 1.10.   
The results of the Fisher’s exact test for individual haplogroups for in Miami Children’s Hospital pediatric intractable 
epilepsy patients and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
Epilepsy          
(n=18) 
       Controls          
         (n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 1 5 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-J 1 5 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-L 1 5 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-M 1 5 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-U5 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
 
 
 
 
 
 
  
91
 Table 1.11.  
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric intractable epilepsy 
male patients and non-epileptic control from NICHD Brain and Tissue Bank   
 
SNPs 
Epilepsy Male     
(n=7) 
       Controls           
         (n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/  
    SNP % 
Positive/  
   SNP % 
  
A1555G 6 86 11 100 0.39 0 0, NaN 0 0, NaN 
G3196A 3 43 11 100 0.01 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
G4309A 6 86 11 100 0.39 0 0, NaN 0 0, NaN 
A4317G 5 71 11 100 0.14 0 0, NaN 0 0, NaN 
G9804A  1 14 0 0 0.39 2.96E9 0, NaN 1.39E9 0, NaN 
G9952A 2 29 0 0 0.14 3.55E9 0, NaN 2.17E9 0, NaN 
A10006G 1 14 11 100 <0.001 0 0, NaN 0 0, NaN 
T10010C 3 43 7 64 0.63 0.43 0.06, 2.97 0.48 0.05, 4.29 
A10398G 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table1. 12. 
The results of the Fisher’s exact test for individual haplogroups for in Miami Children’s Hospital pediatric intractable 
epilepsy male patients and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
Epilepsy Male     
(n=7) 
       Controls           
         (n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-J 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-L 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-M 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-U5 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 1.13.  
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric intractable epilepsy 
female patients and non-epileptic control from NICHD Brain and Tissue Bank   
 
SNPs 
Epilepsy          
Female           
(n=8) 
       Controls           
         (n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/  
    SNP % 
Positive/  
   SNP % 
  
A1555G 6 75 11 100 0.16 0 0, NaN 0 0, NaN 
G3196A 2 25 11 100 0.001 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 0.001 0 0, NaN 0 0, NaN 
G4309A 6 75 11 100 0.16 0 0, NaN 0 0, NaN 
A4317G 7 88 11 100 0.42 0 0, NaN 0 0, NaN 
G9804A 0 0 0 0 1.00 NaN NaN, NaN 1.01 0.87, 1.18 
G9952A 1 13 0 0 0.42 2.54E9 0, NaN 3.15E9 0, NaN 
A10006G 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
T10010C 2 25 7 64 0.17 0.14 0.02, 1.16 0.19 0.25, 1.45 
A10398G 1 13 11 100 <0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 1. 14. 
The results of the Fisher’s exact test for individual haplogroups for in Miami Children’s Hospital pediatric intractable 
epilepsy female patients and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
Epilepsy   
Female         
(n=8) 
       Controls           
         (n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 1 13 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-J 1 13 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-L 1 13 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-M 1 13 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-U5 0 0 9 82 0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 1.15.   
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric intractable epilepsy 
patients with MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
SNPs 
MCD            
(n=12) 
Controls         
(n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/  
    SNP % 
Positive/  
   SNP % 
  
A1555G 10 83 11 100 0.48 0 0, NaN 0 0, NaN 
G3196A 5 42 11 100 0.01 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
G4309A 9 75 11 100 0.22 0 0, NaN 0 0, NaN 
A4317G 9 75 11 0 0.22 0 0, NaN 0 0, NaN 
G9804A 1 8 0 0 1.00 1.62E9 0, NaN 1.01E9 0, NaN 
G9952A 1 8 0 0 1.00 1.62E9 0, NaN 4.27E9 0, NaN 
A10006G 0 0 11 100 <0.001 0 0, NaN --- --- 
T10010C 3 25 7 64 0.10 0.19 0.03, 1.14 0.22 0.04, 1.38 
A10398G 1 8 11 100 <0.001 0 0, NaN 0 0, NaN 
 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
 
  
96
Table 1.16.   
The results of the Fisher’s exact test for individual haplogroups for in Miami Children’s Hospital pediatric intractable 
epilepsy patients with MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
MCD            
(n=12) 
Controls          
(n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 1 8 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-J 1 8 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-L 1 8 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-M 1 8 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-U5 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 1.17.   
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric intractable epilepsy 
patients with non-MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
SNPs 
Non-MCD        
(n=6) 
Controls         
(n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/  
    SNP % 
Positive/  
   SNP % 
  
A1555G 5 83 11 100 0.35 0 0, NaN 0 0, NaN 
G3196A 2 33 11 100 0.01 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
G4309A 6 100 11 100 1.00 NaN 0, NaN NaN 0, NaN 
A4317G 6 100 11 100 1.00 NaN 0, NaN NaN 0, NaN 
G9804A 1 17 0 0 0.35 3.55E9 0, NaN NaN 0, NaN 
G9952A 2 33 0 0 0.11 4.44E9 0, NaN 1.78E10 0, NaN 
A10006G 1 17 11 100 <0.001 0 0, NaN 7.30E13 0, NaN 
T10010C 2 33 7 64 0.34 0.29 0.04, 2.32 1.07 0.07, 16.39 
A10398G 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 1.18.   
The results of the Fisher’s exact test for haplogroups for in Miami Children’s Hospital pediatric intractable epilepsy 
patients with non-MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
Non-MCD        
(n=6) 
Controls         
(n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-J 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-L 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-M 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-U5 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
 
 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 1.19.   
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric intractable epilepsy 
patients with MCD and non-MCD 
 
SNPs 
MCD            
(n=12)           
Non-MCD         
(n=6) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
 Confidence 
Interval 
Positive/  
    SNP % 
Positive/  
   SNP % 
  
A1555G 10 83 5 82 1.00 1.00 0.07, 13.87 0.37 0.02, 6.69 
G3196A 5 42 2 30 1.00 1.43 0.18, 11.09 0 0, NaN 
T3197C 0 0 0 0 1.00 NaN NaN, NaN 0.94 0.75, 1.19 
G4309A 9 75 6 100 0.52 0 0, NaN 0 0, NaN 
A4317G 9 75 6 100 0.52 0 0, NaN 0 0, NaN 
G9804A 1 8 1 17 1.00 0.45 0.02, 8.83 0 0, NaN 
G9952A 1 8 2 33 0.25 0.18 0.01,2.60 0.05 0.90, 548.77 
A10006G 0 0 1 17 0.33 0 0, NaN 0 0, NaN 
T10010C 3 25 2 33 1.00 0.67 0.08, 5.68 0.15 0.39, 111.37 
A10398G 1 8 0 0 1.00 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds ratio using non-MCD as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 1.20.   
The results of the Fisher’s exact test for haplogroups for in Miami Children’s Hospital pediatric intractable epilepsy 
patients with MCD and non-MCD 
 
Haplogroups 
MCD            
(n=12)           
Non-MCD         
(n=6) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 1 8 0 0 1.00 0 0, NaN 0 0, NaN 
Hg-J 1 8 0 0 1.00 0 0, NaN 0 0, NaN 
Hg-L 1 8 0 0 1.00 0 0, NaN 0 0, NaN 
Hg-M 1 8 0 0 1.00 0 0, NaN 0 0, NaN 
Hg-U5 0 0 0 0 1.00 NaN NaN, NaN 0.94 0.75, 1.19 
 
 
aOR, Crude Odds ratio using non-MCD as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 1.21.   
The results of the logistic regression for SNPs/Hg, level of relative mtDNA copy number, level of oxidative mtDNA damage, 
and age in Miami Children’s Hospital pediatric intractable epilepsy patients and non-epileptic control from NICHD Brain 
and Tissue Bank   
 
 
SNP/Hg 
SNP/Hg                
OR (95% CI) 
Level of relative 
mtDNA copy number 
OR (95% CI) 
Level of oxidative 
mtDNA damage         
OR (95% CI) 
Age  
  OR (95% CI) 
A1555G 0.32 (0, NaN) 2.35E17 (0, NaN) 2.34E8 (0, NaN) 1.15 (0.72, 1.84) 
G3196A --- --- --- --- 
T3197C 0 (0, NaN) 9.69E27 (0, NaN) 1.02E23 (0, NaN) 33.39 (0, NaN) 
G4309A 0.12 (0, NaN) 1.49E17 (0, NaN) 2.39E8 (0, NaN) 1.52 (0.72, 1.84) 
A4317G 1.00E8 (0, NaN) 4.40E17 (0, NaN) 2.66E8 (0, NaN) 1.15 (0.72, 1.84) 
G9804A 0 (0, NaN) 4.44E17 (0, NaN) 2.67E8 (0, NaN) 1.15 (0.72, 1.84) 
G9952A 0 (0, NaN) 4.40E17 (0, NaN) 2.66E8 (0, NaN) 1.15 (0.72, 1.84) 
A10006G --- --- --- --- 
T10010C 1.69E38 (0, NaN) 8.32E90 (0, NaN) 8.56E37 (0, NaN) 4.24E4 (0, NaN) 
A10398G --- --- --- --- 
Hg-I --- --- --- --- 
Hg-J --- --- --- --- 
Hg-L --- --- --- --- 
Hg-M --- --- --- --- 
Hg-U5 0 (0, NaN) 9.69E27 (0, NaN) 1.02E23 (0, NaN) 33.39 (0, NaN) 
 
OR, using control group as reference 
NaN = Not a number 
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Table 1.22.  
The results of the logistic regression for SNPs/Hg, level of index of level  relative mtDNA copy number by level of oxidative 
mtDNA damage, and age in Miami Children’s Hospital pediatric intractable epilepsy male patients and non-epileptic 
control from NICHD Brain and Tissue Bank   
 
 
SNP/Hg 
SNP/Hg                 
OR (95% CI) 
Level of Index 
 OR (95% CI) 
Age                         
OR (95% CI) 
A1555G 0 (0, NaN) 0.31 (0.02, 5.93) 1.23 (0.87, 1.74) 
G3196A 0 (0, NaN) 0 (0, NaN) 1.12 (0.74, 1.69) 
T3197C 0 (0, NaN) 0 (0, NaN) 1.18 (0.77, 1.81) 
G4309A --- 0.68 (0.05,8.64) 1.21 (0.91, 1.60) 
A4317G 0 (0, NaN) 1.52 (0.08, 29.20) 1.23 (0.88, 1.72) 
G9804A 4.85E9 (0, NaN) 0.366 (0.02, 6.15) 1.16 (0.88, 1.54) 
G9952A 8.89E9 (0, NaN) 0.31 (0.02, 5.93) 1.23 (0.87, 1.74) 
A10006G --- --- --- 
T10010C 0.89 (0.07, 11.83) 0.68 (0.05, 8.72) 1.20 (0.91, 1.60) 
A10398G --- --- --- 
Hg-I --- --- --- 
Hg-J --- --- --- 
Hg-L --- --- --- 
Hg-M --- --- --- 
Hg-U5 0 (0, NaN) 0 (0, NaN) 1.18 (0.77, 1.81) 
 
OR, using control group as reference 
Nan, not a number 
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Table 1.23.   
The results of the logistic regression for SNPs/Hg, level of relative mtDNA copy number, level of oxidative mtDNA damage, 
and age in Miami Children’s Hospital pediatric intractable epilepsy female patients and non-epileptic control from NICHD 
Brain and Tissue Bank   
 
 
SNP/Hg 
SNP/Hg             
OR (95% CI) 
Level of relative 
 mtDNA copy number  
OR (95% CI) 
Level of oxidative 
 mtDNA damage          
OR (95% CI) 
Age                   
OR (95% CI) 
A1555G 0.15 (0, NaN) 4.02E17 (0, NaN) 3.55E8 (0, NaN) 1.15 (0.72, 1.84) 
G3196A --- --- --- --- 
T3197C 0 (0, NaN) 4.84E28 (0, NaN) 2.59E23 (0, NaN) 35.33 (0, NaN) 
G4309A 0.13 (0, NaN) 2.35E17 (0, NaN) 3.57E8 (0, NaN) 1.15 (0.72, 1.84) 
A4317G --- 7.94E17 (0, NaN) 3.54E8 (0, NaN) 1.15 (0.72, 1.84) 
G9804A --- 7.94E17 (0, NaN) 3.54E8 (0, NaN) 1.15 (0.72, 1.84) 
G9952A --- 7.94E17 (0, NaN) 3.54E8 (0, NaN) 1.15 (0.72, 1.84) 
A10006G --- --- --- --- 
T10010C 2.47E39 (0, NaN) 6.47E93 (0, NaN) 1.14E39 (0, NaN) 6.0E4 (0, NaN) 
A10398G --- --- --- --- 
Hg-I --- --- --- --- 
Hg-J --- --- --- --- 
Hg-L --- --- --- --- 
Hg-M --- --- --- --- 
Hg-U5 0 (0, NaN) 4.84E28 (0, NaN) 2.59E23 (0, NaN) 35.33 (0, NaN) 
 
OR, using control group as reference 
NaN = Not a number 
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Table 1.24.   
The results of the logistic regression for SNPs/Hg, level of relative mtDNA copy number, level of oxidative mtDNA damage, 
and age  for in Miami Children’s Hospital pediatric intractable epilepsy patients with MCD and non-epileptic control from 
NICHD Brain and Tissue Bank 
 
 
SNP/Hg 
SNP/Hg           
OR (95% CI) 
Level of relative 
mtDNA copy number 
OR (95% CI) 
Level of oxidative 
mtDNA damage         
OR (95% CI) 
Age                     
  OR (95% CI) 
A1555G 0 (0, NaN) 35.55 (1.73, 732.75) 1.57 (0.06, 42.17) 1.10 (0.82, 1.50) 
G3196A 0 (0, NaN) 5.60E42 (0, NaN) 12.61 (0, NaN)      9.29E6 (0, NaN)
  T3197C 0 (0, NaN) 1.18E14 (1.40, 620.98) 0 (0, NaN) 38.68 (0, NaN) 
G4309A 0 (0, NaN) 24.39 (1.40, 620.98) 1.95 (0.07, 55.61) 1.10 (0.81, 1.48) 
A4317G 0 (0, NaN) 38.29 (1.89, 777.18) 0.99 (0.05, 21.77) 1.08 (0.81, 1.43) 
G9804A 1.99E8 (0, NaN) 39.24 (1.94, 792.85) 1.00 (0.45, 22.36) 1.07 (0.80, 1.42) 
G9952A --- 44.31 (2.22, 886.30) 1.15 (0.05, 24.90) 1.08 (0.81, 1.45) 
A10006G --- --- --- --- 
T10010C 0.42 (0.02, 9.62) 37.07 (1.78, 771.30) 1.22 (0.06, 26.23) 1.07 (0.80, 1.43) 
A10398G --- --- --- --- 
Hg-I --- --- --- --- 
Hg-J --- --- --- --- 
Hg-L --- --- --- --- 
Hg-M --- --- --- --- 
Hg-U5 0 (0, NaN) 1.18E14 (1.40, 620.98) 0 (0, NaN) 38.68 (0, NaN) 
 
OR, using control group as reference 
NaN = Not a number 
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Table 1.25.   
The results of the logistic regression for haplogroups, level of relative mtDNA copy number, level of oxidative mtDNA 
damage, and age  for in Miami Children’s Hospital pediatric intractable epilepsy patients with non-MCD and non-epileptic 
control from NICHD Brain and Tissue Bank 
 
SNP/Hg 
SNP/Hg            
OR (95% CI) 
Level of relative mtDNA 
copy number  
OR (95% CI) 
Level of oxidative 
mtDNA damage          
OR (95% CI) 
Age                   
OR (95% CI) 
A1555G 0 (0, NaN) 1.54E16 (0, NaN) 1140 (0, NaN) 0  (0, NaN) 
G3196A --- --- --- --- 
T3197C --- --- --- --- 
G4309A --- 1.20E9 (0, NaN) 5.00E8 (0, NaN)) 1.05 (0.62, 1.87) 
A4317G --- 1.28E9 (0, NaN) 5.00E8 (0, NaN)) 1.05 (0.62, 1.87) 
G9804A --- 1.20E9 (0, NaN) 5.00E8 (0, NaN)) 1.08 (0.62, 1.87) 
G9952A 7.86E42 (0, NaN) 1.54E16 (0, NaN) 1140 (0, NaN) 0  (0, NaN) 
A10006G --- --- --- --- 
T10010C 0.0 (0, NaN) 4.42E48 (0, NaN) 2.56E11 (0, NaN) 151.07 (0, NaN) 
A10398G --- --- --- --- 
Hg-I --- --- --- --- 
Hg-J --- --- --- --- 
Hg-L --- --- --- --- 
Hg-M --- --- --- --- 
Hg-U5 0 (0, NaN) 1.18E14 (1.40, 620.98) 0 (0, NaN) 38.68 (0, NaN) 
 
OR, using control group as reference 
NaN = Not a number 
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Table 1.26.   
The results of the logistic regression for haplogroups, level of relative mtDNA copy number, level of oxidative mtDNA 
damage, and age for in Miami Children’s Hospital pediatric intractable epilepsy patients with MCD and non-MCD 
 
SNP/Hg 
SNP/Hg            
OR (95% CI) 
Level of relative mtDNA 
copy number  
OR (95% CI) 
Level of oxidative 
mtDNA damage          
OR (95% CI) 
Age                   
OR (95% CI) 
A1555G --- --- --- --- 
G3196A 0.46 (0, NaN) 0 (0, NaN) 3.99E9 (0, NaN) 0.76 (0.32, 1.84) 
T3197C --- 0 (0, NaN) 3.99E9 (0, NaN) 0.76 (0.32, 1.84) 
G4309A 0.30 (0, NaN) 0 (0, NaN) 5.61E9 (0, NaN) 0.76 (0.32, 1.84) 
A4317G 10.07 (0, NaN) 0 (0, NaN) 4.17E9 (0, NaN) 0.76 (0.32, 1.84) 
G9804A 0.49 (0, NaN) 0 (0, NaN) 4.03E9 (0, NaN) 0.76 (0.32, 1.84) 
G9952A --- --- --- --- 
A10006G --- 0 (0, NaN) 3.99E9 (0, NaN) 0.76 (0.32, 1.84) 
T10010C 0 (0,NaN) 0 (0, NaN) 1.31E117 (0, NaN) 2.50E14 (0, NaN) 
A10398G --- 0 (0, NaN) 3.99E9 (0, NaN) 0.76 (0.32, 1.84) 
Hg-I --- 0 (0, NaN) 3.99E9 (0, NaN) 0.76 (0.32, 1.84) 
Hg-J --- 0 (0, NaN) 3.99E9 (0, NaN) 0.76 (0.32, 1.84) 
Hg-L --- 0 (0, NaN) 3.99E9 (0, NaN) 0.76 (0.32, 1.84) 
Hg-M --- 0 (0, NaN) 3.99E9 (0, NaN) 0.76 (0.32, 1.84) 
Hg-U5 --- 0 (0, NaN) 3.99E9 (0, NaN) 0.76 (0.32, 1.84) 
 
OR, using Non-MCD as reference 
NaN = Not a number 
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Figure 1.2.   
Summary Beyesian network based on the top three Bayesian networks for female 
samples.  Absolute value on influence score higher than 0.1 are shown. 
 
 
Table 1.27. 
Influence scores between selected variables for female samples 
 
Variables Influence Score 
(Epilepsy) ->   (T3197C) 0.7826 
(Epilepsy) ->   (G3196A)    0.6288 
(Epilepsy) ->   (A10398G)    0.5383 
(A10006G) ->  (Epilepsy)    0.4858 
(G9952A) ->  (Epilepsy)    -0.4475 
(Epilepsy) ->   (A1555G) 0.1251 
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Table 1.28.   
Pearson correlation between selected variables based on the influence scores for female samples 
 
    
T3197C G3196A A10006G A10398G G9952A mcd status 
Epilepsy   -.832** -.832** -.832** -.913** .471* -.896**
Sig. 0 0 0 0 0.027 0
mcd status   .746** .817** .556** .853** -.573** 1
Sig. 0 0 0.007 0 0.005   
mtOXDamageDbyA10398G   0.179 0.009 0.383 0.235 0.141 0.088
Sig. 0.426 0.97 0.079 0.292 0.531 0.696
mtOXDamageDbyCopyNum   -.535* -0.383 -.467* -.705** 0.3 -.542**
Sig. 0.01 0.078 0.028 0 0.175 0.009
mtOXDamageD   -0.203 -0.354 0.017 -0.267 0.28 -0.339
Sig. 0.366 0.106 0.941 0.23 0.207 0.123
mtOXDamage   -0.189 -0.373 0.213 -0.246 .575** -0.349
Sig. 0.399 0.087 0.342 0.27 0.005 0.112
CopyNum   -.477* -0.189 -.523* -.628** 0.154 -0.409
Sig. 0.025 0.399 0.013 0.002 0.492 0.059
copyno   -0.221 0.15 -0.317 -0.293 -0.106 -0.145
Sig. 0.323 0.505 0.15 0.186 0.639 0.52
 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Table 1.28. (cont.)  
Pearson correlation between selected variables based on the influence scores for female samples 
 
    mtOXDamage
DbyA10398G 
mtOXDamage
DbyCopyNum 
mtOXDamage
D mtOXDamage CopyNum copyno 
Epilepsy   -0.276 .616** 0.183 0.137 .573** 0.268
Sig.  0.213 0.002 0.416 0.543 0.005 0.228
mcd status   0.088 -.542** -0.339 -0.349 -0.409 -0.145
Sig.  0.696 0.009 0.123 0.112 0.059 0.52
mtOXDamageDby
A10398G 
  1 0.106 .874** .648** -0.347 -0.367
Sig.    0.639 0 0.001 0.114 0.093
mtOXDamageDby
CopyNum 
  0.106 1 .457* 0.351 .865** .432*
Sig.  0.639   0.032 0.11 0 0.045
mtOXDamageD   .874** .457* 1 .765** -0.03 -0.217
Sig.  0 0.032   0 0.895 0.331
mtOXDamage   .648** 0.351 .765** 1 -0.036 -0.253
Sig.  0.001 0.11 0   0.872 0.257
CopyNum   -0.347 .865** -0.03 -0.036 1 .715**
Sig.  0.114 0 0.895 0.872   0
copyno   -0.367 .432* -0.217 -0.253 .715** 1
Sig.  0.093 0.045 0.331 0.257 0   
 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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CHAPTER IV 
 
MANUSCRIPT 2 
MITOCHONDRIAL DNA BACKGROUND AND OXIDATIVE DAMAGE IN 
INTRACTABLE EPILEPSY  
PEDIATRIC PATIENTS WITH BRAIN TUMORS  
Abstract 
Objectives:  Research mitochondrial background and mitochondrial DNA 
(mtDNA) damage in neoplastic pediatric intractable epilepsy patients.  mtDNA 
oxidative damage and copy number are indices of mitochondrial damage. 
Mitochondrial damage may play a role in the pathology of intractable epilepsy.  
The purpose of this study is to determine and compare mtDNA variants (SNPs) 
and mtDNA oxidative damage in neoplastic pediatric intractable epilepsy 
patients with malformations of cortical development (MCD) and non-MCD with 
non-epileptic controls. 
 
Methods:  Brain tissue specimens were collected from 27 neoplastic pediatric 
intractable epilepsy patients from Miami Children’s Hospital and 11 controls 
(non-epileptic) from UMB.  Oxidative mtDNA damage as indicated by 
mtDNA∆Ct (formation of 8-OHdG) and relative mtDNA copy number were 
determined for each tissue by quantitative real-time PCR (QPCR).  A total of 10 
SNPs associated with mitochondrial myopathies were genotyped by allele-
specific oligonucleotide dot (ASO) blot analysis. In female samples, a summary 
Bayesian network was created to investigate the relationship of these variables.  
 
Results:  Relative mtDNA copy number were higher in female neoplastic 
intractable epilepsy patients compared to non-epileptic control samples (p=0.34).  
Oxidative mtDNA damage was higher in female neoplastic epileptic compared to 
control samples (p=0.72).  mtSNP G9952A was found in higher frequencies in 
female neoplastic epilepsy samples. Female neoplastic epilepsy phenotypes were 
predicted by G9952A, level of relative mtDNA copy number, and level of 
oxidative mtDNA damage. Bayesian network showed relationships (p < 0.05) 
between brain tumor with G9952A, A1555G, T3197C, A10006G, A10398G, 
oxidative mtDNA damage with relative mtDNA copy number, and brain tumor 
with relative mtDNA copy number in female samples. 
 
Conclusion:  These data suggest that the mtSNPs explored are associated with 
neoplastic intractable epilepsy phenotypes.  mtDNA copy number and mtDNA∆Ct  
were higher in neoplastic epilepsy samples but did not reach statistical 
significance.  Studies exploring mitochondrial compensation in response to 
oxidative damage in neoplastic epilepsy are needed.  
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Epilepsy is a chronic neurological disorder characterized by spontaneous 
recurring seizures.  The incidence of epilepsy is highest for children and the elderly.  A 
proportion of patients have seizures that are resistant to traditional anti-epilepsy 
medicines (intractable or refractory epilepsy) (Alexander and Godwin, 2006).  Brain 
tumors are a common cause of epilepsy (Govori et al., 2010).  The occurrence of epilepsy 
is highly associated with malformations of cortical development (MCD), which are 
developmental brain lesions that consist of dysplastic neuronal lesions (malformations) 
(Schwartzkroin and Walsh, 2000; Hua and Crino, 2003; Hader et al., 2004; Rickert, 2006; 
Wong, 2007).  MCD are increasingly being recognized as the cause of intractable 
epilepsy.  MCD presents a broad spectrum of structural changes which appear to result 
from changes in precursor neuronal or neuronal cells during cortical development at 
various stages such as: proliferation, migration, differentiation, and apoptosis (Becker et 
al., 2004).  MCDs include gangliomas and dysembryoplastic neuroepithelial tumors 
(DNETs) (Majores et al., 2007).  Gangliogliomas are composed of neoplastic, highly 
differentiated glial cells, and dysplastic neurons (Schick et al., 2007).  DNETs are benign 
lesions of the cerebral cortex that are composed of glial and oligodendrocyte-like cells 
(neuronal elements) which resemble gliomas (Spalice et al., 2010). 
Treatment with anti-epileptic drugs (AEDs) is usually ineffective, and children 
with MCD may require surgical removal of the affected area of the brain (Yasin et al., 
2010).  In surgical series, focal cortical malformations and low-grade tumors were the 
most common in infants with intractable epilepsy.  Gangliogliomas account for 5% of 
childhood tumors (Schick et al., 2007a).  According to Saneto and Wyllie (2000), low-
grade tumors included gangliomas, gangliocytomas, DNETs, and astrocytomas.  DNETs 
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are often present with epilepsy during childhood (Chang et al., 2010).  Gangliogliomas 
are the most frequent tumors found in patients with focal epilepsy (Schick et al., 2007).  
The molecular mechanisms underlying the formation of MCD are still largely unknown 
and the treatments for epilepsy due to MCD are often ineffective or limited (Wong, 
2009).   
Through the mutation and dysregulation of critical genes, oxidative DNA damage 
has been implicated in the development of several human cancers (Kim et al., 2004). 
Oxidative insults may cause molecular damage that can drive the progression of normal 
tissue to cancer.  Oxidative DNA damage has been detected in cancer and 
neurodegenerative diseases (Tsutsui et al., 2001).   Alterations of mitochondria have been 
found in the human cancers including breast, esophageal, gastric, non-small-cell-lung 
cancer, and thyroid cancers (Kim et al., 2004).  Mitochondria contain their own genome, 
mtDNA, which consists of a 16.5-kb circular double-stranded DNA (dsDNA) molecule 
containing 37 genes (Bai et al., 2008).  Mitochondria functions in oxidative 
phosphorylation, heme, lipid, amino acid biosynthesis, and fatty acid oxidation among 
other functions (Sugimoto, 2008).  The major source of ATP in cortical neurons is 
provided by mitochondrial oxidative phosphorylation (Chuang, 2010; Waldbaum and 
Patel, 2010a).  Mammalian cells contain several hundreds to more than a thousand 
mitochondria.  The size, shape and abundance of mitochondria vary drastically in 
different cell types and may change under differing energy demands and physiological or 
environmental conditions.  In a cell, the abundance of mitochondria is determined by 
biogenesis and division of the organelles.  The quantity of mitochondria per cell is tighly 
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regulated by activation of specific transcription factors and signaling pathways (Lee and 
Wei, 2005).   
Mitochondrial metabolism also generates the majority of the reactive oxygen 
species (ROS) production in cells (St-Pierre et al., 2006).  ROS results when unpaired 
electrons escape the electron transport chain.  The most commonly produced base lesion 
by ROS, and the most often measured as an index of oxidative DNA damage is 8-
hydroxyguanosine (8-OHdG) (Wiseman and Halliwell, 1995).  The brain is believed to 
be particularly susceptible to the damaging effects of reactive oxygen species (ROS) 
damage due to its high metabolic rate and reduced capability for cellular regeneration 
compared to other organs (Anderson, 2004).  ROS has been implicated in the initial 
phases of seizure-induced pathology and several studies have reported oxidative stress in 
different regions of the brain following experimental seizures (Devi et al., 2008). 
Mitochondrial oxidative stress and dysfunction are contributing factors to several 
neurological disorders (Shokolenko et al., 2009; Waldbaum and Patel, 2010b).  
Encephalomyopathies have been found in children in association with defects in 
mitochondrial structure and function.  Some of these disorders are acute leukemia, 
Alzheimer’s disease (AD), cardiomyopathy (CM), chronic progressive external 
ophthalmoplegia, colorectal cancer, deafness, fatal infantile cardiomyopathy (FICP), 
gastroesopageal reflux (GER), mitochondrial encephalomyopathy, lactic acidosis and 
stroke-like episodes (MELAS), myoclonic epilepsy with ragged red fibers (MERRF), 
Leber Hereditary Optic Neuropathy (LHON),  Parkinson’s disease (PD), maternally 
inherited hypertropic cardiomyopathy (MHCM), multiple sclerosis (MS), non-insulin 
dependent diabetes mellitus (NIDDM), non-syndromic hearing loss, progressive 
 114 
encephalopathy (PEM), sensorineural hearing loss (SNHL), strokes, and sudden infant 
death syndrome (SIDS) (Filiano et al., 2002; Bai et al., 2007; Tzen et al., 2007).  In this 
study, we investigate the presence of oxidative mtDNA damage, constitutional mtDNA 
copy number, mtDNA SNPs, haplogroups as sources of genetic diversity that may 
contribute to the development of neoplastic intractable epilepsy. 
Methods 
Collection of brain tissue from pediatric intractable epilepsy patients 
Brain tissue samples from 25 pediatric neoplastic intractable epilepsy patients 
who have undergone brain resection surgery at the Miami Children’s Hospital, Miami, 
FL, during 2008-2009 were collected.  Tissues obtained during surgical resection were 
immediately snap-frozen in liquid nitrogen and stored at -80°C.  As references, eleven 
normal, non-epileptic, pediatric brain tissues were obtained from the NICHD Brain and 
Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD 
and stored at -80°C.  This study was approved by the Florida International University’s 
Institutional Review Board. 
DNA extraction  
Freshly excised human neuronal (brain) tissue was stored in liquid nitrogen and 
frozen in -80°C until ready for processing.  The frozen neuronal tissue was homogenized, 
while on ice, using a Janke and Kunkle TP-18-10 blade type homogenizer in which 1 ml 
of Trizol® was added.  The homogenate was transferred to a 2.0-ml microcentrifuge 
tube. DNA was then isolated and purified via Phenol-Chloroform extraction.  The 
precipitated DNA was pelleted and resuspended in1X TE buffer.  The integrity of the 
DNA was verified following electrophoresis through 2% agarose gels.  
 115 
Determination of and mtDNA copy number and mitochondrial DNA oxidative damage 
by quantitative real time PCR 
 Quantitative real-time PCR (QPCR) assays were performed using Applied 
Biosystems 7300 System with a final volume of 25uL reaction mixture containing 50ng 
DNA template, 12.5uL SYBR Green PCR Master Mix (Qiagen), and 10mM of each 
primer.  The sequences for the primers used for the amplification of the mitochondrial 
gene NADH Dehydrogenase 1 (ND1) were: mtF3212, 5’-
CACCCAAGAACAGGGTTTGT-3’ and mtR3319, 5’-TGGCCATGGGATTGTTAA-3’.  
The sequences of the primer for the nuclear housekeeping gene 18s rRNA, used for the 
normalization in the QPCR analysis, were: 18s1546F, 5’-
TAGAGGGACAAGTGGCGTTC-3’and 18s650R, 5’-CGCTGAGCCAGTCAGTGT-3’ 
(Bai et al., 2004; Lin et al, 2008).  The QPCR conditions were set up as follows: hot start 
at 95° C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute.  The fluorescence intensity was measured at the end of the extension phase at 
60°C.  All samples were performed in duplicated and a non-template negative control 
was included in each reaction.   
A total of 50ng of DNA was used in QPCR for the determination of the threshold 
cycle number (Ct) of the 18s rRNA and ND1 genes.  Ct values can be used as a measure 
of input copy number and the Ct value differences were used to quantify the mtDNA 
copy number relative to the 18s rRNA gene with the following equation:                         
Relative copy number= 2∆Ct, where ∆Ct is the Ct 18s rRNA – Ct ND1 (Szuhai et al., 
2001; Bai et al., 2004; Lewis et al., 2007; Edwards, 2009; Lee et al, 2010). 
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Since degree of oxidative mtDNA damage is reflected by an abundance of 8-
OHdG formation in mtDNA, the content of 8-OHdG in mtDNA, an index for cellular 
oxidative damage, was determined by QPCR and presented as ∆Ct (Ayala-Torres et al., 
2000).  As indicated by Lin et al (2008), the amplification efficiency would decrease after 
treatment of the DNA sample with hOGG1 to remove the 8-OHdG residue to form an 
abasic site.  The content of 8-OHdG in the samples’ mtDNA was determined by treating 
the 200ng sample with 2 units of hOGG1 at 37° C for 1 hour and 5 minutes to remove the 
8-OHdG residue to form an basic site.  The digested mtDNA were amplified by QPCR 
using the primers for ND1 gene.  PCR amplification efficiencies of DNA templates 
containing a single 8-OHdG or two 8-OHdGs at least 13 base pairs apart are not 
significantly disturbed (Ct1), however, the presence of an abasic site in DNA after 
treatment of hOGG1 would dramatically reduce the PCR efficiency, thus, increasing the 
Ct value (Ct2) (Lin et al., 2008).  The degree of oxidative mtDNA damage, mtDNA∆Ct, 
was defined as ∆Ct= Ct2 (hOGG1 treatment) – Ct1 (no hOGG1 treatment) (Lin et al., 
2008; Su et al., 2010).  Each analysis was performed in duplicate, and the mean value of 
∆Ct was calculated for each sample. Hence, the larger the ∆Ct, the more abundant the 8-
OHdG and more oxidative damage present in the sample.   
mtDNA genotyping 
A total of 50ng of DNA was used in Quantitative PCR (QPCR) to amplify the 
mitochondrial genome with 19 primer sets (Table A.8) designed by Bai et al (2007) to 
include the mtDNA regions containing 10 reported mtDNA variations (SNPs).  The 
mtDNA variations are distributed along the rRNA, tRNA, COIII and ND3 regions of the 
mitochondrial genome.  The mtDNA variations studied have been reported in patients 
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with varying diseases such as:  Alzheimer’s disease, Parkinson’s disease, Leber’s 
hereditary optic neuropathy (LHON), deafness, chronic progressive external 
ophthalmoplegia (CPEO), chronic intestinal pseudo-obstruction (CIPO) and other 
diseases (Table 2.3). 
QPCR assays to amplify 19 regions of the mitochondrial genome (Table A.8) 
were performed using Applied Biosystems 7300 System with a final volume of 25uL 
reaction mixture containing 50ng DNA template, 12.5uL SYBR Green PCR Master Mix 
(Qiagen), and 10mM of each primer.  The QPCR conditions were set up as follows: hot 
start at 95° C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 
1 minute.  Two microliters of QPCR products were spotted on Hybond N+ membrane 
(GE).  Dot blot preparation and hybridization conditions are available in the Appendix.  
The allele-specific oligonucleotide (ASO) probes for the mtDNA variants are listed in 
Table A.9 (Bai et al, 2007).  These probes were labeled with Dioxigenin (DIG) (Roche, 
DIG Oligonucleotide 3'-End Labeling Kit).  Both the variant and wild type controls for 
each ASO blot were included as controls.  mtDNA haplogroups I, J, L, M and U5 were 
classified according to Table A.7. 
Bayesian network 
 In female samples, Bayesian Network Inference with Java Objects (Banjo) © 
software was used to determine influence scores and to create a directed acyclic graph 
(DAG) to represent the Bayesian network showing  the probablilistic relationships 
between epilepsy status, MCD status, relative mtDNA copy number, oxidative mtDNA 
damage, and the mtSNPs with influence scores (absolute value) higher than 0.1.  The top 
three scoring networks were used to generate a consensus network. 
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Statistical Analysis 
Continuous variables were studentized to identify and remove outliers. 
Logarithmic transformation of data was used since the original values of the relative 
mtDNA copy number and mtDNA oxidative damage showed non normal distributions.  
The continuous variables between groups were compared using the Student’s t-test.  
Pearson’s correlation test was used to test the relationship between mtDNA copy number 
and mtDNA oxidative damage.  Analysis was carried out using Fisher’s exact test for 
each individual SNP and haplogroup.   
Logistic regression was used to determine the odds ratios.  Neoplastic epilepsy 
patients were sub-divided as those being malformations of cortical development (MCD) 
and non-MCD as per Barkovich MCD classification system (Barkovich et al., 2005).  
Logistic regression was also used to explore if neoplastic epilepsy, MCD, or non-MCD 
phenotypes were dependent on mtSNPs, haplogroups, level of mtDNA oxidative damage, 
and level of relative mtDNA copy number, model adjusted by age.  In female samples, 
Banjo © software was used to was used to determine influence scores and to create a  
directed acyclic graph (DAG) to represent the Bayesian network showing the 
probablilistic relationships between brain tumor status, MCD status relative mtDNA copy 
number, oxidative mtDNA damage, and the mtSNPs.  In addition, Pearson correlations 
were determined for these relationships.  Statistical analyses were performed using SPSS 
version 18.0 for Microsoft Windows.  Statistical significance was set at P < 0.05. 
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Results 
Demographics and clinical information 
The demographic and pathology information of the 27 pediatric neoplastic 
intractable epilepsy patients (MCD = 6, non-MCD = 21) are shown in Table 2.1, and for 
the 11 control samples in Table 2.2.  MCD cases accounted for 22% of the neoplastic 
intractable epilepsy cases.  All of the epilepsy patients with MCD are classified as 
malformations due to abnormal glial and neuronal proliferation.  The groups did not 
significantly differ in ages.  Using correlation methods, we demonstrate that mtDNA 
copy number and the degree of oxidative DNA damage were not significantly correlated 
(Pearson correlation=0.14, p=0.45) (Fig. 2.1).  However, in female samples the mtDNA 
copy number and the degree of oxidative DNA damage were significantly correlated 
(Pearson correlation=-0.61, p=0.001) (Table 2.28).   
Relative mtDNA copy number 
The measurement of DNA in individual amplifiable DNA segments is measured 
by quantitative real-time PCR (QPCR).  The use of SYBR green in QPCR assays allows 
for the detection of small difference in the starting template using nanograms of DNA.  
The higher threshold cycle (Ct), or shift of the amplification curve to the right, indicates a 
low amount of starting DNA template, thus, decreased DNA content.  Ratios of 
mtDNA/nuclear DNA were used to obtain the relative mtDNA copy number, where a 
lower ratio is representative of a lower initial DNA template, demonstrating a decrease in 
the amount of mtDNA.  We selected the nuclear 18s rRNA gene and mtDNA coding 
region of ND1 gene.  We used QPCR to analyze the relative mtDNA copy number of the 
neoplastic pediatric intractable epilepsy brain tissues and non-epileptic control brain 
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tissues.  Tables 2.4 -2.8 show the average relative mtDNA copy number for each group.  
The relative mtDNA copy number (p=0.82) did not significantly differ between male and 
female neoplastic epilepsy patients (Table 2.5).  A 21% increase in mtDNA copy number 
for neoplastic epilepsy samples was observed compared to controls (p=0.26).  Both MCD 
(2.03, p=0.14) and non-MCD (1.48, p=0.59) samples demonstrated a trend of higher 
mtDNA copy numbers compared to controls (1.33).  MCD patients had a higher relative 
mtDNA copy number compared to non-MCD patients, however, statistical significance 
was not reached (p=0.33).  In addition, female neoplastic epilepsy samples presented a 
trend of higher mtDNA copy number than controls (p=0.34). 
Oxidative mtDNA damage  
The degree of oxidative mtDNA damage is reflected by an abundance of 8-OHdG 
formation in mtDNA, the content of 8-OHdG in mtDNA, an index for cellular oxidative 
damage, was determined by QPCR and presented as ∆Ct.  The degree of oxidative 
mtDNA damage, mtDNA∆Ct, was determined as ∆Ct= Ct2 (hOGG1 treatment) – Ct1 (no 
hOGG1 treatment), thus, the larger the ∆Ct, the more abundant the 8-OHdG and more 
oxidative damage present in the sample.  Tables 2.4 -2.8 show the oxidative mtDNA 
damage for each group.  The degree of oxidative mtDNA damage (p=0.59) did not 
significantly differ between male and female neoplastic epilepsy patients (Table 5).  
Controls had lower oxidative mtDNA damage (0.59) compared to neoplastic epilepsy 
patients (0.63, p=0.72), MCD (0.63, p=0.84), and non-MCD (0.63, p=0.71) groups, 
however, statistical significance was not reached.   Yet, the degree oxidative mtDNA 
damage in MCD and non-MCD groups did not differ (both means=0.63, p=0.99).  
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Interestingly, female neoplastic epilepsy patients presented a slightly higher degree of 
mtDNA oxidative damage compared to controls (p=0.99) (Table 2.5).   
mtDNA genotyping 
 In this study we analyzed the association between ten mitochondrial SNPs and 
neoplastic intractable epilepsy (MCD and non-MCD).  Neither, neoplastic epilepsy 
patients (MCD and non-MCD) or controls contained the mtSNP of G9804A.  Allele 
G9952A (p<0.001; Adjusted OR=1.19E9, 95% CI [0, NaN]) was found at higher 
frequencies in epilepsy samples compared to controls.  Controls had higher frequencies 
for the mitochondrial SNPs A1555G, G3196A, T3197C, A4317G, A10006G, T10010C, 
and A10398G, and the haplogroups I, J, L, M, and U5 compared to all neoplastic epilepsy 
samples (Tables 2. 9 and 2.10), including MCD  (Tables 2.11 and 2.12) and non-MCD 
(Tables 2.13 and 2.14) sub-groups.   
The neoplastic epilepsy (MCD and non-MCD) samples did not contain any 
T3197C mtSNP, or belong to the European haplogroup (U-5).  The European (I and J), 
African (L and M) and Asian (M) haplogroups were observed in both neoplastic epilepsy 
and control samples.  No difference in the frequencies of SNPs and haplogroups were 
observed when comparing MCD and Non-MCD neoplastic epilepsy patient sub-groups 
(Tables 2.16 and 2.17).  Neoplastic males and females presented similar trends in the 
frequency of SNPs, however, males presented with allele G9804A (Table 2.11), while, 
females did not (Table 2.13).  Interestingly, female neoplastic samples presented higher 
frequencies of G9952A compared to controls (p=0.02) (Table 2.13).   
Logistic regression revealed that neoplastic epilepsy, MCD or non-MCD 
phenotypes did not significantly depend on level of relative mtDNA copy number, level 
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of oxidative mtDNA damage, SNP or haplogroup status (Tables 2.16-2.19).  A trend that 
the levels of relative mtDNA copy number and oxidative mtDNA damage and for the 
SNPs G9952A (OR= 2.94E9, 95% CI [0, NaN]) and T10010C (OR= 1.76, 95% CI [0.28, 
11.28]) predicted neoplastic epilepsy phenotype was observed, yet, there were large 
confidence intervals due large standard error (Table 2.21).  Female neoplastic epilepsy 
phenotypes were predicted by G9952A (OR= 9.91E9, 95% CI [0, NaN]), level of relative 
mtDNA copy number (4.10, 95% CI [0.28, 60.18]), and level of oxidative mtDNA 
damage (OR= 2.34, 95% CI [0.20, 27.21]) (Table 2.23). 
Bayesian network 
 In the female samples we used Banjo© software to learn a Bayesian network to 
study the relationships among epilepsy status, MCD status, relative mtDNA copy 
number, oxidative mtDNA damage, and the mtSNPs. A summary Bayesian network 
based on the top three Bayesian networks for the female samples was created (Figure 
2.2).  In this network brain tumor status is connected to relative mtDNA copy number to 
oxidative mtDNA damage, and 3 mtDNA SNPs (A10006G, T10010C, and A1555G), as 
well as, brain tumor with 6 mtDNA SNPs (G9952A, A10398G, A10006G, T3197C, 
G3196A, and A1555G).  The paths of relative mtDNA copy number- oxidative mtDNA 
copy number- A10006G, G9952A- brain tumor, A10398G-brain tumor, and brain tumor-
A1006G, T3197C, G3196A, and A1555G) are shown in the summary Bayesian network.  
The influence scores between several of these variables are depicted on Table 2.27.  The 
Pearson correlation of between selected variables based on the influence scores are found 
in Table 2.28.  Significant correlations (p < 0.05) were found between brain tumor and 
MCD status; brain tumor with G9952A, T3197C, A10006G, A1555G, and A10398G; 
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oxidative mtDNA damage with relative mtDNA copy number; brain tumor with relative 
mtDNA copy number, to name a few.  Thus, the summary Bayesian network summarizes 
the relationship between mtDNA oxidative damage and copy number, and SNPs (genes) 
and disease (phenotype).   
Discussion 
One of the major risk factors for cancer is oxidative stress (Bai et al., 2007).  
Mitochondria play a crucial role in the production of ROS.  Mitochondrial dysfunction 
may contribute to epileptogenesis (Walbaum and Patel, 2010).  Oxidative stress has been 
suggested to be a significant cause and consequence of excitotoxicity, which plays a 
critical role in epileptic brain damage.  mtDNA variations can cause inefficient oxidative 
phosphorylation which leads to the accumulation of ROS and DNA damage leading to an 
increased risk in cancer (Bai et al., 2007).  In this study we observed a trend of an 
increased relative mtDNA copy number and oxidative mtDNA damage in neoplastic 
epilepsy patients (both MCD and non-MCD).  Female neoplastic samples presented 
higher relative mtDNA copy number and degree of oxidative mtDNA damage compared 
to controls.  No significant differences by gender, regarding relative mtDNA copy 
number and degree of oxidative mtDNA damage, as well as mtDNA SNP and haplogroup 
background, were observed among neoplastic pediatric epilepsy patients.   
The mtDNA variant, G9952A, which codes for COIII and associated with 
mitochondrial encephalopathy, was found in higher frequencies in the neoplastic 
intractable epilepsy (MCD and non-MCD) patients, and most interestingly in female 
neoplastic epilepsy patients.  We also found a trend in which G9952A, along with level 
of mtDNA copy number and level of oxidative mtDNA damage to predicted neoplastic 
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MCD and non-MCD epilepsy phenotypes, as well as, female neoplastic epilepsy samples.  
In female samples, a summary Bayesian  network revealed brain tumor status is 
connected to relative mtDNA copy number to oxidative mtDNA damage, and 3 mtDNA 
SNPs (A10006G, T10010C, and A1555G), as well as, brain tumor with 6 mtDNA SNPs 
(G9952A, A10398G, A10006G, T3197C, G3196A, and A1555G).   Additionally, all of 
the neoplastic MCDs were gangliomas and DNETs which are malformations due to 
abnormal glial and neuronal proliferation.  A key event in brain development is 
proliferation which begins around the 20th week of gestation (Lenroot and Giedd, 2006).   
Oxidative stress can lead to mutations or the formation of damaged proteins and 
may be an important risk factor for the initiation and progression of disease (Migliore and 
Coppede, 2002).  Involvement of the mitochondrion in cancer metabolism and functions 
has been documented (Mayevsky, 2009; Reuter et al., 2010).  Increased ROS production 
contributes to tumorigenicity and cell progression by promoting genomic instability and 
increased DNA damage.  Disturbed redox status may lead to the activation of key 
signaling components that are important in cell proliferation and survival (Myatt et al., 
2011).  Changes in glucose metabolism in cancer cells demonstrate a shift away from 
mitochondrial respiration towards glycolysis for ATP production (Bhrahimi-Horn et al., 
2011). 
Amplification of the mitochondrial genome in response to oxidative stress has 
been noted.  In a cell, the abundance of mitochondria is determined by biogenesis and 
division of the organelles.  The quantity of mitochondria per cell is tightly regulated by 
activation of specific transcription factors and signaling pathways (Lee and Wei, 2005).  
The assembly and functioning of the respiratory enzyme complexes in cells require 
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coordinated expression the interaction of gene products between the mitochondrial and 
nuclear genomes.  Gene expressions of the mitochondria and nucleus respond in a 
complex manner to various physiological and developmental signals such as growth 
activation, neoplastic transformation, muscle contraction, cell differentiation and 
hormone action (Lee and Wei, 2005).  Control of biogenesis in mitochondria is a 
complex process.  Alterations in intracellular level of ROS are associated with changes in 
mitochondrial abundance, mtDNA copy number, and the expression of respiratory genes.  
In aging, increased oxidative stress plays a crucial role in the increase of mitochondrial 
abundance, as well as, mtDNA content in tissue cells during the aging process.  Persistent 
oxidative stress in mitochondria not only contributes to the somatic mtDNA mutations 
but also alter mtDNA replication rate, leading to an overall decline in the mitochondrial 
respiratory function.   
Replication of mtDNA occurs primarily during the S and G2 phases of the cell 
cycle, but most importantly can occur at any point of the cell cycle.  In addition, mtDNA 
replication does not occur concurrently with the growth and division of organelles, hence, 
mtDNA replication can occur without mitochondrial proliferation.  The copy number of 
mtDNA varies with cell type and is maintained within a range.  mtDNA copy number 
may be modulated according to the energy needs of the cell.  Changes in mtDNA copy 
number in response to exercise and hormone treatment have been observed (Lee and Wei, 
2005).  Currently, it is unclear how copy number of mtDNA and the abundance of 
mitochondria are regulated under different physiological and developmental conditions.   
According to Liang and Hays (1996), primary oncocytic tumors have shown 
moderate amounts of increased copy number in mitochondria sequences, treatment of 
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adenocarcenoma cell line with trihelose or rats with diethylnitrosamine revealed increases 
in copy number of mtDNA sequences, and primary and cultured gliomas showed 
substantial alternations in the copy number of mtDNA genome.  In Liang and Hays’ 
(1996) study, as well as our study, the mitochondrial genome shows high degrees of 
amplification, suggesting these increases may be an early event in tumor genesis.  The 
reasons for increases in mtDNA copy number in neoplastic brain cells are unclear.  Liang 
and Hays (1996) suggest this may be due to the general mechanisms of genomic 
instability throughout the entire tumor cell or because a miscommunication between the 
nuclear and mitochondrial genomes.   
Jiang et al. (2005) found an increase mtDNA content in the saliva of patients with 
head and neck squamous cell carcinoma (HNSC).  An increase in mtDNA copy number 
has also been observed in  chronic lymphocytic leukemia (CLL), non-Hodgkin 
lymphoma (NHL), thyroid cancer, renal oncocytome, colorectal cancer, endometrial 
cancer, breast cancer (Mambo et al., 2005; Wang et al., 2005; Lan et al., 2008; Radpour 
et al., 2009; Hosgood III et al., 2010; Shen et al., 2010; Chen et al., 2011).   In contrast, 
decrease in mtDNA content has been reported to be associated with increased risk of 
renal cancer.  Additionally, a decrease in mtDNA copy number in cancer tissue has been 
found in lung cancer, gastric cancer, hepatocellular carcinoma, type 2 diabetes, 
cardiomyopathy, and breast cancer (Yin et al., 2004; Lin et al., 2008; Montier et al., 
2009).  Thus, it seems that changes in mtDNA content is cancer-type specific (Chen et 
al., 2011).   
Oxidative stress stimulates mitochondrial proliferation to meet the energy needs 
for cell survival including repair of damage and synthesis of new proteins.  Yet, oxidative 
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stress causes excess ROS production resulting in further oxidative damage.  The increase 
of mtDNA copy number is dependent of the level of oxidative stress, the capacity of 
intracellular antioxidant system, the quality of mitochondria and mtDNA.  The increase 
of ROS production from a defective respiratory chain is thought to play a role in the 
increase of mitochondrial content.  ROS act as a second messenger to trigger the 
expression of nuclear respiratory factors and mitochondrial transcription factor to induce 
mitochondrial biogenesis and mitochondrial proliferation (Jiang et al., 2005).  
Understanding oxidative-stress induced alterations in mtDNA copy number is important 
for the development of novel drugs to prevent and treat intractable epilepsy. 
mtDNA copy numbers can be modulated when physiological conditions are 
changed.  Environmental exposures can generate ROS and may induce the accumulation 
of mtDNA mutations in human tissue. mtDNA is more susceptible to oxidative damage 
due to its lack of histones and limited capacity to repair DNA damage, thus, consequently 
acquires mutations at greater rates than nuclear DNA.  Mitochondrial function is 
compromised as a result of oxidative damage and damage to mtDNA.  Oxidative stress 
stimulates mitochondrial proliferation to meet the energy needs for cell survival including 
repair of damage and synthesis of new proteins.  Oxidative stress causes excess ROS 
production resulting in further oxidative damage.  The increase of mtDNA copy number 
is dependent of the level of oxidative stress, the capacity of intracellular antioxidant 
system, the quality of mitochondria and mtDNA.  The increase of ROS production from a 
defective respiratory chain is thought to play a role in the increase of mitochondrial 
content.  ROS act as a second messenger to trigger the expression of nuclear respiratory 
factors and mitochondrial transcription factor to induce mitochondrial biogenesis and 
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mitochondrial proliferation (Jiang et al., 2005).  Oxidative damage induces an increase in 
mitochondria and mtDNA to compensate for the decline in the function of mitochondrial 
respiration (Shen et al., 2008).  In other words, ROS resulting from oxidative stress 
interact with genetic signaling systems that upregulate gene expression to counteract 
stressor challenges and to re-establish hemeostatis.   
Overall, we interpret the increase in relative mtDNA copy number as a result of 
compensatory responses induced by mtDNA damage, in order to repress the actions of 
the oxidative damage.  The increase in mtDNA replication, as a response to oxidative 
damage, provides a propagation of mtDNA that has not been damaged by oxidative 
stress.  The resulting mtDNA copies do not contain the damage (DNA adducts), 
presenting an overall lower oxidative mtDNA damage.  Thus, the increase in undamaged 
mtDNA dilutes the presence of damage mtDNA.  Understanding oxidative-stress induced 
alterations in mtDNA copy number is important for the development of novel drugs to 
prevent and treat intractable neoplastic epilepsy. 
Our study found that the mitochondrial SNP G9952A was found in the female 
neoplastic epilepsy patients and not the control samples.  This mitochondrial variant 
codes for COIII.  It is believed that the majority of the ROS are generated by complexes I 
and III, likely due to the release of electrons by NADH and FADH into the ETC.  Hanna 
et al. (1998) identified the G9952A point mutation in a patient with encephalopathy and 
exercise intolerance.  This point mutation is located in 3’ end of the gene for the subunit 
of COIII and is thought to result in the loss of the last 13 amino acids of the C-terminal 
region of this subunit.  Decreased expression of cytochrome c oxidase III has been 
reported in colon tumors compared to non-malignant colonoica mucosa (Penta et al., 
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2001).  Our results suggest that the presence of these mitochondrial mutations in COIII, 
in conjunction with environmental insults, may induce mitochondrial dysfunction in 
neoplastic epilepsy.  Hence, the role and mechanisms dysfunction of COIII of the 
respiratory chain in epileptogenesis and neoplastic MCD needs to be explored further. 
In summary, our study shows a trend of increased relative mtDNA copy number 
in brain tissues from pediatric neoplastic epilepsy patients.  The quantitative changes of 
mtDNA may have implications in neoplastic epilepsy development.  Since all of the 
neoplastic MCDs were gangliomas and DNETs, which are malformations due to 
abnormal glial and neuronal proliferation, our results suggest key events, such as 
environmental insults, occurring during this gestational stage and the occurrence of 
intractable epilepsy warrants further research.  In addition, the use of a summary 
Bayesian network of the female samples demonstrated the statistically significant 
relationships, the network revealed brain tumor status is connected to relative mtDNA 
copy number to oxidative mtDNA damage, and 3 mtDNA SNPs (A10006G, T10010C, 
and A1555G), as well as, brain tumor with 6 mtDNA SNPs (G9952A, A10398G, 
A10006G, T3197C, G3196A, and A1555G).   The summary Bayesian network for the 
female epilepsy samples revealed the following paths:  oxidative mtDNA damage-
epilepsy-relative mtDNA copy number, A10398G, T3197C, G3196A, and A1555G; 
oxidative mtDNA damage-A10006G-epilepsy; oxidative mtDNA damage-relative 
mtDNA copy number; and G9952A-epilepsy. 
To our knowledge, this is the first study to explore mtDNA copy number, 
oxidative mtDNA oxidative stress in MCD neoplastic epilepsy patients.  The main 
limitation of our study is that the number of pediatric neoplastic intractable epilepsy 
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patients and non-epilepsy samples is relatively small.  However, results from this study 
provide the foundation, for proper determination of sample size in pediatric intractable 
epileptics, such as the frequency of mtSNPs in pediatric neoplastic epilepsy patients, and 
the mean and standard deviation for further research regarding measurement of oxidative 
mtDNA damage.   For example, utilizing the results from this study, in order to compare 
oxidative mtDNA damage between brain tumor and control samples, and for the study to 
reach 80% power with an alpha level of 0.05 a sample size of 1766 (883 disease and 883 
control samples) is required.  Hence, in order to acquire these sample sizes, a multi-
facility (and institution) study is needed to explore the oxidative mtDNA damage, 
mtDNA copy number, and mtSNPs in children with neoplastic intractable epilepsy.  In 
addition to its role in apoptosis, the mitochondrion serves as an important element in the 
tumorigenic phenotype, and clinical approaches targeting this organelle have potential for 
the development of effective treatment regimens for patients with neoplastic epilepsy. 
Overall, this study indicates mitochondria may play a role in neoplastic pediatric 
epilepsy.
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Table 2.1.   
Clinical profile of pediatric patients with intractable epilepsy with brain tumors 
 
Sample Age (years) Gender Diagnosis MCD Status Pathology 
1 3 M tumor Non-MCD new tumor dense gliosis 
2 9 F tumor Non-MCD pilocytic astrocytoma 
3 14 M tumor MCD ganglioglioma 
4 8 ms F tumor MCD ganglioglioma 
5 8 M tumor Non-MCD oligodendroglioma 
6 12 F tumor Non-MCD pilocytic astrocytoma 
8 11 F tumor Non-MCD pilocytic astrocytoma 
12 18 M tumor MCD Dysembryoplastic 
Neuroepithelial Tumor 
(DNET) 
13 12 F tumor Non-MCD glioblastoma multiforme 
14 10 F tumor Non-MCD medulloblastoma 
15 10 M tumor Non-MCD pilocytic astrocytoma 
16 8 mos M tumor Non-MCD astrocytoma 
17 6 F tumor Non-MCD choroid plexus papilloma 
19 5 M tumor Non-MCD pilocytic astrocytoma 
21 10 F tumor MCD ganglioglioma 
22 6 M tumor Non-MCD pilocytic astrocytoma, 
glioblastoma, 
hypothalamic tumor 
26 19 F tumor Non-MCD oligodendroglioma 
28 2 M tumor Non-MCD medulloblastoma 
29 4 F tumor Non-MCD pilocytic astrocytoma, 
hypothalamic tumor 
30 5 M tumor MCD glioneuronal 
neoplasm/possible 
ganglioglioma 
32 9 F tumor Non-MCD pilocytic astrocytoma 
35 13 M tumor Non-MCD medulloblastoma 
36 16 F tumor Non-MCD ependymoma 
39 12 F tumor Non-MCD medulloblastoma 
41 7 M tumor Non-MCD anaplastic ependymoma 
44 6 F tumor Non-MCD high grade malignant 
undifferentiated neoplasm 
46 4 F tumor MCD DNET 
 
 137 
Table 2.2   
Profile of control samples obtained from NICHD Brain and Tissue Bank for 
Developmental Disorders at the University of Maryland 
 
Sample  Age (years) Gender History/ Cause of Death 
Control 1 15 F car accident, multiple injuries 
Control 2 18 F car accident, multiple injuries 
Control 3 13 F asphyxia by hanging 
Control 4 2 F drowning 
Control 5 2 F drowning 
Control 6 8 F  asphyxia and multiple injuries 
Control 7 4 F lymphocytic myocarditis  
Control 8 16 F car accident, multiple injuries 
Control 9 2 F car accident, multiple injuries 
Control 10 17 F car accident, multiple injuries 
Control 11 10 F Asthma 
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Table 2.3.  
Mitochondrial SNPs and haplogroups used in this study 
 
Variant Region Reported in Patients 
A1555G 12S rRNA Maternally inherited deafness or aminoglycoside-induced deafness 
G3196A 16S rRNA Alzheimer’s Disease and Parkinson’s Disease (ADPD) 
T3197C 16S rRNA Haplogroup (Hg)-U5 
G4309A tRNA Ile Chronic Progressive External Ophthalmoplegia (CPEO) 
A4317G tRNA Ile Fatal Infantile Cardiomyopathy (FICP) 
G9804A CO III Leber Hereditary Optic Neuropathy (LHON) 
G9952A CO III Mitochondrial Encephalopathy 
A10006G tRNA Gly Chronic intestinal pseudo-obstruction (CIPO) 
T10010C tRNA Gly Progressive encephalopathy (PEM) 
A10398G ND3 ↓PD, ↓AD;A-↑Breast Cancer  (BRCA) in AA, Hg-I, J, L, M 
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Figure 2.1.   
Correlation between the mtDNA copy number and degree of oxidative mtDNA 
damage.  The relative mtDNA copy numbers of the intractable epilepsy neoplastic 
tissues and control tissues with their relationship to degree of oxidative mtDNA damage 
are plotted.  The results show that the two parameters were not significantly correlated 
(Pearson correlation coefficient= 0.14, p= 0.45).
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Table 2.4.   
Comparison of demographic, mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients and non-epileptic control from NICHD Brain and Tissue Bank 
 
  
All Cases  
(n=38) 
Neoplastic 
epilepsy 
 (n=27) 
Control          
(n=11) P-value 
          
Age (years) 8.93 + 5.36 6.96 + 5.37  9.73 + 6.44  0.24 
Sex (M/F) 12/26 12/15 0/11 <0.001 
log Relative mtDNA copy number          
Median 1.45 1.45 1.37   
Mean + S.D. 1.53 + 1.00 1.61 + 1.18 1.33 + 0.21 0.26 
> 1.45 (high) (%)   14 (52) 5 (45) 1.00 
< 1.45 (low) (%) 13 (48) 6 (55)   
          
log Degree of oxidative mtDNA 
damage (∆Ct)         
Median 0.66 0.68 0.63   
Mean + S.D. 0.62 + 0.29 0.63 + 0.30 0.59 + 0.27 0.72 
> 0.66 (high damage) (%)   12 (44) 5 (45) 0.72 
< 0.66 (low damage) (%) 10 (37) 6 (55)   
          
Degree of oxidative mtDNA damage/ 
log Relative mtDNA copy number          
Median 0.46 0.48 0.42   
Mean + S.D. 0.60 + 0.73 0.67 + 0.87 0.46 + 0.25 0.44 
> 0.46 (high damage) (%)   11 (41) 6 (55) 1.00 
< 0.46 (low damage) (%) 11 (41) 4 (36)   
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Table 2.5.   
Comparison of demographic, mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients and non-epileptic control from NICHD Brain and Tissue Bank by gender 
 
  
All Cases 
(n=38) 
Epilepsy 
Male   
(n=12) 
Epilepsy  
Female        
(n=15) 
Control 
Female      
(n=11) aP-value bP-value cP-value 
Age (years) 8.93 + 5.36 7.64 + 5.23 9.38 + 4.76  9.73 + 6.44 0.38 0.40 0.87 
log Relative mtDNA copy number  12/26             
Median   1.44 1.48 1.37       
Mean + S.D. 1.45 1.47 + 0.68 1.55 + 1.14 1.33 + 0.21 0.82 0.52 0.34 
> 1.45 (high) (%) 1.53 + 1.00 4 (33) 9 (60) 0 (0) 0.48 1.00 0.69 
< 1.45 (low) (%)   7 (58) 6 (40) 11 (100)       
log Degree of oxidative mtDNA 
damage (∆Ct)             
Median 0.66 0.69 0.65 0.63       
Mean + S.D. 0.62 + 0.29 0.66 + 0.31 0.60 + 0.28 0.59 + 0.27 0.59 0.61 0.72 
> 0.66 (high damage) (%) 4 (33) 6 (40) 5 (45) 0.67 1.00 0.67 
< 0.66 (low damage) (%) 6 (50) 5 (33) 6 (55)       
Degree of oxidative mtDNA 
damage/ log Relative mtDNA copy 
number                
Median 0.46 0.59 0.44 0.42       
Mean + S.D. 0.60 + 0.73 0.57 + 0.31 0.78 + 1.21 0.46 + 0.25 0.84 0.41 0.41 
> 0.46 (high damage) (%)   7 (58) 4 (27) 4 (36) 1.00 0.40 1.00 
< 0.46 (low damage) (%) 4 (33) 7 (47) 6 (55)     
 
aP-value for Neoplastic Epilepsy, Male vs. Neoplastic Epilepsy, Female 
bP-value for Neoplastic Epilepsy, Neoplastic Male vs. Control 
cP-value for Neoplastic Epilepsy, Female vs. Control 
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Table 2.6.  
Comparison of demographic, mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients with MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
  
All Cases 
(n=17) 
MCD          
(n=6)  
Control         
(n=11) P-value 
          
Age (years) 9.33 + 6.3 6.96 + 5.37  9.73 + 6.44  0.24 
Sex (M/F) 3/14 3/3 0/11 0.03 
log Relative mtDNA copy number          
Median 1.44 1.85 1.37   
Mean + S.D. 1.58 + 0.66 2.03 + 0.97 1.33 + 0.21 0.14 
> 1.44 (high) (%)   4 (67) 5 (45) 0.62 
< 1.44 (low) (%) 2 (33) 6 (55)   
          
log Degree of oxidative mtDNA 
damage (∆Ct)         
Median 0.65 0.69 0.63   
Mean + S.D. 0.61 + 0.32 0.63 + 0.44 0.59 + 0.27 0.84 
> 0.65 (high damage) (%)   3 (50) 5 (45) 1.00 
< 0.65 (low damage) (%) 2 (33) 6 (55)   
          
Degree of oxidative mtDNA damage/ 
log Relative mtDNA copy number          
Median 0.41 0.3 0.42   
Mean + S.D. 0.45 + 0.29 0.40 + 0.37 0.46 + 0.25 0.71 
> 0.40 (high damage) (%)   3 (50) 6 (55) 1.00 
< 0.40 (low damage) (%) 2 (33) 4 (36)   
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Table 2.7.  
Comparison of demographic, mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital 
pediatric intractable epilepsy patients with non-MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
  
All Cases 
(n=32) 
Non-MCD 
(n=21)  
Control          
(n=11) P-value 
          
Age (years) 8.99 + 5.22 8.60 + 4.59  9.73 + 6.44  0.51 
Sex (M/F) 9/23 9/12 0/11 0.01 
log Relative mtDNA copy number          
Median 1.45 1.45 1.37   
Mean + S.D. 1.43 + 1.00 1.48 + 1.23 1.33 + 0.21 0.59 
> 1.45 (high) (%)   11 (52) 0 (0) 1.00 
< 1.45 (low) (%) 10 (48) 11 (100)   
          
log Degree of oxidative mtDNA 
damage (∆Ct)         
Median 0.65 0.66 0.63   
Mean + S.D. 0.61 + 0.26 0.63 + 0.26 0.59 + 0.27 0.71 
> 0.65 (high damage) (%)   9 (43) 5 (45) 1.00 
< 0.65 (low damage) (%) 8 (38) 6 (55)   
          
Degree of oxidative mtDNA damage/ 
log Relative mtDNA copy number          
Median 0.45 0.5 0.42   
Mean + S.D. 0.64 + 0.77 0.75 + 0.96 0.46 + 0.25 0.34 
> 0.45 (high damage) (%)   9 (43) 6 (55) 0.70 
< 0.45 (low damage) (%) 7 (33) 4 (36)   
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Table 2.8.  
Comparison of demographic, mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital 
pediatric neoplastic intractable epilepsy patients with MCD and non-MCD 
 
  
All Cases        
(n=27) 
MCD  
(n=6)  
Non-MCD       
(n=21) P-value 
          
Age (years) 8.60 + 4.96 8.61 + 6.58  8.60 + 4.59 1.00 
Sex (M/F) 12/15 12/9 3/3 1.00 
log Relative mtDNA copy number          
Median 1.45 1.85 1.45   
Mean + S.D. 1.61 + 1.18 2.03 + 0.97 1.48 + 1.23 0.33 
> 1.45 (high) (%)   3 (50) 10 (48) 1.00 
< 1.45 (low) (%) 3 (50) 10 (48)   
        
log Degree of oxidative mtDNA 
damage (∆Ct)         
Median 0.68  0.69 0.67   
Mean + S.D. 0.63 + 0.30 0.63 + 0.44 0.63 + 0.27 0.99 
> 0.68 (high damage) (%)   2 (33) 8 (38) 1.00 
< 0.68 (low damage) (%) 2 (33) 9 (43)   
          
Degree of oxidative mtDNA damage/ 
log Relative mtDNA copy number          
Median 0.48 0.31 0.50   
Mean + S.D. 0.67 + 0.87 0.40 + 0.37 0.75 + 0.96 0.45 
> 0.48 (high damage) (%)   2 (33) 9 (43) 1.00 
< 0.48(low damage) (%) 3 (50) 8 (38)   
 
  
 
145
Table 2.9.   
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric intractable 
neoplastic epilepsy patients and non-epileptic control from NICHD Brain and Tissue Bank   
 
SNPs 
Neoplastic 
epilepsy 
(n=27) 
Controls         
(n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/  
    SNP % 
Positive/  
   SNP % 
  
A1555G 13 48 11 100 0.002 0 0, NaN 0 0, NaN 
G3196A 3 11 11 100 <0.001 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
G4309A 26 96 11 100 1.00 0 0, NaN 0 0, NaN 
A4317G 19 70 11 100 0.08 0 0, NaN 0 0, NaN 
G9804A 0 0 0 0 1.00 NaN 0, NaN NaN 0, NaN 
G9952A 6 22 0 0 <0.001 1.19E9 0, NaN 1.17E9 0, NaN 
A10006G 6 22 11 100 <0.001 0 0, NaN 0 0, NaN 
T10010C 16 59 7 64 1.00 0.83 0.20, 3.54 0.83 0.19, 3.55 
A10398G 7 26 11 100 <0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.10.   
The results of the Fisher’s exact test for individual haplogroups for in Miami Children’s Hospital pediatric intractable 
neoplastic epilepsy patients and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
Neoplastic 
epilepsy 
 (n=27) 
Controls          
(n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
 Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 7 26 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-J 7 26 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-L 7 26 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-M 7 26 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-U5 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.11.  
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric intractable epilepsy 
male neoplastic patients and non-epileptic control from NICHD Brain and Tissue Bank   
 
SNPs 
Neoplastic 
Epilepsy Male      
(n=12) 
       Controls             
         (n=11) 
Fisher's     
exact test    
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/   
    SNP % 
Positive/   
   SNP % 
  
A1555G 8 67 11 100 0.09 0 0, NaN 0 0, NaN 
G3196A 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 <0.001 0 0, NaN 0 0, NaN 
G4309A 11 92 11 100 1.0 0 0, NaN 0 0, NaN 
A4317G 9 75 11 100 0.22 0 0, NaN 0 0, NaN 
G9804A  0 0 0 0 1.00 Infinity 0, NaN Infinity 0, NaN 
G9952A 6 50 0 0 0.01 Infinity 0, NaN Infinity 0, NaN 
A10006G 4 33 11 100 0.001 0 0, NaN 0 0, NaN 
T10010C 8 67 7 64 1.00 1.14 0.21, 6.37 1.23 0.21, 7.14 
A10398G 3 25 11 100 <0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.12. 
The results of the Fisher’s exact test for individual haplogroups for in Miami Children’s Hospital pediatric intractable 
epilepsy male neoplastic patients and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
Neoplastic 
Epilepsy Male      
(n=12) 
       Controls             
         (n=11) 
Fisher's     
exact test    
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/   
   Hg % 
Positive/   
  Hg % 
  
Hg-I 3 25 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-J 3 25 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-L 3 25 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-M 3 25 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-U5 0 0 9 82 <0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.13.  
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric intractable epilepsy 
female neoplastic patients and non-epileptic control from NICHD Brain and Tissue Bank   
 
SNPs 
Neoplastic 
Epilepsy          
Female            
(n=15) 
       Controls             
         (n=11) 
Fisher's     
exact test    
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/   
    SNP % 
Positive/   
   SNP % 
  
A1555G 5 33 11 100 0.001 0 0, NaN 0 0, NaN 
G3196A 3 20 11 100 <0.001 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 <0.001 0 0, NaN 0 0, NaN 
G4309A 15 100 11 100 1.00 NaN NaN, NaN NaN NaN, NaN 
A4317G 10 67 11 100 0.05 0 0, NaN 0 0, NaN 
G9804A 0 0 0 0 1.00 NaN NaN, NaN NaN NaN, NaN 
G9952A 6 40 0 0 0.02 1.97E9 0, NaN 2.04E9 0, NaN 
A10006G 2 13 11 100 <0.001 0 0, NaN 0 0, NaN 
T10010C 8 53 7 64 0.70 0.63 0.13, 3.21 0.60 0.13, 3.20 
A10398G 4 27 11 100 <0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.14. 
The results of the Fisher’s exact test for individual haplogroups for in Miami Children’s Hospital pediatric intractable 
epilepsy female neoplastic patients and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
Neoplastic 
Epilepsy   
Female         
(n=15) 
       Controls           
         (n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 4 27 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-J 4 27 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-L 4 27 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-M 4 27 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-U5 0 0 9 82 <0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds Ratio using control group as reference 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.15.   
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
SNPs 
MCD            
(n=6) 
Controls          
(n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/  
    SNP % 
Positive/  
   SNP % 
  
A1555G 2 33 11 100 0.01 0 0, NaN 0 0, NaN 
G3196A 1 14 11 100 <0.001 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
G4309A 6 100 11 100 1.00 NaN NaN, NaN NaN NaN, NaN 
A4317G 3 50 11 100 0.03 0 0, NaN 0 0, NaN 
G9804A 0 0 0 0 1.00 NaN NaN, NaN NaN NaN, NaN 
G9952A 3 50 0 0 0.03 5.92E9 0, NaN 1.02E10 0, NaN 
A10006G 2 33 11 100 0.01 0 0, NaN 0 0, NaN 
T10010C 4 67 7 64 1.00 1.14 0.14, 9.30 1.25 0.15, 10.81 
A10398G 2 33 11 100 0.01 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds ratio using control group as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.16.   
The results of the Fisher’s exact test for individual haplogroups for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
MCD            
(n=6) 
Controls          
(n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 2 33 11 100 0.01 0 0, NaN 0 0, NaN 
Hg-J 2 33 11 100 0.01 0 0, NaN 0 0, NaN 
Hg-L 2 33 11 100 0.01 0 0, NaN 0 0, NaN 
Hg-M 2 33 11 100 0.01 0 0, NaN 0 0, NaN 
Hg-U5 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds ratio using control group as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.17.   
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with non-MCD and non-epileptic control from NICHD Brain and Tissue Bank 
  
SNPs 
non-MCD  
(n=21) 
Controls         
(n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/  
    SNP % 
Positive/  
   SNP % 
  
A1555G 11 52 11 100 0.01 0 0, NaN 0 0, NaN 
G3196A 2 10 11 100 <0.001 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
G4309A 20 95 11 100 1.00 0 0, NaN 0 0, NaN 
A4317G 16 76 11 100 0.14 0 0, NaN 0 0, NaN 
G9804A 0 0 0 0 1.00 NaN NaN, NaN NaN 0, NaN 
G9952A 9 43 0 0 0.01 1.48E9 0, NaN 1.44E9 0, NaN 
A10006G 4 19 11 100 <0.001 0 0, NaN 0 0, NaN 
T10010C 12 57 7 64 1.00 0.76 0.17, 3.42 0.72 0.16, 3.31 
A10398G 5 24 11 100 <0.001 0 0, NaN 1.05 0.91, 1.21 
 
aOR, using control group as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.18.   
The results of the Fisher’s exact test for haplogroups for in Miami Children’s Hospital pediatric intractable neoplastic 
epilepsy patients with non-MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
non-MCD  
(n=21) 
Controls         
(n=11) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
 Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 5 24 11 100 <0.001 0 0, NaN 0.95 0.91, 1.21 
Hg-J 5 24 11 100 <0.001 0 0, NaN 1.05 0.91, 1.21 
Hg-L 5 24 11 100 <0.001 0 0, NaN 1.05 0.91, 1.21 
Hg-M 5 24 11 100 <0.001 0 0, NaN 0.95 0.91, 1.21 
Hg-U5 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
 
 
aOR, using control group as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
 
 
 
 
 
 
 
  
 
155
Table 2.19.   
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with MCD and non-MCD 
 
SNPs 
MCD            
(n=6)            
Non-MCD         
(n=21) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95%  
Confidence 
Interval 
Positive/  
    SNP % 
Positive/  
   SNP % 
  
A1555G 2 33 11 52 0.65 0.45 0.07, 3.04 0.42 0.32, 17.58 
G3196A 1 17 2 10 0.55 1.90 0.14, 25.45 0.52 0.04, 7.19 
T3197C 0 0 0 0 1.00 NaN NaN, NaN 1.00 0.83, 1.21 
G4309A 6 100 20 95 1.00 0 0, NaN 0 0, NaN 
A4317G 3 50 16 76 0.32 0.31 0.05, 2.07 0.31 0.48, 22.13 
G9804A 0 0 0 0 1.00 NaN NaN, NaN NaN NaN, NaN 
G9952A 3 50 9 43 1.00 1.33 0.22, 8.22 0.75 0.12, 4.62 
A10006G 2 33 4 19 0.59 2.13 0.28, 15.97 0.46 0.06, 3.57 
T10010C 4 67 12 57 1.00 1.50 0.22, 10.08 0.67 0.10, 4.48 
A10398G 2 33 5 24 0.63 1.60 0.22,11.50 0.62 0.09, 4.50 
 
aOR, Crude Odds ratio using non-MCD as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.20.   
The results of the Fisher’s exact test for haplogroups for in Miami Children’s Hospital pediatric intractable epilepsy 
patients with MCD and non-MCD 
 
Haplogroups 
MCD            
(n=6)            
Non-MCD         
(n=21) 
Fisher's    
exact test   
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
 Confidence 
Interval 
Positive/  
   Hg % 
Positive/  
  Hg % 
  
Hg-I 2 33 5 24 0.63 1.60 0.22,11.50 0.62 0.09, 4.50 
Hg-J 2 33 5 24 0.63 1.60 0.22,11.50 0.62 0.09, 4.50 
Hg-L 2 33 5 24 0.63 1.60 0.22,11.50 0.62 0.09, 4.50 
Hg-M 2 33 5 24 0.63 1.60 0.22,11.50 0.62 0.09, 4.50 
Hg-U5 0 0 0 0 1.00 NaN NaN, NaN 1.00 0.04, 7.19 
 
aOR, Crude Odds ratio using non-MCD as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table 2.21.   
The results of the logistic regression for SNPs/Hg, level of relative mtDNA copy number, level of oxidative mtDNA damage, 
and age in Miami Children’s Hospital pediatric neoplastic intractable epilepsy patients and non-epileptic control from 
NICHD Brain and Tissue Bank   
 
SNP/Haplogroup 
SNP/Hg          
OR (95% CI) 
Level of relative 
mtDNA copy number 
OR (95% CI) 
Level of oxidative 
mtDNA damage        
OR (95% CI) 
Age                            
OR (95% CI) 
A1555G 0 (0, NaN) 2.21 (0.34, 20.90) 2.59 (0.37, 18.28) 1.06 (0.89, 1.27) 
G3196A --- --- --- 0.92 (0.60, 1.39) 
T3197C --- 2.02E8 (0, NaN) 0.89 (0.03, 25.33) 1.06 (0.78, 1.42) 
G4309A --- 1.00 (0.19, 5.43) 1.93 (0.40, 9.37) 1.02 (0.88, 1.19) 
A4317G --- 1.15 (0.19, 6.80) 1.51 (0.29, 7.87) 1.01 (0.87, 1.18) 
G9804A --- 1.00 (0.19, 5.43) 1.93 (0.40, 9.37) 1.02 (0.88, 1.19) 
G9952A 2.94E9 (0, NaN) 3.67 (0.43, 31.22) 1.93 (0.29, 13.03) 1.04 (0.87, 1.25) 
A10006G 0 (0, NaN) 0 (0, NaN) 0.25 ( 0.01, 6.04) 0.95 (0.75, 1.21) 
T10010C 1.76 (0.28, 11.18) 1.33 (0.19, 9.41) 1.88 (0.39, 9.16) 1.03 (0.88, 1.20) 
A10398G --- 0.87 (0.9, 8.67) 3.67 (0.36, 37.07) 1.06 (0.85, 1.31) 
Hg-I --- 0.87 (0.9, 8.67) 3.67 (0.36, 37.07) 1.06 (0.85, 1.31) 
Hg-J --- 0.87 (0.9, 8.67) 3.67 (0.36, 37.07) 1.06 (0.85, 1.31) 
Hg-L --- 0.87 (0.9, 8.67) 3.67 (0.36, 37.07) 1.06 (0.85, 1.31) 
Hg-M --- 0.87 (0.9, 8.67) 3.67 (0.36, 37.07) 1.06 (0.85, 1.31) 
Hg-U5 --- 2.02E8 (0, NaN) 0.89 (0.03, 25.33) 1.06 (0.78, 1.42) 
 
 
OR, using control group as reference 
NaN = Not a number 
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Table 2.22.  
The results of the logistic regression for SNPs/Hg, level of relative mtDNA copy number, level of oxidative mtDNA damage, 
and age in Miami Children’s Hospital pediatric intractable epilepsy male neoplastic patients and non-epileptic control 
from NICHD Brain and Tissue Bank   
 
SNP/Hg 
SNP/Hg            
OR (95% CI) 
Level of relative mtDNA 
copy number OR (95% 
CI) 
Level of oxidative 
mtDNA damage          
OR (95% CI) 
Age                   
OR (95% CI) 
A1555G 0 (0, NaN) 0.41 (0.03, 6.73) 0.74 (0.07, 8.51) 1.10 (0.89, 1.37) 
G3196A --- --- --- --- 
T3197C 0 (0, NaN) 1.53E8 (0, NaN) 1.63 (0.05, 53.48) 1.05 (0.78, 1.40) 
G4309A --- 0.36 (0.04, 3.10) 0.98 (0.13, 7.33) 1.02 (0.87, 1.20) 
A4317G 0 (0, NaN) 0.54 (0.06, 5.18) 1.03 (0.12, 8.91) 1.04 (0.89, 1.23) 
G9804A --- 0.36 (0.04, 3.10) 0.98 (0.13, 7.33) 1.02 (0.87, 1.20) 
G9952A 9.79E9 (0, NaN) 1.58 (0.10, 24.97) 0.66 (0.04, 11.80) 1.13 (0.89, 1.43) 
A10006G 0 (0, NaN) 0.50 (0.03, 8.85) 0.59 (0.03, 12.06) 0.95 (0.76, 1.20) 
T10010C 1.44 (0.14, 14.52) 0.42 (0.04, 4.62) 1.04 (0.14, 7.87) 1.03 (0.87, 1.21) 
A10398G 0 (0, NaN) 0 (0, NaN) 0.75 (0.02, 23.25) 0.92 (0.68, 1.25) 
Hg-I 0 (0, NaN) 0 (0, NaN) 0.75 (0.02, 23.25) 0.92 (0.68, 1.25) 
Hg-J 0 (0, NaN) 0 (0, NaN) 0.75 (0.02, 23.25) 0.92 (0.68, 1.25) 
Hg-L 0 (0, NaN) 0 (0, NaN) 0.75 (0.02, 23.25) 0.92 (0.68, 1.25) 
Hg-M 0 (0, NaN) 0 (0, NaN) 0.75 (0.02, 23.25) 0.92 (0.68, 1.25) 
Hg-U5 0 (0, NaN) 1.53E8 (0, NaN) 1.63 (0.05, 53.48) 1.05 (0.78, 1.40) 
 
OR, using control group as reference 
NaN = Not a number 
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Table 2.23.   
The results of the logistic regression for SNPs/Hg, level of relative mtDNA copy number, level of oxidative mtDNA damage, 
and age in Miami Children’s Hospital pediatric intractable epilepsy female neoplastic patients and non-epileptic control 
from NICHD Brain and Tissue Bank   
 
SNP/Hg 
SNP/Hg            
OR (95% CI) 
Level of relative mtDNA 
copy number OR (95% 
CI) 
Level of oxidative 
mtDNA damage          
OR (95% CI) 
Age                   
OR (95% CI) 
A1555G 0 (0, NaN) 1.49E19 (0, NaN) 5.01E23 (0, NaN) 0 (0, NaN) 
G3196A 0 (0, NaN) 0 (0, NaN) 0 (0, NaN) 0.92 (0.60, 1.39) 
T3197C 0 (0, NaN) 6.91E8 (0, NaN) 0.30 (0.02, 37.41) 1.03 (0.65, 1.61) 
G4309A --- 1.33 (0.20, 8.68) 2.07 (0.34, 12.79) 1.01 (0.84, 1.21) 
A4317G 0 (0, NaN) 1.23 (0.16, 9.99) 1.04 (0.13, 8.30) 0.94 (0.77, 1.15) 
G9804A --- 1.31 (0.20, 8.68) 2.07 (0.34, 12.79) 1.01 (0.84, 1.21) 
G9952A 9.91E9 (0, NaN) 4.10 (0.28, 60.18) 2.34 (0.20, 27.21) 0.94 (0.74, 1.20) 
A10006G 0 (0, NaN) 0 (0, NaN) 0 (0, NaN) 1.20 (0.73, 1.97) 
T10010C 1.71 (0.24, 12.04) 1.53 (0.22, 10.88) 1.97 (031, 12.42) 1.01 (0.84, 1.21) 
A10398G 0 (0, NaN) 2.45 (0.15, 40.13) 10.58 (0.41, 271.59) 1.17 (0.85, 1.62) 
Hg-I 0 (0, NaN) 2.45 (0.15, 40.13) 10.58 (0.41, 271.59) 1.17 (0.85, 1.62) 
Hg-J 0 (0, NaN) 2.45 (0.15, 40.13) 10.58 (0.41, 271.59) 1.17 (0.85, 1.62) 
Hg-L 0 (0, NaN) 2.45 (0.15, 40.13) 10.58 (0.41, 271.59) 1.17 (0.85, 1.62) 
Hg-M 0 (0, NaN) 2.45 (0.15, 40.13) 10.58 (0.41, 271.59) 1.17 (0.85, 1.62) 
Hg-U5 0 (0, NaN) 6.91E8 (0, NaN) 0.30 (0.02, 37.41) 1.03 (0.65, 1.61) 
 
OR, using control group as reference 
NaN = Not a number 
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Table 2.24.  
The results of the logistic regression for SNPs/Hg, level of relative mtDNA copy number, level of oxidative mtDNA damage, 
and age  for in Miami Children’s Hospital pediatric neoplastic intractable epilepsy patients with MCD and non-epileptic 
control from NICHD Brain and Tissue Bank 
 
SNP/Haplogroup 
SNP/Hg          
OR (95% CI) 
Level of relative 
mtDNA copy number 
OR (95% CI) 
Level of oxidative 
mtDNA damage        
OR (95% CI) 
Age                           
    OR (95% CI) 
A1555G 0 (0, NaN) 2.12E29 (0, NaN) 4.90E29 (0, NaN) 5.47E4 (0, NaN) 
G3196A --- --- --- --- 
T3197C 0 (0, NaN) 7.64E9(0, NaN) 2768 (0, 1.13E27) 1.63 (0.06, 46.68) 
G4309A --- 1.89 (0.21, 17.01) 1.91 (0.21, 17.45) 1.02 (0.85, 1.23) 
A4317G 0 (0, NaN) 3.07 (0.17, 54.19) 3.00 (0.17, 51.86) 0.96 (0.75, 1.22) 
G9804A --- 1.89 (0.21, 17.01) 1.91 (0.21, 17.45) 1.02 (0.85, 1.23) 
G9952A 2.85E18 (0, NaN) 7.72E8 (0, NaN) 1.19 (0.04, 38.39) 1.16 (0.81, 1.65) 
A10006G 0 (0, NaN) 0 (0, NaN) 0.88 (0.03, 31.17) 0.98 (0.76, 1.26) 
T10010C 3.76 (0.21, 65.95) 3.00 (0.26, 35.00) 1.72 (0.16, 18.42) 1.05 (0.85, 1.29) 
A10398G 0 (0, NaN) 1.73 (0.06, 49.31) 1.50 (0.06, 37.91) 1.09 (0.81, 1.47) 
Hg-I 0 (0, NaN) 1.73 (0.06, 49.31) 1.50 (0.06, 37.91) 1.09 (0.81, 1.47) 
Hg-J 0 (0, NaN) 1.73 (0.06, 49.31) 1.50 (0.06, 37.91) 1.09 (0.81, 1.47) 
Hg-L 0 (0, NaN) 1.73 (0.06, 49.31) 1.50 (0.06, 37.91) 1.09 (0.81, 1.47) 
Hg-M 0 (0, NaN) 1.73 (0.06, 49.31) 1.50 (0.06, 37.91) 1.09 (0.81, 1.47) 
Hg-U5 0 (0, NaN) 7.64E9(0, NaN) 2768 (0, 1.13E27) 1.63 (0.06, 46.68) 
 
 
OR, using control group as reference 
NaN = Not a number 
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Table 2.25.  
The results of the logistic regression for SNP/ haplogroups, level of relative mtDNA copy number, level of oxidative 
mtDNA damage, and age for in Miami Children’s Hospital pediatric neoplastic intractable epilepsy patients with non-
MCD and non-epileptic control from NICHD Brain and Tissue Bank 
 
SNP/Haplogroup 
SNP/Hg          
OR (95% CI) 
Level of relative 
mtDNA copy number 
OR (95% CI) 
Level of oxidative 
mtDNA damage        
OR (95% CI) 
Age                      
 OR (95% CI) 
A1555G 0 (0, NaN) 1.58(0.20, 12.28) 1.30  (0.20, 8.38) 1.05 (0.89, 1.24) 
G3196A 0 (0, NaN) 0 (0, NaN) 0 (0, NaN) 0.92 (0.60, 1.39) 
T3197C 0 (0, NaN) 4.69E8 (0, NaN) 0.55 (0.21, 14.51) 1.13 (0.81, 1.59) 
G4309A --- 1.14 (0.22, 6.12) 1.36 (0.28, 6.55) 1.04 (0.89, 1.21) 
A4317G 0 (0, NaN) 0.89 (0.14, 5.76) 1.24(0.23, 6.70) 1.02 (0.87, 1.19) 
G9804A --- 1.15 (0.22, 6.12) 1.36 (0.28, 6.55) 1.04 (0.89, 1.21) 
G9952A 2.86E9 (0, NaN) 1.93 (0.25, 15.03) 1.85 (0.28, 12.28) 1.01 (0.85, 1.20) 
A10006G 0 (0, NaN) 1.47 (0.12, 17.63) 0.41 (0.03, 5.92) 1.14 (0.90,1.44) 
T10010C 1.34 (0.24, 7.54) 1.25 (0.22, 7.18) 1.31 (0.27, 6.37) 1.03 (0.89, 1.21) 
A10398G 0 (0, NaN) 2.06 (0.22, 19.30) 2.10 (0.22, 20.34) 1.07 (0.86, 1.33) 
Hg-I 0 (0, NaN) 2.06 (0.22, 19.30) 2.10 (0.22, 20.34) 1.07 (0.86, 1.33) 
Hg-J 0 (0, NaN) 2.06 (0.22, 19.30) 2.10 (0.22, 20.34) 1.07 (0.86, 1.33) 
Hg-L 0 (0, NaN) 2.06 (0.22, 19.30) 2.10 (0.22, 20.34) 1.07 (0.86, 1.33) 
Hg-M 0 (0, NaN) 2.06 (0.22, 19.30) 2.10 (0.22, 20.34) 1.07 (0.86, 1.33) 
Hg-U5 0 (0, NaN) 4.69E8 (0, NaN) 0.55 (0.21, 14.51) 1.13 (0.81, 1.59) 
 
OR, using control group as reference 
NaN = Not a number 
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Table 2.26.  
The results of the logistic regression for SNP/haplogroups, level of relative mtDNA copy number, level of oxidative mtDNA 
damage, and age for in Miami Children’s Hospital pediatric neoplastic intractable epilepsy patients with MCD and using 
non-MCD as control group 
 
      
SNP/Haplogroup 
Haplogroup     
OR (95% CI) 
Level of relative 
mtDNA copy number 
OR (95% CI) 
Level of oxidative 
mtDNA damage        
OR (95% CI) 
Age                            
OR (95% CI) 
A1555G 6.36E8 (0, NaN) 2.43 (0.16, 37.63) 1.08 (0.04, 30.30) 1.10 (0.73, 1.63) 
G3196A 9.21E8 (0, NaN) 4.31 (0.28, 67.47) 1.56 (0.11, 21.76) 1.14 (0.86, 1.50) 
T3197C --- 3.65 (0.24, 56.02) 1.19 (0.09, 15.19) 1.12 (0.85, 1.47) 
G4309A --- 3.65 (0.24, 56.02) 1.19 (0.09, 15.19) 1.12 (0.85, 1.47) 
A4317G 4.43 (0.25, 78.98) 3.17 (0.20, 49.63) 2.41 (0.08, 75.88) 1.19 (0.82, 1.71) 
G9804A --- 3.65 (0.24, 56.02) 1.19 (0.09, 15.19) 1.12 (0.85, 1.47) 
G9952A 0.41 (0.02, 8.47) 2.11 (0.08, 53.18) 1.44 (0.09, 22.05) 1.11 (0.84, 1.48) 
A10006G 0.21 (0.01, 3.36) 2.45 (0.15, 40.19) 0.77 (0.04, 15.25) 1.10 (0.84, 1.45) 
T10010C 0 (0, NaN) 1.92 (0.13, 28.45) 1.57 (0.08, 31.52) 1.19 (0.83, 1.70) 
A10398G 0.23 (0.01, 4.03) 3.17 (0.20, 49.63) 2.41 (0.8, 75.88) 1.19 (0.82, 1.71) 
Hg-I 0.23 (0.01, 4.03) 3.17 (0.20, 49.63) 2.41 (0.8, 75.88) 1.19 (0.82, 1.71) 
Hg-J 0.23 (0.01, 4.03) 3.17 (0.20, 49.63) 2.41 (0.8, 75.88) 1.19 (0.82, 1.71) 
Hg-L 0.23 (0.01, 4.03) 3.17 (0.20, 49.63) 2.41 (0.8, 75.88) 1.19 (0.82, 1.71) 
Hg-M 0.23 (0.01, 4.03) 3.17 (0.20, 49.63) 2.41 (0.8, 75.88) 1.19 (0.82, 1.71) 
Hg-U5 --- 3.65 (0.24, 56.02) 1.19 (0.09, 15.19) 1.12 (0.85, 1.47) 
 
NaN = Not a number 
 
 163 
 
Figure 2.2.   
Summary Beyesian network based on the top three Bayesian networks for female 
samples.  Absolute value on influence score higher than 0.1 are shown. 
 
 
Table 2.27. 
Influence scores between selected variables for female samples. 
 
Variables Influence Score 
(BrainTumor) ->   (T3197C) 0.7882 
(BrainTumor) ->   (A10006G) 0.7407 
(BrainTumor) ->   (A1555G) 0.6156 
(A10398G) ->  (BrainTumor) 0.4746 
(G9952A) ->  (BrainTumor) -0.4587 
(BrainTumor) ->   (G3196A) 0.2076 
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Table 2.28.   
Pearson correlation between selected variables based on the influence scores for female samples. 
 
    
T3197C A10006G A1555G A10398G G9952A mcd status 
BrainTumor   -.850** -.856** -.677** -.733** .469* -.946**
Sig.  0 0 0 0 0.016 0
mtOXDamageDbyA10006G   .490* .520** 0.29 .623** -0.07 .583**
Sig.  0.011 0.007 0.15 0.001 0.736 0.002
CopyNumbyG3196A   0.03 -0.123 0.304 -0.284 -.463* 0.129
Sig.  0.885 0.55 0.131 0.16 0.017 0.53
mtOXDamageDbyCopyNum   -0.277 -.467* 0.043 -.418* -0.27 -0.201
Sig.  0.171 0.016 0.834 0.034 0.182 0.325
mtOXDamageD   0.19 0.081 0.089 0.359 0.015 0.228
Sig. 0.354 0.695 0.664 0.072 0.943 0.262
mtOXDamage   0.166 0.231 -0.055 0.385 0.132 0.198
Sig.  0.417 0.256 0.79 0.052 0.521 0.331
CopyNum   -0.336 -.462* 0.009 -.539** -0.253 -0.288
Sig.  0.093 0.018 0.965 0.004 0.212 0.153
 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Table 2.28.  (cont.) 
Pearson correlation between selected variables based on the influence scores for female samples. 
 
    mtOX 
DamageDby
A10006G 
CopyNumby
G3196A 
mtOX 
DamageDby
CopyNum 
mtOX 
DamageD 
mtOX 
Damage CopyNum copyno 
BrainTumor   -.639** -0.035 0.291 -0.296 -0.286 .396* 0.195
Sig.  0 0.865 0.149 0.142 0.157 0.045 0.34
mtOXDamageD 
by A10006G 
  1 -0.228 -0.113 .894** .786** -.544** -0.369
Sig.    0.262 0.582 0 0 0.004 0.064
CopyNumby            
G3196A 
  -0.228 1 .835** -0.202 -.468* .879** .493*
Sig.  0.262   0 0.323 0.016 0 0.011
mtOXDamageD 
byCopyNum 
  -0.113 .835** 1 0.113 -0.216 .863** .426*
Sig.  0.582 0   0.582 0.29 0 0.03
mtOXDamageD   .894** -0.202 0.113 1 .796** -.392* -0.311
Sig. 0 0.323 0.582   0 0.048 0.123
mtOXDamage   .786** -.468* -0.216 .796** 1 -.610** -0.344
Sig.  0 0.016 0.29 0   0.001 0.085
CopyNum   -.544** .879** .863** -.392* -.610** 1 .577**
Sig.  0.004 0 0 0.048 0.001   0.002
 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Chapter V 
 
CONCLUSIONS 
This study revealed the following major findings:  
 
1. Relative mtDNA copy number were higher in female intractable epilepsy 
patients compared to non-epileptic control samples (p=0.01).   
2. Oxidative mtDNA damage was lower in female epileptics compared to non-
epileptic control samples (p=0.24), and lower in MCD compared to non-MCD 
(p=0.58). 
3. The frequency of mtDNA SNP G9952A was higher in female epilepsy 
samples compared to controls.  
4. Bayesian network showed significant relationships (p < 0.05) between 
epilepsy, mcd, oxidative mtDNA damage, mtDNA copy number, and 
G9952A. 
5. Relative mtDNA copy number were higher in female neoplastic intractable 
epilepsy patients compared to non-epileptic control samples (p=0.34).  
6. Oxidative mtDNA damage was higher in female neoplastic epileptic 
compared to control samples (p=0.74), and no differences in MCD epilepsy 
patients compared to non-MCD (p=0.99).   
7. The frequency of mtDNA G9952A was found in higher frequencies in 
neoplastic epilepsy samples compared to controls.   
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8. Female neoplastic epilepsy phenotypes were predicted by G9952A (OR= 
9.91E9, 95% CI [0, NaN]), level of relative mtDNA copy number (4.10, 95% 
CI [0.28, 60.18]), and level of oxidative mtDNA damage (OR= 2.34, 95% CI 
[0.20, 27.21]) 
9. Bayesian network showed relationships (p < 0.05) between brain tumor with 
G9952A, A1555G, T3197C, A10006G, A10398G, oxidative mtDNA damage 
with relative mtDNA copy number, and brain tumor with relative mtDNA 
copy number in female samples. 
10.  These data suggest that mitochondria play a critical role in the development 
of both epilepsy and brain tumor. 
 
Directions for future research 
The results of the present study are intended to inspire research regarding the 
possible roles of mitochondrial dysfunction in MCD intractable epilepsy.  The data show 
that changes in mtDNA copy number, oxidative mtDNA damage, and function of COIII 
in the mitochondria as areas of interest for research in MCD intractable epilepsy.  Our 
results suggest that changes in mtDNA copy number may depend on the levels of the 
environmental insult that result in changes in metabolic activity and production of ROS 
in the mitochondria.  Thus, more studies exploring and elucidating the role of 
mitochondrial proliferation as a compensatory response to oxidative stress are needed.  
Hence, a study which measures, in addition to the mtSNPs, oxidative mtDNA damage 
and relative mtDNA copy number,  the expression of both nuclear and mitochondrial 
genes and proteins involved in mitochondrial biogenesis, replication, mitochondrial base 
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excision repair and antioxidant response elements in response to oxidative damage is 
needed. 
Since a trend that both MCD and non-MCD samples, as well as, female epilepsy 
samples were predicted by levels of mtDNA copy number and the mtSNP: G9952A, our 
results indicate that research regarding mitochondrial dysfunction mediated by COIII 
activities and increase in mtDNA content in epileptogenesis in MCD is greatly needed.  
Lastly, since the majority of the MCD patients are classified as malformations due to 
abnormal glial and neuronal proliferation in the epilepsy patients, research regarding the 
environmental exposures in this stage of brain development and epileptogenesis is 
warranted.  Since mitochondrial gene expression and regulation are becoming 
increasingly relevant to human diseases determination of the potential signaling pathways 
involved in mtDNA copy number replication and regulation will help us to develop new 
approaches to maintaining healthy mitochondria and preventing epileptogenesis. 
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Table A.1.   
Clinical characteristics of the intractable epilepsy patients and controls 
 
Sample 
Age 
(years) Gender Initial Diagnosis MCD Status Pathology Location in brain 
1 3 M intractable epilepsy Non-MCD new tumor dense gliosis right frontal region 
2 9 F tumor Non-MCD pilocytic astrocytoma post fossa, right cerebellar 
3 14 M intractable epilepsy MCD ganglioglioma left temporal 
4 8 ms F tumor MCD ganglioglioma right frontal temporal 
5 8 M tumor Non-MCD oligodendroglioma left parietal 
6 12 F tumor Non-MCD pilocytic astrocytoma right posterior fossa 
7 15 F intractable epilepsy MCD cortical dysplasia, type Ia right frontal temporal  
region 
8 11 F tumor Non-MCD pilocytic astrocytoma right tectal 
9 18 F intractable epilepsy MCD focal cortical dysplasia, Taylor type 
IIB 
right prefrontal cortex 
10 6 M intractable epilepsy Non-MCD mild neuronal disorganization frontocentral cortex 
11 13 F intractable epilepsy Non-MCD cystic encephalomalacia right parietal lobe 
12 18 M tumor MCD Dysembryoplastic Neuroepithelial 
Tumor (DNET) 
right frontal 
13 12 F tumor Non-MCD glioblastoma multiforme left temporal region 
14 10 F tumor Non-MCD medulloblastoma posterior fossa 
15 10 M tumor Non-MCD pilocytic astrocytoma left cerebellum 
16 8 mos M tumor Non-MCD astrocytoma right frontal temporal 
region 
17 6 F tumor Non-MCD choroid plexus papilloma IV ventricle 
18 3 F intractable epilepsy Non-MCD meningioangiomatosis right parietal tumor 
19 5 M tumor Non-MCD pilocytic astrocytoma hypothalamic tumor 
20 2 M intractable epilepsy Non-MCD gliosis right temporal lobe 
21 10 F tumor MCD ganglioglioma right frontal region 
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Table A.1 (cont).  Clinical characteristics of the intractable epilepsy patients and controls 
Sample 
Age 
(years) Gender Initial Diagnosis MCD Status Pathology Location in brain
22 6 M tumor Non-MCD pilocytic astrocytoma, glioblastoma, 
hypothalamic tumor 
hypothalamus 
23 7 F intractable epilepsy MCD cortical dysplasia with Rasmussen's 
encephalitis 
left anterior temporal lobe, left 
uncal region, left hippocampus 
24 4 M intractable epilepsy MCD cortical dysplasia, type IIA left frontal temporal lobe 
25 4 F intractable epilepsy MCD tuberous sclerosis left temporal lobe 
26 19 F tumor Non-MCD oligodendroglioma left temporoparietal region 
27 16 F intractable epilepsy MCD cortical dysplasia,  type IIB left parietal area 
28 2 M tumor Non-MCD medulloblastoma right cerebellum 
29 4 F tumor Non-MCD pilocytic astrocytoma, hypothalamic 
tumor 
hypothalamus 
30 5 M intractable epilepsy MCD glioneuronal neoplasm/possible 
ganglioglioma 
right frontal lobe 
31 N/A  N/A  intractable epilepsy Non-MCD Information not available Information not available 
32 9 F tumor Non-MCD pilocytic astrocytoma posterior fossa 
33 N/A   N/A intractable epilepsy Non-MCD Information not available Information not available 
34 3 M intractable epilepsy MCD cortical dysplasia parieto-occipital lobe 
35 13 M tumor Non-MCD medulloblastoma posterior fossa 
36 16 F tumor Non-MCD ependymoma left cerebellar medullary 
37 2 F intractable epilepsy MCD cortical dysplasia with Rasmussen's 
encephalitis 
right frontotemporal parietal 
region 
38 17 F intractable epilepsy Non-MCD Information not available left temporal lobe 
39 12 F tumor Non-MCD medulloblastoma IV ventricle 
       
 
 
  
 
192
Table A.1 (cont).  Clinical characteristics of the intractable epilepsy patients and controls 
Sample 
Age 
(years) Gender Initial Diagnosis MCD Status Pathology Location in brain 
40 10 F intractable epilepsy MCD cortical dysplasia, Palmini type IA right temporal lobe 
41 7 M tumor Non-MCD anaplastic ependymoma IV ventricle 
42 3 F intractable epilepsy MCD cortical dysplasia, type 1A left frontal lobe,  hippocampus 
43 9 M intractable epilepsy MCD neuronal disorganization, Type 1a 
cortical dysplasia 
fronto-parietal 
44 6 F tumor Non-MCD high grade malignant 
undifferentiated neoplasm 
Information not available 
45  N/A N/A  intractable epilepsy Non-MCD Information not available Information not available 
46 4 F tumor MCD DNET right temporal region 
47 4 mos M tumor MCD cortical dysplasia, type 2B left temporoparietal cortex 
48 6 M intractable epilepsy MCD cortical dysplasia, Palmini type 1B parietal cortex 
Control 1 15 F Control Sample Diseased car accident, multiple injuries frontal temporal region 
Control 2 18 F Control Sample Diseased car accident, multiple injuries prefrontal cortex 
Control 3 13 F Control Sample Diseased asphyxia by hanging parietal lobe 
Control 4 2 F Control Sample Diseased drowning frontal lobe 
Control 5 2 F Control Sample Diseased drowning parietal lobe 
Control 6 8 F Control Sample Diseased asphyxia and multiple injuries temporal lobe 
Control 7 4 F Control Sample Diseased lymphocytic myocarditis temporal lobe 
Control 8 16 F Control Sample Diseased car accident, multiple injuries parietal lobe 
Control 9 2 F Control Sample Diseased car accident, multiple injuries temporal lobe 
Control 10 17 F Control Sample Diseased car accident, multiple injuries temporal lobe 
Control 11 10 F Control Sample Diseased asthma temporal lobe 
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Table A.2.   
Mitochondrial copy number relative to 18s rRNA gene content as determined from 
the Ct differences 
 
Sample 18s rRNA Ct mtDNA Ct ∆Cta Rcb logRc 
1 21.43 16.60 4.83 28.44 1.45 
2 22.51 20.20 2.31 4.96 0.70 
3 24.40 19.60 4.80 27.76 1.44 
4 27.83 23.63 4.20 18.32 1.26 
5 17.25 15.04 2.21 4.63 0.67 
6 21.92 16.62 5.30 39.26 1.59 
7 16.77 12.00 4.78 27.38 1.44 
8 23.47 17.34 6.13 70.03 1.85 
9 23.75 17.07 6.68 102.18 2.01 
10 25.26 18.97 6.29 77.98 1.89 
11 24.76 18.50 6.27 76.90 1.89 
12 24.94 20.99 3.95 15.45 1.19 
13 24.37 18.82 5.55 46.85 1.67 
14 22.76 22.27 0.49 1.40 0.15 
15 26.42 24.49 1.93 3.80 0.58 
16 20.53 15.74 4.79 27.67 1.44 
17 21.70 17.25 4.45 21.86 1.34 
18 23.96 22.18 1.78 3.42 0.53 
19 24.49 17.37 7.13 139.58 2.14 
20 31.35 24.52 6.83 113.38 2.05 
21 25.84 18.16 7.68 204.36 2.31 
22 19.63 16.84 2.80 6.94 0.84 
23 17.23 12.30 4.93 30.38 1.48 
24 21.12 15.13 5.99 63.34 1.80 
25 33.30 25.60 7.70 207.94 2.32 
26 19.37 13.99 5.39 41.79 1.62 
27 22.37 15.98 6.39 83.58 1.92 
28 22.69 19.15 3.54 11.59 1.06 
29 19.74 24.44 -4.70 0.04 -1.41 
30 25.21 17.73 7.48 178.53 2.25 
31 23.14 13.81 9.33 643.59 2.81 
32 17.67 15.21 2.46 5.48 0.74 
a∆Ct= Ct18s rRNA - Ct mtDNA (ND1) 
bRc , Relative mtDNA copy number 
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Table A.2. (cont.) 
Mitochondrial copy number relative to 18s rRNA gene content as determined from 
the Ct differences 
 
Sample 18s rRNA Ct mtDNA Ct ∆Cta Rcb logRc 
33 25.89 16.46 9.44 692.18 2.84 
34 25.14 18.07 7.07 134.36 2.13 
35 20.08 14.35 5.73 53.08 1.72 
36 24.15 17.26 6.90 119.02 2.08 
37 32.08 24.01 8.08 269.66 2.43 
38 24.63 18.52 6.11 69.07 1.84 
39 36.57 25.49 11.08 2157.28 3.33 
40 30.34 24.22 6.13 69.79 1.84 
41 32.39 23.03 9.36 654.84 2.82 
42 34.69 23.04 11.65 3202.54 3.51 
43 37.00 21.88 15.13 35733.76 4.55 
44 32.69 16.88 15.81 57250.47 4.76 
45 36.57 22.73 13.84 14613.36 4.16 
46 35.92 23.48 12.44 5537.43 3.74 
47 25.20 19.58 5.62 49.18 1.69 
48 29.13 19.19 9.94 978.89 2.99 
Control 1 20.12 15.17 4.95 30.91 1.49 
Control 2 19.4 14.52 4.88 29.45 1.47 
Control 3 21.75 16.66 5.09 33.94 1.53 
Control 4 19.13 15.5 3.63 12.34 1.09 
Control 5 20.16 15.24 4.92 30.27 1.48 
Control 6 18.91 13.41 5.5 45.25 1.66 
Control 7 16.96 13.18 3.78 13.74 1.14 
Control 8 19.35 15.02 4.33 20.04 1.30 
Control 9 19.61 15.07 4.54 23.26 1.37 
Control 10 19.86 16.48 3.38 10.45 1.02 
Control 11 21.2 17.53 3.67 12.77 1.11 
a∆Ct= Ct18s rRNA - Ct mtDNA (ND1) 
bRc , Relative mtDNA copy number 
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Table A.3.   
Mitochondrial DNA oxidative damage determined from Ct differences 
 
Sample 
ND1 Ct            
(hOGG1 treated) 
ND1 Ct                 
(no hOGG1 treatment) ∆Cta log∆Ct 
1 17.80 16.60 1.20 0.08 
2 25.38 20.20 5.19 0.71 
3 25.57 19.60 5.97 0.78 
4 24.51 23.63 0.88 -0.06 
5 17.53 15.04 2.50 0.40 
6 21.98 16.62 5.36 0.73 
7 11.54 12.00 -0.46 ---  
8 23.70 17.34 6.37 0.80 
9 32.95 17.07 15.88 1.20 
10 30.85 18.97 11.88 1.07 
11 32.82 18.50 14.32 1.16 
12 34.97 20.99 13.98 1.15 
13 28.31 18.82 9.50 0.98 
14 26.60 22.27 4.33 0.64 
15 28.24 24.49 3.75 0.57 
16 27.13 15.74 11.40 1.06 
17 19.97 17.25 2.72 0.43 
18 36.29 22.18 14.11 1.15 
19 22.02 17.37 4.66 0.67 
20 24.32 24.52 -0.20 ---  
21 22.15 18.16 3.99 0.60 
22 19.99 16.84 3.16 0.50 
23 21.97 12.30 9.67 0.99 
24 16.65 15.13 1.52 0.18 
25 23.72 25.60 -1.88 ---  
26 20.51 13.99 6.53 0.81 
27 21.08 15.98 5.10 0.71 
28 28.01 19.15 8.86 0.95 
29 18.17 24.44 -6.28 ---  
30 22.60 17.73 4.87 0.69 
31 20.12 13.81 6.32 0.80 
32 16.92 15.21 1.71 0.23 
a∆Ct= Ct mtDNA (ND1; hOGG1 treated) - Ct mtDNA (ND1, not treated with hOGG1) 
a∆Ct, mtDNA oxidative damage 
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Table A.3. (cont.)  
Mitochondrial DNA oxidative damage determined from Ct differences 
 
Sample 
ND1 Ct            
(hOGG1 treated) 
ND1 Ct                 
(no hOGG1 treatment) ∆Cta log∆Ct 
33 22.13 16.46 5.68 0.75 
34 26.83 18.07 8.76 0.94 
35 16.98 14.35 2.63 0.42 
36 23.28 17.26 6.03 0.78 
37 24.27 24.01 0.27 -0.58 
38 24.34 18.52 5.82 0.76 
39 19.90 25.49 -5.60 ---  
40 25.24 24.22 1.02 0.01 
41 16.83 23.03 -6.21 ---  
42 23.25 23.04 0.20 -0.69 
43 17.16 21.88 -4.72 --- 
44 14.19 16.88 -2.69 ---  
45 25.74 22.73 3.01 0.48 
46 17.94 23.48 -5.55 --- 
47 18.06 19.58 -1.53 --- 
48 26.57 19.19 7.38 0.87 
Control 1 19.46 15.17 4.29 0.63 
Control 2 17.77 14.52 3.25 0.51 
Control 3 22.83 16.66 6.17 0.79 
Control 4 20.78 15.5 5.28 0.72 
Control 5 18.70 15.24 3.46 0.54 
Control 6 18.01 13.41 4.6 0.66 
Control 7 15.55 13.18 2.38 0.38 
Control 8 15.85 15.02 0.83 -0.08 
Control 9 19.35 15.07 4.28 0.63 
Control 10 25.11 16.48 8.63 0.94 
Control 11 24.10 17.53 6.57 0.82 
 
a∆Ct= Ct mtDNA (ND1; hOGG1 treated) - Ct mtDNA (ND1, not treated with hOGG1) 
a∆Ct, mtDNA oxidative damage 
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Table A.4.    
Comparison of Malformation of Cortical Development (MCD) intractable epilepsy 
patients and control group 
 
  
    MCD 
(n=18) 
Control 
(n=11) P-value 
Age (years) 7.28 + 5.47 9.73 + 6.44 0.28 
Sex (M/F) 8/10 0/11 0.01 
log Relative mtDNA copy number  
Median 2.03 1.37 
Mean + S.D. 2.24 + 0.92 1.33 + 0.21 0.001 
> 1.53 (high) (%) 13 (72) 1 (9) 0.004 
< 1.53 (low) (%) 5 (28) 9 (82) 
log Degree of oxidative mtDNA damage (∆Ct) 
Median 0.69 0.63 
Mean + S.D. 0.43 + 0.60 0.59 + 0.27 0.39 
> 0.65 (high damage) (%) 7 (39) 5 (45) 1.00 
< 0.65 (low damage) (%) 6 (33) 6 (55) 
log Degree of oxidative mtDNA damage/ log 
Relative mtDNA copy number  
Median 0.29 0.42 
Mean + S.D. 0.27 + 0.34 0.46 + 0.25 0.13 
> 0.37 (high damage) (%) 4 (22) 7 (64) 0.22 
< 0.37 (low damage) (%) 9 (50) 4 (36) 
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Table A.5.   
Comparison of Non Malformation of Cortical Development intractable epilepsy 
patients and control group 
 
  
Non-MCD 
(n=27) 
Control 
(n=11) P-value 
Age (years) 8.57 + 4.86 9.73 + 6.44 0.56 
Sex (M/F) 11/13 0/11 0.02 
log Relative mtDNA copy number  
Median 1.67 1.37 
Mean + S.D. 1.73 + 1.24 1.33 + 0.21 0.12 
> 1.49 (high) (%) 16 (59) 2 (18) 0.06 
< 1.49 (low) (%) 11 (41) 8 (73) 
log Degree of oxidative mtDNA damage (∆Ct) 
Median 0.72 0.63 
Mean + S.D. 0.67 + 0.26 0.59 + 0.27 0.47 
> 0.67 (high damage) (%) 12 (44) 4 (36) 0.47 
< 0.67 (low damage) (%) 10 (37) 7 (64) 
log Degree of oxidative mtDNA damage/ log 
Relative mtDNA copy number  
Median 0.45 0.42 
Mean + S.D. 0.66 + 0.86 0.46 + 0.25 0.48 
> 0.44 (high damage) (%) 11 (41) 5 (45) 1.00 
< 0.44 (low damage) (%) 11 (41) 6 (55) 
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Table A.6.   
Comparison of Malformation of Cortical Development intractable epilepsy patients 
and Non-MCD epilepsy patients 
 
  
MCD 
(n=18) 
Non-MCD 
(n=27) P-value 
Age (years) 7.28 + 5.47 8.57 + 4.86 0.42 
Sex (M/F) 8/10 11/13 1.00 
log Relative mtDNA copy number  
Median 2.03 1.67 
Mean + S.D. 2.24 + 0.92 1.73 + 1.24 0.15 
> 1.84 (high) (%) 10 (56) 10 (37) 0.23 
< 1.84 (low) (%) 7 (39) 16 (59) 
log Degree of oxidative mtDNA damage (∆Ct) 
Median 0.69 0.72 
Mean + S.D. 0.43 + 0.60 0.67 + 0.26 0.20 
> 0.71 (high damage) (%) 8 (44) 12 (44) 0.49 
< 0.71 (low damage) (%) 5 (28) 10 (37) 
log Degree of oxidative mtDNA damage/ log 
Relative mtDNA copy number  
Median 0.29 0.45 
Mean + S.D. 0.27 + 0.34 0.66 + 0.86 0.13 
> 0.38 (high damage) (%) 4 (22) 13 (48) 0.16 
< 0.38 (low damage) (%) 9 (50) 9 (33) 
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Table A.7.   
Mitochondrial SNPs and haplogroups  
 
Region Variant Reported in Patients 
12S rRNA G709A Non-syndromic hearing loss 
12S rRNA T710C Colorectal tumor, mtDNA haplogroup (Hg)-L1b 
12S rRNA A1555G Maternally inherited deafness  or aminoglycoside-induced deafness 
16S rRNA G1719A Hg-I, X 
16S rRNA T1738C colorectal tumor 
16S rRNA G3196A Alzheimer’s Disease and Parkinson’s Disease (ADPD) 
16S rRNA T3197C Hg-U5 
ND1 T3308C Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like 
episodes (MELAS); colorectal tumor 
ND1 T3394C Leber Hereditary Optic Neuropathy (LHON);  Non-insulin dependent 
diabetes mellitus (NIDDM); acute leukemia 
ND1 C3594T Hg-L (L1 or L2) 
ND1 A3397G ADPD 
ND1 A4136G LHON 
tRNA Ile A4295G Maternally inherited hypertropic cardiomyopathy (MHCM) 
tRNA Ile G4298A 
Chronic Progressive External Ophthalmoplegia (CPEO) / Multiple 
Sclerosis (MS) 
tRNA Ile G4309A CPEO 
tRNA Ile A4317G Fatal Infantile Cardiomyopathy (FICP) 
tRNA Gln T4336C ADPD 
ND2 A4917G LHON, Hg-T 
COX II G8251A Sensorineural Hearing Loss (SNHL); Hg-I,W 
ATP6 G8994A SNHL; Hg-W 
ATP6 G9055A Hg-K, longevity, ↓PD 
CO III G9438A LHON 
CO III G9738T LHON 
CO III G9804A LHON 
CO III G9952A Mitochondrial Encephalopathy 
CO III T9957C Progressive encephalopathy (PEM); MELAS 
tRNA Gly T9997C MHCM 
tRNA Gly A10006G Chronic intestinal pseudo-obstruction (CIPO) 
tRNA Gly T10010C PEM 
tRNA Gly T10034C Hg-I 
tRNA Gly A10044G Gastroesophageal reflux (GER) /Sudden infant death syndrome (SIDS) 
ND3 A10398G ↓PD, ↓AD;A-↑Breast Cancer  (BRCA)  in AA, Hg-I, J, L, M 
ND3 C10400T Hg-M 
tRNA LeuCUN A12308G Hg-U&K; CPEO / Stroke / Cardiomyopathy (CM) 
ND5 G13368A Hg-T 
ND5 G13708A Hg-J; LHON 
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Table A.8.   
mtDNA haplogroups J, L, M, T, U, and X 
 
Haplogroups SNPs 
L 10398G 
J 4216C, 10398G, 13708A, 16069T 
L0, L1, L2 3594T
L3 3594C
M 10398G 
T 4216C, 7028T, 10398A, 12308G, 13368A, 15607G 
U 9055G, 10398A, 12308G 
X 1719X, 7028T, 10398A, 14470C 
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Table A.9.    
Sequences for amplifying mitochondrial genome 
 
Name Forward Primers, Sequence (5' - 3') Name Reverse Primers, Sequence (5' - 3') 
Amplicon 
Size (bp) 
MtF537 CATACCCCGAACCAACCA MtR828 GTTAATCACTGCTGTTTCC 292 
MtF1351 GCAAGAAATGGGCTACAT MtR1762 TATCTATTGCGCCAGGTT 412 
F1672 CTAAACCTAGCCCCAAACC R1895 GCTTTGGCTCTCCTTGCAA 224 
MtF3116 CCTCCCTGTACGAAAGGAC MtG3460na GAGTTTTATGGCGTCAGCGAA 356 
F3212 CACCCAAGAACAGGGTTTGT R3758 AGTAGAATGATGGCTAGGGTGAC 546 
MtF4013 CCCTCACCACTACAATCTT MtR4490 GATGGTAGAGTAGATGACG 478 
F4103 CCCTCACCACTACAATCTT 4917na GCTTACGTTTAGTGAGGGA 825 
MtF4881 CCCATCTCAATCATATACC MtR5501 TAGTATAAAAGGGGAGATAGG 621 
MtF5460 GCC CTTACCACGCTA CTCC MtR5843 TTAGGCCTCTTTTTACCAGC 384 
F6872 ACTCGCCACACTCCACGG R7282 GAATGA GCCTACAGATGA T 409 
F8209 CATCGTCCTAGAATTAATTCC R9169 TGAAAA CGTAGGCTTGGA T 961 
MtF9402 ACATACCAAGGCCACCACAC MtR10108 AGTAGTAAGGCTAGGAGGG 707 
G9952ns GATGTGGTT TGACTATTTC TG R10629 GCA CAA TAT TGG CTA AGA G 688 
F12093 TCCTCCTATCCCTCAACCCC R12360 GGTTATAGTAGTGTGCATG 268 
F14437 AGGATACTCCTCAATAGC C R15185 GGCGGATAGTAAGTTTGT 766 
MtF15539 CCTCCCCACATCAAGCCC MtR15964 TTTCTCTGATTTGTCCTTGG 426 
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Table A.10.   
Sequences for the mtDNA SNPs and haplogroups 
 
Oligonucleotide 
Name Oligo sequence (5' to 3') 
Oligonucleotide 
Name Oligo sequence (5' to 3') 
709-10-ns GCATCCCCGTTCCAGTGA T4274C-ms TAAGAAATATGTCCGATAAAAG 
G709A-ms CATCCCCATTCCAGTGAG T4285-ns GATAAAAGAGTTACTTTGATAG 
T710C-ms CATCCCCGCTCCAGTGA T4285C-ms GATAAAAGAGCTACTTTGATAG 
A1555-ns TACGACTTGTCTCCTCTAT A4295-na CTATTATTTACTCTATCAAAGTA 
A1555G-ms TACGACTTGCCTCCTCTAT A4295G-ma CTATTATTTACTCCATCAAAGTA 
G1719-ns ACAACCTTAGCCAAACCAT G4298A-ma CTATTATTTATTCTATCAAAGTA 
G1719A-ms ACAACCTTAACCAAACCAT A4300G-ma CTATTATTCACTCTATCAAAGTA 
A1738-ns TTTACCCAAATAAAGTATAGG G4309-na TAAGGGGGTTTAAGCTCCTAT 
T1738C-ms TTACCCAAACAAAGTATAGG G4309A-ma TAAGGGGGTTTAAGCTTCTAT 
G3196-ns CTCAACTTAGTATTATACC A4317G-ma TAAGGGGGCTTAAGCTCCTA 
G3196A-ms CTCAACTTAATATTATACC C4320T-ma TAAGGAGGTTTAAGCTCCTAT 
T3197C-ms CTCAACTTAGCATTATACCC T4336-ns TTCTAGGACTATGAGAATC 
T3308-ns TTAACAACATACCCATGGC T4336C-ms TTCTAGGACCATGAGAATC 
T3308C-ms TAACAACACACCCATGGC T4409-ns CTAAAGTAAGGTCAGCTAAATA 
T3394--ns TAGGCTATATACAACTAACG T4409C-ms CTAAAGTAAGGCCAGCTAAAT 
T3394C-ms ATTCTAGGCCATATACAACT G4450-ns GAAAATGTTGGTTATACCCTT 
C3594-ns ACCCCCTGGTCAACCTCA G4450A-ms GAAAATGTTGATTATACCCTT 
C3594T-ms ACCCCCTGGTTAACCTCA A4529-ns CTCATCACAGCGCTAAGC 
A3397-na GTAGTTGTATATAGCCTAG A4529T-ms CTCATCACTGCGCTAAGC 
A3397G-ma GTAGTTGTACATAGCCTAG G4580-na TAAAAGCTAGCATGTTTATTTC 
A4136-na ATCGGGGGTATGCTGTTC G4580A-ma TAAAAGCTAGTATGTTTATTTC 
A4136G-ma ATCGGGGGCATGCTGTTC A4917-na GCTTACGTTTAGTGAGGGA 
T4160-ns ACGACCAACTCATACACCT A4917G-ma GCTTACGTCTAGTGAGGGA 
T4160C-ms ACGACCAACCCATACACCT G5460-ns ACACTCATCGCCCTTACCA 
T4216-ns TACTTATATGATATGTCTCCAT G5460A-ms CACTCATCACCCTTACCAC 
T4216C-ms TACTTATATGACATGTCTCCAT G5460T-ms CACTCATCTCCCTTACCAC 
A4269-ns TAAGAAATATGTCTGATAAAAG G5521-ns ATAGAAATTTAGGTTAAATACAG 
A4269G-ms TAAGAAATGTGTCTGATAAAAG G5521A-ms ATAGAAATTTAAGTTAAATACAG 
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Table A.10. (cont.)   
Sequences for the mtDNA SNPs and haplogroups 
 
Oligonucleotide 
Name Oligo sequence (5' to 3') 
Oligonucleotide 
Name Oligo sequence (5' to 3') 
A5537-ns ATACAGACCAAGAGCCTTCA G9952-ns GATGTGGTTTGACTATTTCTG 
A5537insT-ms ATACAGACCATAGAGCCTTC G9952A-ms GATGTGGTTTAACTATTTCTG 
G5549-ns AGCCTTCAAAGCCCTCAG T9957C-ms ATGTGGTTTGACTACTTCTG 
G5549A-ms AGCCTTCAAAACCCTCAG T9997-ns GTCTTACTCTTTTAGTATAAATA 
T5692-ns CAAACACTTAGTTAACAGCT T9997C-ms GTCTTACTCTTCTAGTATAAAT 
T5692C-ms CAAACACTTAGCTAACAGCT A10006-na AGTTAACGGTACTATTTATACT 
T5814-ns TATGAAAATCACCTCGGAG A10006G-ma GTTAACGGTACTACTTATACT 
T5814C-ms TATGAAAACCACCTCGGAG T10010C-ma GTTAACGGTGCTATTTATACT 
C7028-ns CGTTGTAGCCCACTTCCA T10034-ns TTCCAATTAACTAGTTTTGAC 
C7028T-ms CGTTGTAGCTCACTTCCA T10034C-ms TTCCAATTAACTAGCTTTGAC 
G8251-na AAATACGGGCCCTATTTCAA A10044-na CTCTTTTTTGAATGTTGTCAAA 
G8251A-ma AAATACGGGTCCTATTTCAA A10044G-ma CTCTTTTTTGAACGTTGTCAA 
G8994-na CGTACGGCCAGGGCTATT A10398-na TACCAATTCGGTTCAGTCT 
G8994A-ma CGTACGGCTAGGGCTATT A10398G-ma TACCAATTCGGCTCAGTCT 
G9055-na CTAGGGTGGCGCTTCCA C10400T-ma TACCAATTCAGTTCAGTCT 
G9055A-ma CTAGGGTGGTGCTTCCA A12308-na CCAAAATTTTTGGGGCCTA 
G9438-ns GTCCAAAAAGGCCTTCGATA A12308G-ma CCAAAATTCTTGGGGCCTA 
G9438A-ms GTCCAAAAAAGCCTTCGATA G13368-na ATGATGGACCCGGAGCAC 
G9738-ns CTCCTACAAGCCTCAGAGT G13368A-ma ATGATGGATCCGGAGCAC 
G9738T-ms CTCCTACAATCCTCAGAGT G13708-na TTCCGGCTGCCAGGCGTT 
G9804-ns TTTTGTAGCCACAGGCTTC G13708A-ma TTCCGGCTGTCAGGCGTT 
G9804A-ms TTTTTGTAACCACAGGCTTC     
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Table A.11. 
Hybridization temperatures for ASO Dot Blots 
 
Probe Tm (C°) Probe Tm (C°) Probe Tm (C°) 
709-10-ns 47 T4336-ns 52 G9952-ns 58 
G709A-ms 47 T4336C-ms 54 G9952A-ms 52 
T710C-ms 47 T4409-ns 54 T9957C-ms 56 
A1555-ns 46 T4409C-ms 58 T9997-ns 56 
A1555G-ms 46 G4450-ns 56 T9997C-ms 56 
G1719-ns 47 G4450A-ms 54 A10006-na 56 
G1719A-ms 47 A4529-ns 56 A10006G-ma 56 
A1738-ns 47 A4529T-ms 56 T10010C-ma 56 
T1738C-ms 47 G4580-na 56 T10034-ns 54 
G3196-ns 46 G4580A-ma 54 T10034C-ms 56 
G3196A-ms 47 A4917-na 56 A10044-na 56 
T3197C-ms 46 A4917G-ma 50 A10044G-ma 56 
T3308-ns 47 G5460-ns 58 A10398-na 54 
T3308C-ms 47 G5460A-ms 58 A10398G-ma 54 
T3394--ns 47 G5460T-ms 58 C10400T-ma 52 
T3394C-ms 47 G5521-ns 56 A12308-na 56 
C3594-ns 47 G5521A-ms 54 A12308G-ma 56 
C3594T-ms 47 A5537-ns 58 G13368-na 58 
A3397-na 47 A5537insT-ms 58 G13368A-ma 56 
A3397G-ma 47 G5549-ns 56 G13708-na 60 
A4136-na 56 G5549A-ms 54 G13708A-ma 58 
A4136G-ma 58 T5692-ns 40 
T4160-ns 56 T5692C-ms 54 
T4160C-ms 58 T5814-ns 54 
T4216-ns 56 T5814C-ms 56 
T4216C-ms 58 C7028-ns 56 
A4269-ns 52 C7028T-ms 52 
A4269G-ms 54 G8251-na 56 
T4274C-ms 64 G8251A-ma 54 
T4285-ns 56 G8994-na 58 
T4285C-ms 58 G8994A-ma 56 
A4295-na 56 G9055-na 67 
A4295G-ma 58 G9055A-ma 54 
G4298A-ma 54 G9438-ns 64 
A4300G-ma 58 G9438A-ms 56 
G4309-na 60 G9738-ns 54 
G4309A-ma 58 G9738T-ms 56 
A4317G-ma 60 G9804-ns 56 
C4320T-ma 58 G9804A-ms 56 
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Table A.12.   
The results of the Fisher exact test for individual SNP for Malformations of Cortical Development (MCD) and Non-MCD 
pediatric intractable epilepsy patients 
 
SNPs MCD (n=19) Non-MCD (n=29) 
Crude 
OR 95% CI 
Fisher's exact test       
P value                     
Positive % Positive %   Lower Upper 
G709A 18 95 29 100 0 0 NaN 0.40 
T710C 19 100 29 100 0 0 NaN 1.00 
A1555G 12 63 17 59 1.21 0.37 3.98 0.77 
G1719A 1 5 1 3 1.56 0.09 26.47 1.00 
T1738C 3 16 3 10 1.63 0.29 9.05 0.67 
G3196A 6 32 4 14 2.88 0.69 12.07 0.16 
T3197C 0 0 0 0 NaN NaN NaN 1.00 
T3308C 1 5 0 0 0 0 NaN 0.40 
T3394C 29 100 19 100 NaN NaN NaN 1.00 
C3594T 1 5 0 0 0 0 NaN 0.40 
A3397G 1 5 0 0 0 0 NaN 0.40 
A4136G 19 100 29 100 NaN NaN NaN 1.00 
A4317G 13 68 24 82 0.45 0.12 1.77 0.30 
A4295G 0 0 1 3 0 0 NaN 1.00 
G4309A 16 84 28 97 0.19 0.02 1.99 0.29 
T4336C 0 0 0 0 NaN NaN NaN 1.00 
A4917G 18 95 27 93 1.33 0.11 15.82 1.00 
G8251A 0 0 1 3 0 0 NaN 1.00 
G8994A 0 0 2 7 0 0 NaN 1.00 
NaN = Not a number 
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Table A.12. (cont.).   
The results of the Fisher exact test for individual SNP for Malformations of Cortical Development (MCD) and Non-MCD 
pediatric intractable epilepsy patients 
 
SNPs   MCD (n=19) Non-MCD (n=29) OR 95% CI 
Fisher's exact test     
P value              
Positive/ 
haplogroup % 
Positive/ 
haplogroup %   Lower Upper 
G9438A 1 5 1 3 1.56 0.09 26.47 1.00 
G9738T 0 0 2 7 0 0 NaN 0.51 
G9804A 1 5 1 3 1.47 0.09 25.03 1.00 
G9952A 5 26 13 45 0.32 0.13 1.54 0.24 
T9957C 10 53 19 66 0.58 0.18 1.91 0.55 
T9997C 11 58 19 66 0.72 0.22 2.38 0.76 
A10006G 2 11 7 24 0.37 0.07 2.01 0.29 
T10010C 8 42 16 55 0.59 0.18 1.90 0.56 
T10034C 16 84 26 90 0.62 0.11 3.43 0.67 
A10044G 8 42 14 48 0.78 0.24 2.50 0.77 
A10398G 3 16 5 17 0.90 0.19 4.30 1.00 
C10400T 5 26 7 24 1.12 0.30 4.24 0.56 
A12308G 18 95 27 93 1.33 0.11 15.82 1.00 
G13368A 19 100 29 100 NaN NaN NaN 1.00 
G13708A 14 74 22 76 0.89 0.24 3.37 1.00 
      
 
NaN = Not a number 
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Table A.13.  
The results of the Fisher exact test for individual haplogroups for Malformations of Cortical Development (MCD) and 
Non-MCD pediatric intractable epilepsy patients 
 
Haplogroups MCD (n=19) Non-MCD (n=29) OR 95% CI 
Fisher's exact 
test            
P value          
Positive/ 
haplogroup % 
Positive/ 
haplogroup %   Lower Upper 
      
I  14 74 22 76 0.93 0.24 3.37 1.00 
J  14 74 22 76 0.93 0.24 3.37 1.00 
L  1 5 0 0 NaN NaN NaN 0.40 
M  5 26 7 24 1.12 0.30 4.24 1.00 
X  1 5 1 3 1.56 0.09 26.47 1.00 
T 18 95 27 93 1.33 0.11 15.82 1.00 
U 18 95 27 93 1.33 0.11 15.82 1.00 
 
 
NaN = Not a number
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Table A.14.  
Characteristics of Miami Children’s Hospital neoplastic intractable epilepsy 
patients 
 
Sample Pathology 
WHO 
Classification 
Tumor 
Classification Tumor Grade 
1 new tumor dense gliosis I N/A Low 
2 pilocytic astrocytoma I astrocytoma Low 
3 ganglioglioma I/II astrocytoma Low 
4 ganglioglioma I/II astrocytoma Low 
5 oligodendroglioma II oligodendroglioma Low 
6 pilocytic astrocytoma I astrocytoma Low 
8 pilocytic astrocytoma I astrocytoma Low 
12 Dysembryoplastic 
Neuroepithelial Tumor 
(DNET)  
I DNET Low 
13 glioblastoma multiforme IV astrocytoma High 
14 medulloblastoma IV medulloblastoma High 
15 pilocytic astrocytoma I astrocytoma Low 
16 astrocytoma I astrocytoma Low 
17 choroid plexus papilloma I glioma Low 
19 pilocytic astrocytoma I astrocytoma Low 
21 ganglioglioma I/II astrocytoma Low 
22 pilocytic astrocytoma, 
glioblastoma, hypothalamic 
tumor 
IV astrocytoma High 
26 oligodendroglioma II oligodendroglioma Low 
28 medulloblastoma IV medulloblastoma High 
29 pilocytic astrocytoma, 
hypothalamic tumor 
I astrocytoma Low 
30 glioneuronal 
neoplasm/possible 
ganglioglioma 
I/II astrocytoma Low 
32 pilocytic astrocytoma I astrocytoma Low 
35 medulloblastoma IV medulloblastoma High 
36 ependymoma II ependymoma Low 
39 medulloblastoma IV medulloblastoma High 
41 anaplastic ependymoma III ependymoma Low 
44 high grade malignant 
undifferentiated neoplasm 
IV N/A High 
46 DNET I DNET Low 
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Table A.15.   
Comparison of demographic, and mitochondrial DNA copy number and oxidative damage in Miami Children’s Hospital pediatric 
neoplastic intractable epilepsy patients by tumor grade and non-epileptic control from NICHD Brain and Tissue Bank 
 
  
All Cases 
(n=38) 
Tumor  
Low Grade 
(n=20) 
   Tumor 
High Grade 
(n=7) 
Control     
(n=11) aP-value bP-value cP-value 
Age (years) 8.93 + 5.36 8.57 + 5.31 8.71 + 4.11  9.73 + 6.44 0.95 0.59 0.72 
Sex (M/F) 12/26 9/11 3/4 0/11 1.0 0.01 0.04 
log Relative mtDNA copy number                
Median 1.45 1.45 1.67 1.37       
Mean + S.D. 1.53 + 1.00 1.49 + 1.03 1.93 + 1.59 1.33 + 0.21 0.40 0.62 0.23 
> 1.45 (high) (%)   9 (45) 4 (57) 5 (45) 1.00 1.00 1.00 
< 1.45 (low) (%) 10 (20) 3 (43) 6 (55)       
log Degree of oxidative mtDNA 
damage (∆Ct)               
Median 0.66 0.69 0.64 0.63       
Mean + S.D. 0.62 + 0.29 0.61 + 0.32 0.69 + 0.26 0.59 + 0.27 0.60 0.87 0.49 
> 0.66 (high damage) (%)   9 (45) 2 (29) 5 (45) 0.64 0.69 0.71 
< 0.66 (low damage) (%) 7 (35) 3 (43) 6 (55)       
Degree of oxidative mtDNA 
damage/ log Relative mtDNA copy 
number                
Median 0.46 0.44 0.59 0.42       
Mean + S.D. 0.60 + 0.73 0.48 + 0.31 1.33 + 1.70 0.46 + 0.25 0.05 0.89 0.32 
> 0.46 (high damage) (%)   9 (45) 2 (29) 6 (55) 0.64 0.69 0.28 
< 0.46 (low damage) (%) 7 (35) 3 (43) 4 (36)     
 
aP-value for Brain Tumor Low Grade (WHO Tumor Grading < 2) vs. High Grade (WHO Tumor Grading > 2)  
bP-value for Brain Tumor Low Grade vs. Control 
cP-value for Brain Tumor High Grade vs. Control 
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Table A.16.   
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with high tumor grade and non-epileptic control from NICHD Brain and Tissue Bank 
 
SNPs 
High Tumor 
Grade            
(n=7)             
Control 
(n=11) 
Fisher's     
exact test    
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/   
    SNP % 
Positive/   
   SNP % 
  
A1555G 3 43 11 100 0.04 0 0, NaN 0 0, NaN 
G3196A 2 29 11 100 0.002 0 0, NaN 0 0, NaN 
T3197C 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
G4309A 7 100 11 100 1.00 1.62E9 0, NaN 1.46E9 0, NaN 
A4317G 7 100 11 100 1.00 1.62E9 0, NaN 1.46E9 0, NaN 
G9804A 0 0 0 0 1.00 NaN 0, NaN NaN NaN, NaN 
G9952A 1 14 0 0 0.39 0 0, NaN 0 0, NaN 
A10006G 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
T10010C 3 43 7 64 0.63 0.42 0.06, 2.97 0.44 0.32, 15.93 
A10398G 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds ratio using control as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table A.17.   
The results of the Fisher’s exact test for haplogroups for in Miami Children’s Hospital pediatric intractable epilepsy 
patients by high tumor grade and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
High Tumor 
Grade            
(n=7)             
Control 
(n=11) 
Fisher's     
exact test    
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/   
   Hg % 
Positive/   
  Hg % 
  
Hg-I 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-J 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-L 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-M 0 0 11 100 <0.001 0 0, NaN 0 0, NaN 
Hg-U5 0 0 9 82 0.002 0 0, NaN 0 0, NaN 
 
aOR, Crude Odds ratio using control as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table A.18.   
The results of the logistic regression for SNPs/Hg, level of relative mtDNA copy number, level of oxidative mtDNA damage, 
and age in Miami Children’s Hospital pediatric neoplastic intractable epilepsy patients by high tumor grade and non-
epileptic control from NICHD Brain and Tissue Bank 
 
SNP/Haplogroup 
SNP/Hg               
OR (95% CI) 
Level of relative 
mtDNA copy number 
OR  (95% CI) 
Level of oxidative  
mtDNA damage           
 OR (95% CI) 
Age                
OR (95% CI) 
A1555G 7.12E9 (0, NaN) 0.99 (0.04, 23.15) 1.42 (0.08, 25.70) 0.92 (0.73, 1.17) 
G3196A 74.91E25 (0, NaN) 3.16E8 (0, NaN) 2.60E8 (0, NaN) 1.01 (0.72, 1.66) 
T3197C 3.61E17 (0, NaN) 0 (0, NaN) 1.42 (0.03, 77.68) 0.90 (0.63, 1.28) 
G4309A --- 0.81 (0.07, 9.09) 0.99 (0.11, 9.07) 0.96 (0.78, 1.17) 
A4317G --- 0.81 (0.07, 9.09) 0.99 (0.11, 9.07) 0.96 (0.78, 1.17) 
G9804A --- 0.81 (0.07, 9.09) 0.99 (0.11, 9.07) 0.96 (0.78, 1.17) 
G9952A 0 (0, NaN) 0.40 (0.03, 6.30) 0.57 (0.05, 6.51) 0.92 (0.73, 1.16) 
A10006G --- --- --- --- 
T10010C 0.80 (0.06, 10.77) 0.72 (0.04, 11.79) 0.99 (0.11, 9.12) 0.95 (0.76, 1.18) 
A10398G --- --- --- --- 
Hg-I --- --- --- --- 
Hg-J --- --- --- --- 
Hg-L --- --- --- --- 
Hg-M --- --- --- --- 
Hg-U5 3.61E17 (0, NaN) 0 (0, NaN) 1.42 (0.03, 77.68) 0.90 (0.63, 1.28) 
 
OR, using control group as reference 
NaN = Not a number 
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Table A.19.   
The results of the Fisher’s exact test for individual SNP loci for in Miami Children’s Hospital pediatric neoplastic 
intractable epilepsy patients with low tumor grade and non-epileptic control from NICHD Brain and Tissue Bank  
 
SNPs 
Low Tumor 
Grade            
(n=20)            
Control 
(n=11) 
Fisher's     
exact test    
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/   
    SNP % 
Positive/   
   SNP % 
  
A1555G 9 45 11 100 0.004 0 0, NaN 2.16E9 0, NaN 
G3196A 1 5 11 100 <0.001 0 0, NaN 5.25E10 0, NaN 
T3197C 0 0 9 82 0.002 0 0, NaN 1.62E10 0, NaN 
G4309A 19 95 11 100 1.00 0 0, NaN 8.69E8 0, NaN 
A4317G 12 60 11 100 0.03 0 0, NaN 1.44E9 0, NaN 
G9804A 0 0 0 0 1.00 NaN 0, NaN 0.96 0.84, 1.11 
G9952A 11 55 0 0 0.002 0 0, NaN 0 0, NaN 
A10006G 6 30 11 100 <0.001 0 0, NaN 3.29E9 0, NaN 
T10010C 13 65 7 64 1.00 1.06 0.23, 4.92 0.94 0.20, 4.37 
A10398G 7 35 11 100 <0.001 0 0, NaN 2.23E9 0, NaN 
 
aOR, Crude Odds ratio using control as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table A.20.   
The results of the Fisher’s exact test for haplogroups for in Miami Children’s Hospital pediatric intractable epilepsy 
patients by low tumor grade and non-epileptic control from NICHD Brain and Tissue Bank 
 
Haplogroups 
Low Tumor 
Grade            
(n=7)             
Control 
(n=11) 
Fisher's     
exact test    
P value     
(2-sided) ORa 
95% 
Confidence 
Interval 
Adjusted 
ORb 
95% 
Confidence 
Interval 
Positive/   
   Hg % 
Positive/   
  Hg % 
  
Hg-I 7 35 11 100 <0.001 0 0, NaN 2.23E9 0, NaN 
Hg-J 7 35 11 100 <0.001 0 0, NaN 0, NaN 0, NaN 
Hg-L 7 35 11 100 <0.001 0 0, NaN 2.23E9 0, NaN 
Hg-M 7 35 11 100 <0.001 0 0, NaN 2.23E9 0, NaN 
Hg-U5 0 0 9 82 0.002 0 0, NaN 1.62E10 0, NaN 
 
aOR, Crude Odds ratio using control as reference category 
bORs adjusted for age using logistic regression 
NaN = Not a number 
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Table A.21.   
The results of the logistic regression for SNPs/Hg, level of relative mtDNA copy number, level of oxidative mtDNA damage, 
and age in Miami Children’s Hospital pediatric neoplastic intractable epilepsy patients by low tumor grade using non-
epileptic control from NICHD Brain and Tissue Bank as reference 
 
SNP/Haplogroup 
SNP/Hg               
OR (95% CI) 
Level of relative 
mtDNA copy number   
OR (95% CI) 
Level of oxidative  
mtDNA damage           
OR (95% CI) 
Age               
OR (95% CI) 
A1555G 7.00E9 (0, NaN) 0.34 (0.02, 4.77) 0.16 (0.01, 2.14) 0.95 (0.78, 1.16) 
G3196A --- --- --- --- 
T3197C 5.72E17 (0, NaN) 0 (0, NaN) 1.03 (0.03, 39.97) 0.97 (0.71, 1.33) 
G4309A --- 1.05 (0.18, 6.13) 0.42 (0.08, 2.29) 0.98 (0.84, 1.15) 
A4317G 1.69E9 (0, NaN) 0.86 (0.13, 5.92) 0.54 (0.09, 3.42) 1.00 (0.86, 1.17) 
G9804A --- 1.05 (0.18, 6.13) 0.42 (0.08, 2.29) 0.98 (0.84, 1.15) 
G9952A 0 (0, NaN) 0.17 (0.01, 2.43) 0.45 (0.04, 4.94) 1.00 (0.82, 1.23) 
A10006G 1.08E18 (0, NaN) 5.89E8 (0, NaN) 4.06 (0.17, 99.64) 1.05 (0.83, 1.34) 
T10010C 0.47 (0.06, 3.70) 0.71 (0.09, 5.84) 0.44 (0.08, 2.43) 0.98 (0.84, 1.14) 
A10398G 3.19E9 (0, NaN) 1.15 (0.12, 11.40) 0.27 (0.03, 2.76) 0.95 (0.76, 1.17) 
Hg-I 5.72E17 (0, NaN) 0 (0, NaN) 1.03 (0.03, 39.97) 0.97 (0.71, 1.33) 
Hg-J 5.72E17 (0, NaN) 0 (0, NaN) 1.03 (0.03, 39.97) 0.97 (0.71, 1.33) 
Hg-L 5.72E17 (0, NaN) 0 (0, NaN) 1.03 (0.03, 39.97) 0.97 (0.71, 1.33) 
Hg-M 5.72E17 (0, NaN) 0 (0, NaN) 1.03 (0.03, 39.97) 0.97 (0.71, 1.33) 
Hg-U5 5.72E17 (0, NaN) 0 (0, NaN) 1.03 (0.03, 39.97) 0.97 (0.71, 1.33) 
 
OR, using control group as reference 
NaN = Not a number 
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DNA ISOLATION PROTOCOL 
1. Tissue 
a. Homogenize cells in 1mL TRizol Reagent (under Fume Hood). 
b. Pipette into epi tube (Lyse cells by repetitive pipetting). 
2. Phase Separation 
a. Incubate cells/TRizol at 15-30 C for 5 min. 
b. Add 200uL of chloroform (per 1mL TRizol used- under the Fume Hood). 
c. Cap tubes and vortex for 15 seconds. 
d. Incubate at 15-30 C (room temp) for 15 minutes. 
e. Centrifuge samples @ 12K rpm @4 C for 15 min. 
*After centrifugation : aqueous = RNA 
                                  interphase = protein/DNA 
                                  organic = DNA 
3. DNA Precipitation 
a. Remove aqueous phase (RNA) into new epi. Tube.  
b. Add 300uL 100% Ethanol (200 proof EtOH) per 1mL TRizol used to 
interphase/organic phase. 
c. Vortex gently. 
d. Incubate samples at 15-30 C for 2-3 min. 
e. Centrifuge at 12K rpm @ room T for 5 min. 
4. DNA Wash 
a. Remove phenol/ethanol sup (contains protein) to waste. 
b. Wash DNA pellet 2 times with 0.1M sodium citrate (Add 1mL Na Citrate 
for every 1mL TRizol used). 
c. Gently vortex. 
d. Incubate samples at 15-30 C for 15 min. 
e. Spin at 12K rpm at room 4C for 5 min. 
f. Resuspend DNA in 1mL 75% Ethanol (per 1mL TRizol used). 
g. Incubate at room T for 10-20 min. 
h. Centrifuge at 12K rpm @ room T for 5 min. 
i. Remover supernatant with p200 pipettor. 
j. Briefly dry pellet for 2-5 min under vacuum (can leave on bench). 
5. Redissolving of DNA 
a. Dissolve pellet in 60uL of 1X TE Buffer with a pipette. 
b. Aliquot DNA into three 10uL samples. 
c. Store -80 C. 
d. Run 2% agarose gel (quality) 
e. Check DNA conc. by spec. (quantity) 
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DOT BLOT PROTOCOL 
 
1. Cut membrane to appropriate size, make a grid with pencil. 
2. Denature PCR products by heating at  95°C for 10 minutes, then place on ice. 
3. Place 2uL of PCR product on membrane. 
4. Let air membrane air dry (~1 hour). 
5. UV crosslink membrane for 4 minutes. 
6. Dip membrane in ddH2O. 
7. Place membrane in pre-heated hybridization solution for 15 minutes. 
8. Add DIG-labeled Oligonucleotide (30uL of Miracle Hyb. And 3uL of probe). 
9. Hybridize at proper temperature, over night. 
10. Place membrane in 2X SSC + 0.1% SDS for 15 minutes, 2 times. 
11. Place membrane in 0.1X SSC + 0.1% SDS at hybridization temperature for 30 
minutes. 
12. Place membrane in washing buffer for 5 minutes. 
13. Place membrane in blocking buffer for 30 minutes. 
14. Place membrane in anti-DIG solution for 30 minutes. 
15. Place membrane in washing buffer for 15 minutes, 2 times. 
16. Place membrane in detection solution for 3 minutes. 
17. Add 250uL of CSPD to membrane. 
18. Place in clear wrap. 
19. Place in 37°C for 10 minutes. 
20. Visualize in X-Ray developer or VersaDoc® Imager. 
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